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ACRONYMS AND ABBREVIATIONS
AIDS acquired immune deficiency syndrome
ARQ Annual Reports Questionnaire (of the Commission on Narcotic Drugs)
ART antiretroviral therapy
ATS amphetamine-type stimulants 
BMT buprenorphine maintenance treatment
BSS behavioural surveillance survey 
Comprehensive Package the comprehensive package of nine interventions endorsed by WHO, 
UNODC and UNAIDS for the prevention, treatment and care of HIV 
among people who inject drugs 
EC European Commission
EMCDDA European Monitoring Centre for Drugs and Drug Addiction
FHI 360 formerly Family Health International
Global Fund Global Fund to Fight AIDS, Tuberculosis and Malaria
GAR Global AIDS Report 
HAV hepatitis A virus 
HBV hepatitis B virus
HCV hepatitis C virus
HDSS high dead-space syringes
HIV human immunodeficiency virus
HTC HIV testing and counselling
IDU injecting drug use (see also note below)
IEC information, education and communication 
ILO International Labour Organization
IPT isoniazid preventive therapy
LDSS low dead-space syringes
MMT methadone maintenance treatment
NCPI National Composite Policy Index
NGO non-government organization
NSP needle and syringe programme
OST opioid substitution therapy
PEPFAR The United States President’s Emergency Plan for AIDS Relief
PITC provider-initiated testing and counselling
PLHIV people living with HIV
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PMTCT prevention of mother-to-child transmission (of HIV) 
PSI Population Services International
PWID people/person who inject/s drugs (see note below)
RITA recent infection testing algorithm
STI sexually transmitted infection
TB tuberculosis
UIC unique identifier code
UN United Nations
UNAIDS Joint United Nations Programme on HIV/AIDS 
UNDP United Nations Development Programme
UNFPA United Nations Population Fund
UNGASS United Nations General Assembly Special Session on HIV/AIDS
UNODC United Nations Office on Drugs and Crime
WHO World Health Organization
Note: In this document the abbreviation IDU is used to refer to injecting drug use as was written in 
the 2009 version. In other documents, IDUs is also commonly used to denote injecting drug users. 
Currently, the term people who inject drugs is preferred. 
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1. INTRODUCTION
1.1 BACKGROUND
This document provides technical guidance to countries on monitoring efforts to prevent and treat 
HIV infection among people who inject drugs (PWID) and for setting ambitious but achievable national 
targets for scaling up towards universal access.
This tool has been developed collaboratively by three United Nations (UN) agencies—the World Health 
Organization (WHO), the United Nations Office on Drugs and Crime (UNODC) and the Joint United 
Nations Programme on HIV/AIDS (UNAIDS)—and through a process of consultation with international 
experts in the field.
The first version of this Technical Guide built on earlier WHO, UNODC (1) and UNAIDS (2) guidance and 
adhered to the principles therein. The Guide is intended to provide consistent methods of measuring 
and comparing countries’ progress towards national targets to scale up comprehensive programmes 
for universal access to prevention, treatment, care and support for HIV and AIDS (3,4). These aims are 
based upon the 2006 Political Declaration on HIV/AIDS, in which countries committed to scale up 
towards universal access, and the earlier Declaration of Commitment on HIV/AIDS (5). Member States 
reaffirmed these commitments in the 2011 Political declaration on HIV/AIDS: Intensifying our efforts 
to eliminate HIV/AIDS. The UNAIDS Secretariat and its cosponsors have supported the launch of this 
broader effort by developing further, more specific operational guidance to countries (3,4,6,7).
Since the publication of the first version in 2009, the Technical Guide has been endorsed by high-level 
political bodies including the UN General Assembly (8), the Economic and Social Council (9), the UN 
Commission on Narcotic Drugs (10), and the UNAIDS Programme Coordinating Board (11). In addition, 
donor agencies, including the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) and 
the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), have committed to using this framework.
The Technical Guide has been rolled out, and training on its application has been provided in numerous 
countries across all world regions. 
1.2 REVISIONS IN THIS PUBLICATION
The revisions made for the current version of the Technical Guide were informed by findings from a 
study examining the application of the guide in a range of countries, by systematic reviews, conducted 
by the Reference Group to the United Nations on HIV and Injecting Drug Use, assessing the availability 
of relevant data, and through consultation with a broad range of stakeholders and experts from around 
the world.
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In this revision efforts have been made to make the guide more readable, with more explanation provided 
on each of the indicators and with guidance on how the indicators may be reported if some data are 
lacking. The package of evidence-based interventions has not been modified.
A number of indicators included in the first version have been excluded, as field experience has revealed 
limitations in the feasibility of their application or in their relevance to policy and programming. 
Also, a more extensive framework for assessing the quality of intervention delivery has been included.
1.3 FUNCTION AND SCOPE OF THIS DOCUMENT
This document provides countries with:
•	 a comprehensive package of interventions for the prevention, treatment and care of HIV infection 
among people who inject drugs, which has not changed from the 2009 version of this guidance;
•	 a set of indicators to monitor and evaluate the implementation and impact of these interventions;
•	 advice on setting targets for scale-up, to maximize the impact of HIV prevention and care 
among people who inject drugs;
•	 examples of data sources and useful tools to assist with programme development, implementation, 
monitoring and evaluation.
This Technical Guide is intended to assist government agencies, non-government organizations (NGOs), 
communities and service providers involved in developing, implementing, monitoring and evaluating 
HIV prevention, treatment and care programmes for people who inject drugs (PWID). The framework 
proposed can be applied at regional, national, sub-national and service-delivery levels. 
There are a number of international reporting mechanisms that include indicators related to injecting 
drug use or to the monitoring and evaluation of HIV prevention, treatment and care services for PWID. 
These include:
•	 Monitoring progress in the health sector towards achieving universal access to HIV prevention, 
treatment and care (WHO);
•	 Global AIDS Response progress reporting (12) (formerly, Reporting on monitoring the UNGASS 
Declaration of Commitment on HIV/AIDS) (UNAIDS);
•	 Commission on Narcotic Drugs Annual Report Questionnaire (ARQ) (UNODC).
Member States are obligated to submit reports for each of these global data collection processes. 
The indicators related to injecting drug use included in these obligatory reporting mechanisms can 
be considered the minimum set of indicators needed to gain a broad understanding of the response 
to injecting drug use and HIV, useful in particular for comparing data from different countries and for 
building a picture of regional and global progress. 
2012 Revision
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The majority of the 22 indicators related to injecting drug use included in these global reporting 
mechanisms are also included in this Technical Guide. This guide goes further and includes additional 
indicators that enable a more in-depth assessment of HIV prevention, treatment and care programmes 
for PWID. Countries are not obligated to report on these additional indicators as part of any international 
data collection process. Instead, the information that these additional indicators provide is important 
for HIV policy development and effective programming. 
These indicators can also be used for the preparation of proposals or reporting on progress 
to donor organizations; such as the Global Fund and PEPFAR.
The primary focus of this document is on interventions for people who inject drugs. Dependent or 
problematic non-injecting drug users may also face significant levels of HIV risk associated with drug 
use and may also be at risk of initiation into injecting drug use. Hence, it is also important to consider 
non-injecting drug users in the response to HIV, and it is relevant to set targets for HIV interventions 
targeting these individuals as well. Further, with the exception of needle and syringe programmes, 
the interventions included in the Comprehensive Package presented in this Technical Guide are also 
applicable to the prevention, treatment and care of HIV among non-injecting drug users. 
WHO, UNODC, UNAIDS Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users
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2.1 THE COMPREHENSIVE PACKAGE
Addressing HIV associated with injecting drug use is one of the key challenges in the health sector 
response to HIV. 
A Comprehensive Package of interventions for the prevention, treatment and care of HIV among 
people who inject drugs has been endorsed widely, by WHO, UNAIDS, UNODC, the UN General 
Assembly  (8), the Economic and Social Council (9), the UN Commission on Narcotic Drugs (10), the 
UNAIDS Programme Coordinating Board (11), the Global Fund and PEPFAR. The Comprehensive 
Package includes:
1 Needle and syringe programmes (NSPs)
2 Opioid substitution therapy (OST) and other evidence-based drug dependence 
treatment
3 HIV testing and counselling (HTC)
4 Antiretroviral therapy (ART)
5 Prevention and treatment of sexually transmitted infections (STIs)
6 Condom programmes for people who inject drugs and their sexual partners
7 Targeted information, education and communication (IEC) for people who inject drugs 
and their sexual partners 
8 Prevention, vaccination, diagnosis and treatment for viral hepatitis
9 Prevention, diagnosis and treatment of tuberculosis (TB).
Note: In this document this suite of interventions will be referred to as the “Comprehensive Package”.
These interventions are included in the Comprehensive Package because of the scientific evidence 
available supporting their efficacy in preventing the spread of HIV, in addition to reducing other harms 
associated with drug use (13–15). It is beyond the scope of this document to provide a thorough discussion 
of the evidence available on the effectiveness of the interventions included in the Comprehensive 
Package; this information is well documented elsewhere (see box). The Comprehensive Package may 
be revised in the future in light of emerging evidence. 
2. HIV PREVENTION, TREATMENT AND CARE AMONG PEOPLE 
WHO INJECT DRUGS
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The interventions included in the Comprehensive Package are commonly referred to as a harm reduction 
approach to injecting drug use (8,9,11). Harm reduction in response to drug use may also encompass 
other interventions; those included in the Comprehensive Package relate in particular to HIV and other 
co-infections.
Models for the delivery of interventions included in the package are discussed in section 2.6. It is 
important to note that these interventions can contribute the most to preventing and treating HIV when 
available in combination (15). Each intervention addresses different factors relating to HIV transmission 
and illness. Therefore, to successfully halt the spread of HIV, and its consequences, a comprehensive 
approach is required. Empirical studies and extensive modelling have demonstrated that single 
interventions alone have only limited impact; to significantly reduce HIV transmission and other harms, 
combined interventions with high levels of coverage are required (15).
For the development and monitoring of programmes to deliver the interventions in the Comprehensive 
Package, it is useful to distinguish between services that can be regarded as drug-user-specific (NSPs 
and drug dependence treatment) and interventions that are not drug-user-specific and often function 
as services relevant to the wider community. 
To successfully address HIV where injecting drug use occurs, countries should prioritise 
implementing NSPs and evidence-based drug dependence treatment (specifically OST). 
Countries should also as ensure that people who inject drugs are successfully reached by the other 
interventions of the Comprehensive Package. Most countries have some level of provision of the 
interventions from the Comprehensive Package that are not specific to drug users. 
It is also important to understand the context in which injecting drug use occurs and in which 
interventions to address drug use and HIV are implemented. So-called structural factors, which relate to 
the physical, social and legal environment, can shape HIV risk, just as access to, coverage and impact 
of HIV-focused interventions can (16). While interventions that specifically address structural factors are 
not included in the Comprehensive Package, investing in such measures is essential to the broader HIV 
response (17). Structural factors and responses to address them are discussed further in section 2.4.
Documents that review and summarize evidence relating to the interventions included in the 
Comprehensive Package
•	 The	WHO/UNODC/UNAIDS	Evidence	for	Action	series	and	policy	briefs	(18):  
http://www.who.int/hiv/pub/idu/evidence_for_action/en/index.html
•	 Institute	of	Medicine.	Committee	on	the	Prevention	of	HIV	Infection	Among	Injecting	Drug	Users	in	
High-Risk	Countries.	Preventing HIV infection among injecting drug users in high-risk countries: an 
assessment of the evidence.	Washington,	DC,	National	Academies	Press,	2006	(14).
•	 Gowing	L	et	al.	Substitution	treatment	of	injecting	opioid	users	for	prevention	of	HIV	infection	(review).	
Cochrane	Database	of	Systematic	Reviews,	2008;	2:CD004145	(19).
•	 Degenhardt	L	et	al.	HIV	prevention	for	people	who	inject	drugs:	why	individual,	structural,	and	
combination	approaches	are	required.	The Lancet,	2010,	376(9737):285−301	(15).
•	 Altice	FL	et	al.	Treatment	of	medical,	psychiatric,	and	substance-use	comorbidities	in	people	infected	
with	HIV	who	use	drugs.	The Lancet,	2010,	376(9738):367−387	(20).
•	 MacArthur	G	et	al.	Opiate	substitution	treatment	and	HIV	transmission	in	people	who	inject	drugs:	
systematic	review	and	meta-analysis.	BMJ,	2012,	345	(137).)
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1 NEEDLE AND SYRINGE PROGRAMMES 
Distributing sterile injecting equipment to people who inject drugs facilitates the use of clean needles and 
syringes and reduces the number of injections with used needles and syringes (14,15,21–23). Various models 
of needle and syringe distribution and service delivery may be implemented. Needle and syringe programmes 
(NSPs) are defined in this document to include programmes in which needles and syringes are provided free 
of charge. NSPs may operate at fixed sites as well as through mobile and outreach services. 
Other types of distribution, such as the sale of injecting equipment, are considered separately. Injecting 
equipment may be available for purchase through pharmacies or other outlets. Where access to NSPs 
is difficult or places people who use drugs at risk of being apprehended by police, pharmacy sales of 
injecting equipment are an important, and sometimes the most significant, source of sterile injecting 
equipment accessible to people who inject drugs (24,25). Automated vending machines may also be 
used to dispense injecting equipment, either free or for purchase (26).
For many PWID needle and syringe programmes often are a rare point of contact with a health service. 
For that reason NSPs may serve as an important point of entry to other services. NSPs should aim to 
engage people who use drugs on a regular basis and to facilitate access to drug dependence treatment, 
to HIV treatment, care and support and to other important health and welfare services. If they have 
the capacity, some NSPs may themselves offer basic health care, addressing specific issues that may 
commonly affect PWID, such as wound care.
The injecting equipment available should be appropriate for the local context, taking into account 
factors such as the type and preparation of drugs that are commonly injected. It may be beneficial to 
encourage the use of low dead-space syringes (LDSS), as there is evidence that the provision of LDSS 
leads to a reduction in the transmission of HIV and HCV. LDSS commonly have a nondetachable needle 
joined directly to the syringe barrel and are designed to reduce the amount of blood remaining in the 
syringe after completely pushing down the syringe plunger. WHO suggests that needle and syringe 
programmes also offer LDSS and provide information about their potential prevention effect (27–29,95). 
In addition to needles and syringes, other injecting-related paraphernalia may also be provided, including 
alcohol swabs, vials of sterile water, filters, tourniquets, mixing vessels (e.g. spoons or “cookers”) and 
acidifiers (e.g. ascorbic acid or citric acid powders) to assist with dissolving the substance to be injected. 
The safe disposal of used injecting equipment is also important. NSPs can encourage and facilitate 
safe disposal by receiving used syringes or by providing puncture-resistant safe disposal containers to 
clients. If the carrying of used needles and syringes is a criminal offence or may be used as evidence 
of drug use, however, PWID may be reluctant to take used equipment to NSPs for disposal. 
Sources of guidance on needle and syringe programmes
•	 Guide to starting and managing needle and syringe programmes.	Geneva,	World	Health	Organization,	
Department	of	HIV/AIDS,	2007	(27).	 
http://www.who.int/hiv/pub/idu/needleprogram/en/index.html
•	 Evidence for action: Effectiveness of sterile needle and syringe programming in reducing HIV/AIDS 
among injecting drug users.	Geneva,	World	Health	Organization,	2004	(22).	 
http://www.who.int/hiv/pub/idu/e4a-needle/en/index.html
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2 OPIOID SUBSTITUTION THERAPY AND OTHER DRUG DEPENDENCE 
TREATMENT
Interventions that are effective in controlling drug dependence can reduce illicit drug use and, hence, 
the frequency of injection, as well as improving health and social functioning.
For the purpose of the monitoring and evaluation framework outlined in this document, drug dependence 
treatment interventions are grouped into the following categories, adapted from those used in the WHO 
ATLAS on substance use (31):
•	 agonist opioid substitution therapy (OST) (as maintenance treatment)
•	 inpatient detoxification
•	 outpatient drug dependence treatment
•	 inpatient short-term treatment
•	 inpatient or residential long-term treatment
•	 peer-based support groups (such as 12-step Narcotics Anonymous groups)
•	 brief intervention delivered in non-specialist settings.
Agonist opioid substitution therapy (OST) as maintenance is highly effective in reducing injecting 
behaviours that put opioid-dependent injectors at risk for HIV (14,15,19,32). In addition, OST has 
been demonstrated to improve both access and adherence to ART and to reduce mortality (33–36). 
Accordingly, OST is particularly important in the response to HIV associated with drug use, especially 
because in many countries the majority of people who are opioid-dependent are also injecting drug 
users, and, globally, a substantial, although currently unquantified, proportion of people who inject 
drugs inject opioids. 
A number of different opioid agonists are used for opioid substitution therapy, the most common being 
methadone and buprenorphine, both of which are listed as essential medicines by WHO (37). Other 
preparations, including pharmaceutical heroin (diamorphine) and slow-release morphine preparations, 
also are used in a limited number of countries. OST for non-injecting opioid-dependent people is 
also considered in the indicators presented here. Transition to injecting among this group is not 
uncommon (38); treatment for opioid dependence reduces the likelihood of initiation into injecting and, 
hence, can be considered part of an HIV prevention strategy.
To be most effective, it is important that maintenance OST is provided at adequate doses and for 
sufficient duration (see Guidelines for psychosocially assisted pharmacotherapy for the management of 
opioid dependence. Geneva, WHO, 2009 (39)).
While the evidence currently available on the impact of other forms of drug dependence treatment 
on HIV incidence is less compelling than that for OST (40), these other interventions remain strongly 
recommended for settings where non-opioid drugs such as amphetamine-type stimulants (ATS), 
cocaine and benzodiazepines are widely used and also where OST remains unavailable. Such 
treatment should be evidence-based. Interventions might include cognitive–behavioural therapy (41) 
or contingency management for amphetamine dependence (42); brief psychosocial interventions 
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delivered in non-specialized settings (i.e. those that are not specialized drug treatment services) are 
also recommended (43). Inpatient, medically supervised drug withdrawal (detoxification) can assist in the 
completion of the withdrawal process, but it is not effective on its own in achieving sustained abstinence 
from drug use (44). Detoxification may comprise symptomatic relief to reduce the discomfort of 
withdrawal; opioid withdrawal can be managed with opioid substitution therapy in diminishing doses (39).
In a number of countries drug users are apprehended and confined to detention centres, ostensibly for 
the purpose of drug treatment and rehabilitation, but without trial or clinical assessment of dependence, 
and the duration of detention is rarely determined by clinical treatment outcomes. Typically, in these 
centres there is no medical supervision of drug withdrawal, and evidence-based drug dependence 
treatment is not offered; detainees are frequently forced to participate in unpaid labour or military-style 
drills and may be subject to physical punishment. Following release from these centres, many relapse to 
drug use; risk of overdose may be increased (45). There is no evidence that these types of approaches 
are effective in reducing drug dependence. Hence, they do not fall into the category of drug dependence 
treatment as part of the Comprehensive Package described in this document.
Sources of guidance on drug dependence treatment
•	 Guidelines for psychosocially assisted pharmacotherapy for the management of opioid dependence.	
Geneva,	World	Health	Organization,	2009	(39).	 
http://www.who.int/hiv/pub/idu/opioid/en/index.html
•	 Operational guidelines for the management of opioid dependence in the South-East Asia Region.	New	
Delhi,	WHO	Regional	Office	for	South-East	Asia,	2008	(46).	 
http://www.who.int/hiv/pub/idu/op_guide_opioid_depend/en/index.html
•	 mhGAP intervention guide for mental, neurological and substance use disorders in non-specialized 
health settings.	Geneva,	World	Health	Organization,	Department	of	Mental	Health	and	Substance	
Abuse,	2011	(43).	 
http://www.who.int/mental_health/publications/mhGAP_intervention_guide/en/index.html
•	 WHO,	UNODC.	Principles of drug dependence treatment—discussion paper.	Geneva,	World	Health	
Organization,	2008	(47).	 
http://www.who.int/substance_abuse/publications/principles_drug_dependence_treatment.pdf
•	 Basic principles for treatment and psychosocial support of drug dependent people living with HIV/
AIDS.	Geneva,	World	Health	Organization,	2006	(48).	 
http://www.who.int/substance_abuse/publications/basic_principles_drug_hiv.pdf
•	 Technical	briefs	on	amphetamine	type	substances.	Manila,	World	Health	Organization	Regional	Office	
for	the	Western	Pacific,	2011	(49).	 
http://www.who.int/hiv/pub/idu/ats_tech_brief/en/index.html
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3 HIV TESTING AND COUNSELLING 
HIV testing and counselling (HTC) is an important gateway to HIV treatment and care.
Rapid testing techniques make possible testing and obtaining results during the same contact. Rapid 
testing can be offered in a variety of settings and ways, including by out-reach workers in the field. 
This community-based testing has the potential to reach greater numbers of people, including those 
who inject drugs, who may be unlikely to go to a facility for testing or to return for a later follow-up visit 
to receive test results. 
It is important that, wherever testing is performed, there are clear and robust links to HIV care and 
treatment for those who test positive. When this linkage is poor, it impedes the effective and timely 
uptake of care and ART. It is also important to have clear procedures in place, which follow national 
HIV testing strategies, to confirm positive field HIV test results.
In most circumstances provider-initiated HIV testing and counselling (PITC) for people who inject drugs 
is recommended, as long as it is not compulsory and is linked to the provision of HIV treatment and 
care in line with WHO guidelines. When PITC is undertaken, particular attention should be given to 
providing accurate information, and informed consent must be obtained. PITC may also be appropriate 
for PWID’s intimate partners.
Support and counselling concerning disclosure of HIV status should be provided; couples counselling 
for PWID and their intimate partners may be appropriate. 
Sources of guidance on HIV testing and counselling
•	 WHO,	UNAIDS.	Guidance on provider-initiated HIV testing and counselling in health facilities.	Geneva,	
WHO,	2007	(50).	 
http://www.who.int/hiv/topics/vct/PITC/en/index.html
•	 UNODC,	WHO,	UNAIDS.	Testing and counselling in prisons and other closed settings.	Vienna,	UNODC,	
2009.	 
http://www.who.int/hiv/pub/idu/tc_prisons/en/index.html
•	 WHO-SEARO,	WHO-WPRO,	UNODC.	Guidance on testing and counselling for HIV in settings attended 
by people who inject drugs: improving access to treatment, care and prevention.	Manila,	WHO	WPRO,	
2009	(51).	 
http://www.who.int/hiv/pub/idu/searo_wpro_tc/en/index.html
•	 EMCDDA.	Guidelines for testing HIV, viral hepatitis and other infections in injecting drug users: 
a manual for provider-initiated medical examination, testing and counselling.	Lisbon,	European	
Monitoring	Centre	for	Drugs	and	Drug	Addiction,	2010	(52).	 
www.emcdda.europa.eu/attachements.cfm/att_120808_EN_Guidelines_HIVtesting_Final.pdf
•	 Delivering HIV test results and messages for re-testing and counselling in adults.	Geneva,	World	
Health	Organization,	2010	(53).	 
http://www.who.int/hiv/pub/vct/hiv_re_testing/en/index.html
•	 A handbook for improving HIV testing and counselling services: field-test version.	Geneva,	World	
Health	Organization,	2010	(54).	 
http://www.who.int/hiv/pub/vct/9789241500463/en/index.html
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4 ANTIRETROVIRAL THERAPY 
The provision of antiretroviral therapy (ART) to people who inject drugs has population-wide health 
benefits. People who inject drugs can successfully undergo treatment and benefit from ART (36, 55–57). 
There is also increasing evidence that ART may have a role in HIV prevention through lowering viral 
load and reducing HIV transmission (58–63). People who inject drugs, however, typically have poorer 
levels of access to ART than non-injectors; this may be due to multiple factors including restrictions or 
health-care provider practices limiting the provision of ART for people who inject drugs (36).
Drug dependence treatment, particularly OST where indicated, improves treatment outcomes and 
adherence to ART among people living with HIV who are opioid dependent (36).
It is difficult to determine the number of people who inject drugs receiving ART. Countries may have 
registries of patients on ART as well as pre-ART registers recording patients who have yet to start 
treatment. Most of these systems, however, do not report whether or not patients have a history of 
injecting drug use. If these systems do record a patient’s history of injecting drug use, it is critical 
that client confidentiality is maintained, that injecting drug use history or current status should not be 
shared with law enforcement agencies, and that drug use history or status should not prejudice access 
to treatment.
In addition, it is critical to consider the prevention of mother-to-child transmission (PMTCT) in the case 
of HIV-positive pregnant women who may inject drugs or who are sexual partners of male PWID. 
Management of drug dependence during pregnancy, particularly the provision of OST during pregnancy 
to women who are opioid-dependent, should also be provided.
Sources of guidance on antiretroviral therapy
•	 Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health 
approach—2010 revision.	Geneva,	World	Health	Organization,	2010	(64).	 
http://www.who.int/hiv/pub/arv/adult2010/en/index.html
•	 Chapter	5.	HIV/AIDS	treatment	and	care	for	injecting	drug	users.	In:	HIV/AIDS treatment and care: 
clinical protocols for the WHO European Region.	Copenhagen,	World	Health	Organization	Regional	
Office	for	Europe,	2006	(65).	 
http://www.who.int/hiv/pub/idu/euro_treatment/en/index.html
•	 Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants.	Geneva,	
World	Health	Organization,	2010	(66).	 
http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html
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5 PREVENTION AND TREATMENT OF SEXUALLY TRANSMITTED INFECTIONS
Sexually transmitted infections (STIs) can biologically increase the sexual transmission of HIV (67). 
Potential exposure to STIs is elevated for PWID who engage in sex work and for male PWID who have 
sex with other men (68,69).
Condom distribution programmes and promotion of safer sex practices through information and 
education are two important strategies for the prevention of STIs and are components of the 
Comprehensive Package, listed as interventions 6 and 7, respectively. 
Strategies to increase STI treatment rates among PWID might include:
•	 the development of the STI screening and treatment capacity of health services that are 
accessed by PWID; 
•	 the co-location of STI diagnosis and treatment services at sites accessed by people who inject 
drugs (such as NSPs or drug treatment services); 
•	 the establishment of active referral pathways and the integration of screening and testing 
programmes between STI treatment services and other services that are accessed by PWID; 
•	 ensuring that mainstream STI treatment services are accessible and responsive to the needs 
of people who inject drugs.
Sources of guidance on prevention and control of sexually transmitted infections
•	 Global strategy for the prevention and control of sexually transmitted infections: 2006−2015: breaking 
the chain of transmission.	Geneva,	World	Health	Organization,	2007	(70).	 
http://www.who.int/reproductivehealth/publications/rtis/9789241563475/en/index.html
•	 Training modules for the syndromic management of sexually transmitted infections.	Geneva,	World	
Health	Organization,	2007	(71).	 
http://www.who.int/reproductivehealth/publications/rtis/9789241593407/en/index.html
•	 Sexually transmitted and other reproductive tract infections.	Geneva,	World	Health	Organization,	2005	(72). 
http://www.who.int/reproductivehealth/publications/rtis/9241592656/en/index.html
•	 Guidelines for the management of sexually transmitted infections.	Geneva,	World	Health	Organization,	
2004	(73).	 
http://www.who.int/hiv/pub/sti/pub6/en/
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6 CONDOM	PROGRAMMES	FOR	PEOPLE	WHO	INJECT	DRUGS	AND	THEIR	
SEXUAL PARTNERS
Sexual transmission of HIV among people who inject drugs, and between people who inject drugs and 
their sexual partners who do not inject drugs, constitutes an important pathway of HIV infection. There 
is also a significant association between stimulant use, through both injecting and non-injecting routes 
of administration, and risky sexual behaviours (74,75). People who inject drugs and also engage in sex 
work and male injectors who have sex with men may be further exposed to risk (76). 
Increasing the accessibility and use of condoms among people who use drugs and their partners 
through targeted distribution programmes is, therefore, an important component of the Comprehensive 
Package. While condoms may be widely available for purchase in most countries, provision of free 
condoms to populations at high risk aims to significantly increase accessibility and use by removing 
any barrier that cost may pose. 
Provision of both male and female condoms plus lubricants may further increase condom acceptability 
and use (76,77). It is also important to offer family planning to women who may inject drugs or who are 
sexual partners of male PWID.
Sources of guidance on condom programming
•	 Condom programming for HIV prevention: a manual for service providers.	New	York,	United	Nations	
Population	Fund,	2005	(78).	 
http://www.unfpa.org/public/global/pid/1291
•	 UNFPA,	WHO,	PATH.	Condom programming for HIV prevention: an operations manual for programme 
managers.	New	York,	UNFPA,	2005	(76).	 
http://www.unfpa.org/public/global/pid/1292 
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7 TARGETED INFORMATION, EDUCATION AND COMMUNICATION 
When combined with other measures, such as the provision of sterile injecting equipment and of 
condoms and treatment for drug dependence, targeted information and education help to increase 
and sustain positive change in HIV risk behaviours (13,79). Repeated exposure is important to maintain 
the benefit from these strategies. 
Specific content will vary among settings but should always address: HIV risk associated with drug use 
and how to reduce it; sexual risk and risk reduction strategies; other risks associated with drug use and 
how to reduce them; how to obtain services and support; basic information on the drugs being used; 
access to legal rights and support; and overdose prevention.
Communication for behavioural change can take various forms and use various media. Information 
materials produced should be relevant to the local context, be appropriate to the needs of people 
who use drugs, and communicate effectively to the intended audience. Individual, couples and group 
counselling can support adoption of safer sex and injecting practices; peer-led interventions have been 
shown to be particularly effective (80).
Given that overdose remains a primary cause of death among people who inject drugs, even in the 
context of an HIV epidemic, IEC strategies focusing on overdose prevention are particularly important. 
In addition to information on preventing overdose, information might also include how to respond to 
overdose if it occurs. This might include training on resuscitation for people who inject drugs, their 
families, partners and peers and on the role of naloxone (an opioid antagonist able to reverse respiratory 
depression in opioid overdose), if available (81–84).
Sources of guidance on targeted information, education and communication
•	 Salem	RM	et	al.	Communication	for	better	health.	Population Reports,	Series	J,	No.	56,	2008	(85).	
•	 International	HIV/AIDS	Alliance,	Asia	Pacific	Network	of	Sex	Work	Projects.	Guide to participatory 
production of resources for HIV prevention among vulnerable populations.	Brighton,	International	HIV/
AIDS	Alliance,	2005	(86).	 
http://www.aidsalliance.org/Publicationsdetails.aspx?Id=194
•	 HIV/AIDS and human rights advocacy and training resource manual.	Windhoek,	Namibia,	AIDS	Rights	
Alliance	for	Southern	Africa,	2008	(87).	 
http://www.arasa.info/index.php/trainingmanuals/83-hivaids-and-human-rights-advocacy-and-
training-resource-manual18
•	 Curtis	M,	Guterman	L.	Overdose prevention and response: a guide for people who use drugs and harm 
reduction staff in Eastern Europe and Central Asia.	New	York,	Open	Society	Institute,	2009	(88).	 
http://www.soros.org/sites/default/files/overdose_20090604.pdf
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8 PREVENTION, VACCINATION, DIAGNOSIS AND TREATMENT FOR VIRAL 
HEPATITIS 
While this document and the Comprehensive Package of interventions focus primarily on HIV, it is 
important to consider and address the transmission and treatment of other blood-borne viruses, in 
particular hepatitis B and C viruses (HBV and HCV). Recent reviews indicate that, worldwide, 10 million 
people who inject drugs may be living with hepatitis C (89), compared with the 3 million estimated to 
be living with HIV (90). HCV co-infection is common among PWID who are living with HIV (91). Also, 
hepatitis B is typically more prevalent among people who inject drugs than in the general population 
(89,92,93). Viral hepatitis is, accordingly, a significant cause of disease burden among PWID. HIV co-
infection is associated with more rapid progression of liver disease and mortality among those infected 
with HCV or HBV (91).
Since blood-borne transmission is common to HIV and hepatitis viruses, interventions effective in 
preventing HIV among people who inject drugs help to prevent HCV/HBV transmission and vice 
versa. Because HCV is more virulent than HIV, however, higher levels of intervention coverage may be 
necessary to achieve comparable reductions in incidence (14,94).
WHO has issued guidance on prevention of viral hepatitis B and C among people who inject drugs (95). 
This guidance recommends offering PWID the rapid hepatitis B vaccination regimen and to offer 
incentives to increase PWID’s uptake and completion of the hepatitis B vaccine schedule. It is suggested 
that needle and syringe programmes also provide low dead-space syringes and that there are peer 
intervention programmes in place. Such programmes need to be flexible and pragmatic, making use 
of opportunistic contact with the target population. 
It is important to appropriately manage HIV co-infection with HBV or HCV (or both) among people who 
inject drugs (93). Chronic active HBV infection necessitating treatment is an indication for initiation of 
ART among those living with HIV (64). 
Sources of guidance on prevention, diagnosis and treatment of viral hepatitis
•	 Guidance on prevention of viral hepatitis B and C among people who inject drugs.	Geneva,	World	
Health	Organization,	2012	(95).	 
http://www.who.int/hiv/pub/guidelines/hepatitis/en/index.html
•	 In:	HIV/AIDS treatment and care: clinical protocols for the WHO European Region.	Copenhagen,	World	
Health	Organization	Regional	Office	for	Europe,	2006	(65):
	 Chapter	6.	Management	of	hepatitis	C	and	HIV	coinfection.	
	 Chapter	7.	Management	of	hepatitis	B	and	HIV	coinfection.	
	 Chapter	8.	Prevention	of	hepatitis	A,	B	and	C	and	other	hepatotoxic	factors	in	people	living	with	HIV. 
http://www.euro.who.int/en/what-we-publish/abstracts/hivaids-treatment-and-care.-clinical-
protocols-for-the-who-european-region
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9 PREVENTION, DIAGNOSIS AND TREATMENT OF TUBERCULOSIS
People who inject drugs may have an increased risk of acquiring tuberculosis (TB) disease independent 
of their HIV status. HIV infection further increases their risk of developing TB disease (20).
It is recommended that services used by those at elevated risk of TB, such as PWID, as well as facilities 
that serve those in confined and crowded conditions, such as prisons, implement a TB infection control 
strategy and have a case-finding protocol for both TB and HIV (96). 
Isoniazid preventive therapy (IPT) should be accessible to drug users living with HIV, once active TB is 
reasonably ruled out (97), and treatment for active TB should be provided as indicated (96). PWID should 
be informed about their risk of TB and how to obtain screening regularly.
Active referral pathways between TB treatment services and services for PWID, and integrated 
screening and testing programmes, also are important. Mainstream TB treatment services should be 
accessible and responsive to the needs of people who inject drugs. 
Sources of guidance on prevention, diagnosis and treatment of tuberculosis
•	 WHO,	UNODC,	UNAIDS.	Policy guidelines for collaborative TB and HIV services for injecting and other 
drug users: an integrated approach.	Evidence	for	Action	Technical	Papers.	Geneva,	WHO,	2008	(96).	 
http://www.who.int/hiv/pub/idu/tb_hiv/en/index.html
•	 Guidelines for intensified tuberculosis case finding and isoniazid preventive therapy for people living 
with HIV in resource-constrained settings.	Geneva,	World	Health	Organization,	2011	(97).	 
http://www.who.int/hiv/pub/tb/9789241500708/en/index.html
•	 Treatment of tuberculosis guidelines, fourth edition.	Geneva,	World	Health	Organization,	2010	(98).	 
http://www.who.int/tb/publications/2010/9789241547833/en/index.html
2.2 OUTREACH
Community-based outreach accesses and engages populations of PWID in locations where they 
may spend time rather than through fixed-site services. In many contexts community-based outreach 
is a highly effective means of delivering HIV/AIDS prevention interventions, such as NSPs, condom 
programmes and targeted IEC, to people who inject drugs, as well as a useful access point for the 
referral of people who inject drugs to interventions such as OST, other drug dependence treatment 
and ART (30). 
Because it is a modality for delivering services rather than a service per se, community-based outreach 
is not included as a separate intervention in the Comprehensive Package. However, outreach is strongly 
recommended as an essential component of all HIV prevention and care programmes and as an 
especially effective method for reaching people who inject drugs, a group often difficult to reach (30). 
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Other diverse service delivery models may also be appropriate and effective in different contexts; see 
section 2.6 for further discussion of models of service delivery for interventions from the Comprehensive 
Package.
Sources of guidance on outreach
•	 Effectiveness of community-based outreach in preventing HIV/AIDS among injecting drug users.	
Evidence	for	Action	Series.	Geneva,	World	Health	Organization,	2004	(30).	 
http://www.who.int/hiv/pub/idu/e4a-outreach/en/index.html 
•	 Training guide for HIV prevention outreach to injecting drug users: workshop manual.	Geneva,	World	
Health	Organization,	2004	(99).	 
http://www.who.int/hiv/pub/idu/hivpubidu/en/index.html 
•	 Practical guidelines for intensifying HIV prevention.	Geneva,	UNAIDS,	2007	(100).	 
http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/manual/2007/20070306_
prevention_guidelines_towards_universal_access_en.pdf
2.3 OTHER INTERVENTIONS NOT INCLUDED IN THE COMPREHENSIVE PACKAGE
A number of interventions have not been included in the Comprehensive Package because of the 
relative lack of evidence of their effectiveness or other considerations. This should not, however, rule 
out the delivery of additional interventions—as pilot programmes or full-scale interventions—where the 
local context requires them. 
For interventions intended to address injecting drug use and HIV that are not included in the Comprehensive 
Package, emphasis should be placed on building evidence and on evaluation. For example, although 
WHO has not reviewed the evidence on the effectiveness of supervised drug consumption/injection 
facilities in preventing HIV infection, evaluations in high-income countries where these facilities have been 
implemented have reported reduced risk behaviours among attending clients (101,102).
Strategies to address structural factors that influence HIV risk and intervention impact are discussed 
in section 2.4.
Source of guidance on other interventions to address injecting drug use and HIV
•	 Good practice guide—HIV and drug use: community responses to injecting drug use and HIV.	
Brighton,	International	HIV/AIDS	Alliance,	2010	(103).	 
http://www.aidsalliance.org/includes/Publication/GPG_drug%20use_07.06.12.pdf
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2.4 STRUCTURAL FACTORS INFLUENCING RISK AND INTERVENTION IMPACT
It is important to consider the context in which injecting drug use occurs and in which services for 
people who inject drugs are delivered. This consideration involves identifying structural factors such as 
societal norms, policies and laws and other factors that may influence HIV risk or impede the delivery of 
interventions. Successfully addressing those factors creates a more supportive environment, conducive 
to reducing HIV risk and other harms.
PWID are commonly marginalized, criminalized and subjected to stigma, discrimination and, due to the 
illegality of drug use, often face legal sanctions or limited access to essential services. Changes in drug 
supply can bring about changes in injecting practices that may consequently affect HIV transmission. 
Laws and law enforcement practices can inadvertently increase the risk of HIV transmission and impede 
the delivery and scaling up of HIV prevention services.
Steps to address these structural factors are an important part of the broader HIV response. Structural 
barriers that restrict access to interventions can be addressed directly; strategies to do so are outlined 
in section 2.5 on universal access. Strategies to create a more supportive environment include the 
following critical enablers (17):
•	 securing political commitment and investing in advocacy
•	 reviewing, and revising where necessary, laws, legal policies and practices
•	 community mobilization
•	 stigma reduction.
A number of items included in the National Composite Policy Index (NCPI) of the UNAIDS Global AIDS 
Report HIV monitoring and reporting process relate to a structurally based response to injecting drug 
use and HIV (available at: http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/
manual/2009/jc1676_core_indicators_2009_en.pdf) (7).
Sources of guidance on addressing policy and structural factors
•	 Reshevska	I	et	al.	Policy advocacy toolkit for medication-assisted treatment (MAT) for drug 
dependence.	Washington,	DC,	The	Futures	Group,	Health	Policy	Initiative,	2010	(104).	 
http://www.healthpolicyinitiative.com/index.cfm?ID=publications&get=pubID&pubID=1449
•	 A new investment framework for the global HIV response.	Geneva,	UNAIDS,	2011	(17).	 
http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2244_
InvestmentFramework_en.pdf
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2.5 THE PRINCIPLES OF UNIVERSAL ACCESS
The High-Level Meeting on HIV/AIDS in 2006 adopted the goal of universal access as a commitment 
to scale up national programmes for HIV treatment, prevention, care and support for all those who need 
them (105). While clearly an ambitious and desirable goal, universal access is also a concrete process, 
driven by countries that have organized national consultations to identify critical obstacles to scaling 
up and have planned measures to address these obstacles.
Universal access encompasses the principles of equity, equality, non-discrimination, comprehensiveness, 
accessibility and sustainability, which guide the development of interventions in the Comprehensive 
Package. These interventions must:
•	 be physically accessible (geographically distributed, e.g. available beyond major cities and to 
those living in hard-to-reach locations);
•	 be affordable (cost at the point of service should not be a barrier, e.g. patients should not have 
to pay for their treatment);
•	 be equitable and non-discriminatory (there should be no exclusion criteria except medical ones; 
e.g. OST should not be limited only to those who use drugs who are HIV-infected or who have 
failed on other drug dependence treatment; likewise, access to ART should not be conditional 
on the cessation of drug use);
•	 be unrationed (supply should be determined by need and not limited by cost or other 
considerations; e.g. NSPs with strict limits on the number of syringes provided to each client 
are less successful than those that do not impose such restrictions) (106).
Furthermore, access to the interventions included in the Comprehensive Package should not be 
restricted by socio-demographic or other criteria such as:
•	 age: programmes should not impose age restrictions (i.e. there should be no minimum age 
requirement for accessing services; in the case of children and young people who inject drugs, 
special provisions may be required where parental consent is ordinarily required for children to 
obtain medical or other services);
•	 sex/gender, sexual orientation or sexual behaviour;
•	 citizenship, nationality, country of origin, race/ethnicity, asylum-seeking status, or religion/
religious convictions;
•	 employment status and profession, including sex work, illegal employment, etc.
•	 confinement to a facility/setting—imprisonment, military service, health institution, orphanage, etc.;
•	 health insurance status;
•	 substance use status—for example, current injecting should not be a barrier to access;
•	 housing status (for example, homelessness);
•	 mental health status;
•	 pregnancy status.
All interventions should be offered on a voluntary basis in an enabling environment created by supportive 
legislation, policies and strategies.
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2.6 SERVICE DELIVERY AND SERVICE INTEGRATION
The development of service delivery models in different settings should be pragmatic and responsive 
to local conditions.
As noted in section 2.1, the interventions included in the Comprehensive Package can be characterized 
as either drug-user-specific interventions (NSPs and drug-dependence treatment) or interventions that 
are not drug-user-specific and that are generally present as services relevant to the wider community. 
To successfully address HIV, countries where injecting drug use occurs will need to implement NSPs 
and evidence-based drug dependence treatment (including specifically OST) as a priority as well as 
to ensure that people who inject drugs are successfully reached by the other interventions of the 
Comprehensive Package that are also relevant to the wider community. Typically, most countries have 
some level of provision of these other interventions, even if these are not targeted to PWID specifically.
Some of the interventions in the Comprehensive Package are commonly delivered by the same service 
or by the same workers. For example, OST and ART can be effectively and efficiently delivered at the 
same location. Similarly, NSP outreach workers may, in addition to providing sterile injecting equipment, 
distribute condoms, deliver targeted information, education and communication (IEC), perform rapid 
testing for HIV and refer PWID to drug dependence treatment and other medical and welfare services.
Services that are targeted to people who inject drugs, such as NSPs and drug treatment services, can 
function as important points of entry to other interventions included in the Comprehensive Package 
and to the health care system more broadly. Access to these other interventions can be enhanced 
through various integrated service delivery models including the co-location of interventions at a 
single site or through strong and coordinated linkage and referral between different service providers. 
Establishing active referral pathways and protocols fosters such linkages; this is discussed in more 
detail in section 3.1. 
As previously noted, PWID commonly have poor access to health services. This may be due to a 
variety of reasons, which can include hostility or discrimination experienced when accessing services 
previously, apprehension that health services will disclose sensitive information, including drug use 
history, to government authorities; requirements that clients be drug-free to be eligible for services; 
prohibitive costs; and staff inexperienced in providing services for PWID. To succeed in reaching PWID, 
services must be accessible and acceptable to PWID and responsive to their needs. Approaches to 
make services more “drug-user friendly” include: 
•	 co-location of interventions and cross-training of providers (for example, the provision of ART 
at drug treatment services); 
•	 scheduling service hours that are routine and dependable and that suit clients’ lifestyles; 
•	 strategic location of services (for example, in hotspots); 
•	 peer-community involvement in service development, promotion, delivery, monitoring and evaluation; 
•	 staff training on working with PWID; 
•	 taking steps to ensure that law enforcement activities do not interfere with clients’ access to a service.
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2.7 PWID IN PRISONS AND OTHER DETENTION SETTINGS 
Drug users have high rates of incarceration, and, globally, a disproportionate number of inmates have 
a history of drug use. Drug use, including by injection, is consistently documented to occur in prisons 
throughout the world. High rates of sharing of injecting equipment, unsafe sex and often high levels of 
HIV prevalence produce elevated HIV risk in prison environments.
The principle of equivalency of care (107) declares that prisoners are entitled, without discrimination, to 
the same standard of health care that is found in the outside community, including preventive measures 
and ART. In addition, it is critical that there be continuity of care for those entering closed settings 
who have been receiving ongoing treatment (such as ART, OST or treatment for TB) in the community; 
interruption of treatment has serious consequences for the health of these detainees and may also, in 
the case of treatment of HIV or TB, lead to drug resistance.
The interventions in the Comprehensive Package to address injecting drug use and HIV are appropriate 
for implementation in prisons and other closed settings such as pre-trial, refugee or immigration 
detention facilities. UNODC, UNAIDS, WHO, United Nations Development Program (UNDP) and 
the International Labour Organization (ILO) have defined a specific comprehensive package of 
interventions for HIV prevention, treatment and care in prisons and other closed settings. This package 
of 15 interventions includes all 9 interventions in the Comprehensive Package targeting PWID as well 
as additional interventions to address broader HIV risk, including interventions for the prevention of 
mother-to-child transmission of HIV, measures to combat sexual violence, post-exposure prophylaxis, 
precautions to prevent transmission through medical and dental services, measures to make tattooing, 
piercing and other forms of skin penetration safer, and interventions for staff (108). It is anticipated that 
a technical guide on monitoring and evaluating these interventions in prisons and other closed settings 
will be developed as a companion to this guide.
It is recommended that the indicators included in this guide assessing the availability of interventions 
be applied to prisons and other closed settings.
Sources of guidance on HIV prevention and treatment in prisons and other detention settings
•	 Status	paper	on	prisons,	drugs	and	harm	reduction.	Copenhagen,	World	Health	Organization	Regional	
Office	for	Europe,	2005	(109).	 
http://www.euro.who.int/__data/assets/pdf_file/0006/78549/E85877.pdf
•	 WHO,	UNODC,	UNAIDS.	Policy	Brief:	Reduction	of	HIV	transmission	in	prisons.	Geneva,	WHO,	
2004	(23).	 
http://www.who.int/hiv/pub/idu/prisons_reduction/en/index.html
•	 WHO,	UNODC,	UNAIDS.	Effectiveness	of	interventions	to	address	HIV	in	prisons.	Geneva,	WHO,	
2007	(110).	 
http://www.who.int/hiv/pub/idu/prisons_effective/en/index.html
•	 UNODC,	WHO,	UNAIDS.	HIV/AIDS	prevention,	care,	treatment,	and	support	in	prison	settings:	A	
framework	for	an	effective	national	response.	New	York,	United	Nations,	2006	(111).	 
http://www.unodc.org/pdf/HIV-AIDS_prisons_July06.pdf
•	 UNODC,	ILO,	UNDP.	HIV	prevention,	treatment	and	care	in	prisons	and	other	closed	settings:	a	
comprehensive	package	of	interventions.	Vienna,	UNODC,	2012	(108).	 
http://www.unodc.org/documents/hiv-aids/HIV_prisons_advance_copy_july_2012_leaflet_UNODC_
ILO_UNDP_Ebook.pdf
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The following framework provides a method to monitor the implementation of the Comprehensive 
Package, explains how to interpret the results of this process and describes how to determine the 
targets that should be pursued. 
This process requires participation from multiple stakeholders, including civil society and, in particular, 
people who use drugs. These groups have an invaluable role to play in contributing to programme 
design and evaluation of progress, highlighting strategies for improvement and developing targets. 
Many donor organizations and international reporting mechanisms stipulate active participation by civil 
society groups in these processes.
Monitoring national progress requires data collection at the service delivery level and for these data to 
be collated and analysed centrally. For data from different services to be aggregated, data collection 
systems must be consistent across services. This guide outlines a set of indicators that assess the 
availability, coverage, quality and outcome/impact of the components of the Comprehensive Package.
As discussed above, maximum benefit is gained from the Comprehensive Package when all nine 
components are implemented together. Therefore, it is advantageous to conduct ongoing monitoring 
and evaluation for all of these interventions. However, countries are at different stages of establishing 
a comprehensive response, and there may be limitations on the extent of monitoring and evaluation 
possible. It is advised that at least NSP, OST, HTC and ART are monitored, if capacity to monitor all 
nine interventions of the Comprehensive Package is limited.
3.1 MONITORING “DRUG-USER-SPECIFIC” VERSUS “GENERAL POPULATION” 
INTERVENTIONS 
The distinction between interventions in the Comprehensive Package that are drug-user-specific (NSPs 
and drug dependence treatment) and those that are also provided for the wider population has important 
implications for the approach taken to monitoring service provision for people who inject drugs. 
When examining interventions that are not specific to drug users, it is important to determine whether 
or not people who inject drugs are being effectively reached by these services. For a range of reasons, 
drug users typically underutilize health care services. Drug users may not have equitable access to 
mainstream services, and in some cases they may be actively excluded from them. Mainstream services 
are commonly not designed to meet the needs of specific populations; staff may not be experienced 
with providing services to people who use drugs; and these services may be unsuited to the needs 
of people who use drugs. Accordingly, it is necessary to evaluate efforts to facilitate access to these 
services by people who inject drugs as well as the levels of access achieved.
3. THE MONITORING AND TARGET-SETTING PROCESS
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As outlined above, people who inject drugs can be reached by services delivering these non-drug user 
specific interventions by: (a) providing equitable access to these interventions through services that 
specifically target people who use drugs; for example, by providing ART at drug treatment centres; and 
(b) by making mainstream services more accessible, sensitive and responsive to the needs of people 
who inject drugs.
Access can be facilitated through the co-location of interventions at a single site or through strong 
and coordinated linkage and referral between different service providers. Establishing active referral 
pathways and protocols that foster such linkages might require the following:
•	 The referring service has a roster of services to which clients may be referred and has links 
with these services.
•	 Services to which clients are referred are sensitive, supportive and responsive to the needs of 
people who inject drugs, are located close to the referring service or are easily accessed by 
the client.
•	 Follow-up and continuity of care is strengthened through case management instituted by the 
referring service.
Strategies such as accompanied or peer-facilitated referral may also help to increase the success of 
referral.
A number of the proposed indicators examine the extent of this integration and related levels of 
coverage.
Availability
HTC.A.1: •	 Number	of	PWID-targeted	services	where	HTC	is	provided
ART.A.2: •	 Number	of	PWID-targeted	services	where	ART	is	provided
Hep.A.1: •	 Number	of	PWID-targeted	services	providing	HBV	vaccination	
Hep.A.2: •	 Number	of	PWID-targeted	services	and	ART	provision	sites	providing	HBV	treatment	
Hep.A.4: •	 Number	of	PWID-targeted	services	and	ART	provision	sites	providing	HCV	management	and	treatment
TB.A.2: •	 Number	of	PWID-targeted	services	providing	TB	preventive	therapy
TB.A.3: •	 Number	of	PWID-targeted	services	providing	TB	diagnosis	and	treatment
Coverage
STI.C.1: •	 PWID	screened	or	treated	for	STIs	at	services	targeting	PWID
Cdm.C.1: •	 Quantity	of	condoms	distributed	by	services	targeting	PWID
Hep.C.1: •	 PWID	receiving	HBV	vaccination	from	PWID-targeted	services
Hep.C.2: •	 PWID	receiving	HBV	treatment	from	PWID-targeted	services	and	ART	provision	sites	
Hep.C.3: •	 PWID	receiving	HCV	treatment	from	PWID-targeted	services	and	ART	provision	sites.
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3.2 MEASURING POPULATION SIZE
To measure whether services are of sufficient scale, it is necessary to know the size of the population 
being targeted. 
Many of the indicators of coverage described here involve measuring the proportion of the target 
population who have been reached or who have received an intervention.
For example, a generic coverage indicator to determine the percentage of the target population who 
have received an intervention can be defined as:
  Number of people who received intervention 
x 100
Total number of people in the target population 
Thus, estimates of the target population are required for the denominator in these indicators (hence, 
these are sometimes referred to as “denominator populations”); programme data are used for the 
numerator. 
The indicators described in this document relate to interventions that target a number of different, 
specifically defined populations. Accordingly, to determine coverage for these specific populations, it 
is necessary to make size estimates for each population.
To be able to disaggregate indicator data, it is necessary for these population size estimates to be 
disaggregated as well. Therefore, population estimates need to be made for different gender and age 
groups and in some cases for the type of drug injected.
ESTIMATING	THE	SIZE	OF	PWID	POPULATIONS
Estimates of the prevalence of injecting drug use and the number of people who inject drugs are 
required as the denominators for many of the indicators described in this Guide. 
Estimating the prevalence of injecting drug use requires defining a PWID. Various criteria may be applied, 
depending on the purpose of the estimate. Generally, the most important defining criterion relates to 
the time period when a person has injected a drug.  
Estimating the prevalence of “lifetime injecting drug use”, or the number of people “who have ever injected 
drugs”, is applicable to determining how many people may have ever been exposed to injecting-related 
harms; for example, it may be relevant to look at those who engaged in injected drug use in the period 
since the emergence of HIV in a particular location in order to estimate the number of people potentially 
exposed to HIV though injecting drug use.
A variety of definitions for “current injecting drug use”, or “active PWID”, exist in the literature or are 
used by different bodies. Such estimates are needed to determine the size of the target population for 
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interventions such as NSPs. For the purpose of the indicators in this guide, the definition of an 
active PWID is a person who has injected at any time within the past 12 months. This definition 
of active PWID is particularly relevant for an indicator that looks at the provision of services for PWID 
over a 12-month period. It is important to note, however, that some data reporting systems use other 
definitions. For example, the European Monitoring Centre on Drugs and Drug Addiction (EMCDDA) 
defines people who inject drug as those who have injected in the last four weeks. 
In some countries people may self-inject medicines for medical purposes. This practice is commonly 
referred to as therapeutic injection and is distinct from injecting drug use, which is the focus of this 
guide. Those who have self-injected medicines for medical purposes only (rather than self-injection 
of pharmaceuticals for non-medical purposes) are not included in the definition of injecting drug use 
given above.
Because injecting drug use and drug dependence occur predominantly amongst adults, it is common 
practice to calculate estimates of injecting drug use prevalence and population size for adult 
populations—for example, those ages 15 to 64 years. This approach is taken by organizations such as 
the EMCDDA and in global reviews undertaken by the Reference Group to the United Nations on HIV 
and Injecting Drug Use (90).
Determining the size of PWID populations can be challenging. Surveys of the general population, such as 
household surveys, may markedly underestimate the prevalence of injecting drug use—because injectors 
are less likely to be included in the sample and because drug injecting is an illicit and stigmatized 
behaviour that respondents are likely to be reluctant to disclose. Indirect estimation methods, such 
as multiplier and benchmark calculations that make use of existing data sources (police arrest data, 
drug-dependence treatment data, drug-related deaths) and capture–recapture methods are extremely 
useful; guidance on these methods is available (see box). 
It is important to clarify here that use of data from multiple sources for the purpose of population size 
estimation does not require linkage of these data sources or sharing identifying data from treatment 
or other services with law enforcement agencies. As stated elsewhere in this document, it is important 
to maintain the confidentiality of individuals utilizing drug treatment services and other HIV prevention 
programmes.
ENSURING DENOMINATORS AND NUMERATORS MATCH
Most of the interventions in the Comprehensive Package target PWID irrespective of the type of 
drug they may use. OST programmes, however, obviously are relevant specifically to people who are 
opioid-dependent, including both those who inject and those who use opioids via non-injecting routes 
of administration. Hence, for the purpose of estimating coverage of OST programmes, it is necessary 
to estimate the number of people who are opioid-dependent and the number of PWID who are opioid-
dependent. 
If interventions specific to other substances are also underway, the relevant population size estimates 
should be made. For example, if the coverage of a programme that specifically addresses stimulant 
dependence is to be measured, an estimate of the number of stimulant-dependent PWID is required.
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QUALITY OF POPULATION SIZE ESTIMATES
When interpreting an indicator that has been calculated using an estimate of population size, it is 
important to consider the source of the data and how it was derived. Some methods of estimation are 
more reliable than others, particularly when attempting to measure the size of drug-using populations. 
The following framework ranks methods used to estimate prevalence and population size. It is adapted 
from a grading system used in global reviews undertaken by the Reference Group to the United Nations 
on HIV and Injecting Drug Use (90). Grades range from Grade A, the highest, to the Grades C or D, 
the lowest.
Estimates of the prevalence of drug dependence and injecting drug use
Grade A: •	 Indirect	prevalence	estimation	methods	(e.g.	capture–recapture,	multiplier	methods,	etc.)
Grade B: •	 General	population	surveys
Grade C: •	 Experts’	judgement	informed	by	evidence	gathered	through	various	methods	(e.g.	rapid	assessment)
•	 Delphi	method	or	other	consensus	estimates
•	 Government	registration	of	drug	users.
Estimates of the prevalence of HIV, hepatitis C virus among people who inject drugs
Grade A: •	 Sero-prevalence	studies	involving	samples	from	multiple	sites	(including	sentinel	surveillance	sites)	and	
sample	types	(e.g.	treatment	service	or	outreach-based	samples)
Grade B: •	 Sero-prevalence	studies	involving	a	single	sample	type	and/or	a	single	site
Grade C: •	 Registration	or	notification	of	cases	of	HIV	or	HCV	infection
Grade D: •	 Prevalence	studies	using	self-reported	HIV	or	HCV	status.
The most recent and highest graded prevalence and population size estimates available should be used 
when calculating coverage indicators. 
The limitations of estimation methods should be acknowledged and considered when interpreting 
indicators that involve prevalence and population size estimates.
There may be some instances in which an estimate of prevalence or population size is given in a 
document or report, but there is no indication of the method by which the estimate was derived. It is 
strongly recommended to avoid using estimates if their methodology is unknown, as any limitations 
and related uncertainty cannot be accounted for. 
The use of HIV prevalence estimates based on self-reported HIV status (Grade D), rather than on 
diagnostic tests of sero-status, also should be avoided.
It is recommended that national expert group meetings be held regularly to evaluate available data 
and to reach consensus on the estimate or range of estimates that should be used. These meetings 
should involve researchers and key government personnel, NGOs and organizations of people who 
use drugs. Member States are encouraged to organize such meetings annually to facilitate response 
to the mandated UNODC Annual Reports Questionnaire, which includes items related to population 
size estimates.
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Where recent, high-quality estimates are not available, it is recommended that countries make efforts 
to acquire such estimates. Technical and financial resources are required for such estimation research 
activities. If resource constraints exist, countries can seek external donor assistance for these types 
of research activities as part of funding for the broader response to HIV. The Global Fund encourages 
countries to include population size estimation activities in funding applications and in ongoing grants, 
as one of the monitoring and evaluation system strengthening activities for improving the availability of 
data on key populations at risk (112). Similarly, PEPFAR supports operational research and strengthening 
of monitoring and evaluation systems (113).
If an appropriate population size estimate is not available for use as the denominator, it is 
still useful and important to record and report the indicator numerator. The numerators alone 
can provide some useful, although limited, indication of the extent of programme delivery and 
may be particularly useful in monitoring progress over time as well as assist with estimating 
population size.
Sources of guidance on population size estimation methods
•	 UNAIDS/WHO	Working	Group	on	Global	HIV/AIDS	and	STI	Surveillance.	Guidelines on estimating the 
size of populations most at risk to HIV.	Geneva,	World	Health	Organization,	2010	(114).	 
http://www.who.int/hiv/pub/surveillance/final_estimating_populations_en.pdf
•	 Estimating prevalence: indirect methods for estimating the size of the drug problem.	Vienna,	United	
Nations	Office	on	Drugs	and	Crime,	2003	(115).	 
http://www.unodc.org/documents/data-and-analysis/statistics/Drugs/GAP_module_2.pdf
•	 Hickman	M	et	al.	Estimating	the	prevalence	of	problematic	drug	use:	a	review	of	methods	and	their	
application.	UN Bulletin on Narcotics,	2002,	54:15−32	(116).	 
http://www.unodc.org/pdf/bulletin/bulletin_2002_01_01_Art2.pdf
•	 U.S.	Department	of	Health	and	Human	Services,	Centers	for	Disease	Control	(HHS-CDC),	GAP	
Surveillance	Team.	Most at risk populations sampling strategies and design tool.	Atlanta,	HSS-CDC,	
2009	(117).	 
http://globalhealthsciences.ucsf.edu/sites/default/files/content/pphg/surveillance/CDC-MARPs/index.htm 
3.3 MEASURING THE AVAILABILITY OF INTERVENTIONS
To assess the availability of interventions in the Comprehensive Package, several types of indicators 
are proposed.
RESTRICTIONS ON ACCESS
For ART and HCV treatment, the presence of restrictions on access for people who inject drugs should 
be recorded (i.e. specifically whether or not a person who currently injects or who has previously injected 
drugs is excluded from access to treatment).
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TYPE OF INTERVENTION AVAILABLE
For drug dependence treatment, the type of treatment available is recorded. It is useful when evaluating 
and reporting on the provision of drug dependence treatment to describe the specific treatment 
modalities available. Several main categories are defined; these are based on categories used by the 
WHO Mental Health and Substance Abuse department in the ATLAS on substance use (31). They include:
•	 agonist opioid substitution therapy (OST) (as maintenance treatment)
•	 inpatient detoxification
•	 outpatient drug dependence treatment
•	 inpatient short-term treatment
•	 inpatient or residential long-term treatment
•	 peer-based support groups
•	 brief interventions provided in non-specialized settings.
NUMBER	OF	SITES	WHERE	INTERVENTION	IS	AVAILABLE
Definitions of what constitutes an intervention site differ for each intervention; suggested definitions 
are provided for each indicator in section 4.
For the purpose of assessing the provision of non-drug-user-specific interventions to people who inject 
drugs, this guide includes indicators examining the delivery of these interventions by services targeting 
people who inject drugs as well as the integration and linkage with mainstream services. 
For example, in the case of HIV testing and counselling, the following indicators are proposed:
•	 Number and percentage of NSP sites providing HIV testing and counselling;
•	 Number and percentage of drug dependence treatment sites providing HIV testing and 
counselling;
•	 Number of other services that target PWID (such as drop-in services or health centres targeting 
PWID specifically) and that offer HIV testing and counselling;
•	 Are there any mobile or outreach services targeting PWID that provide HIV testing and 
counselling in community settings?
If data from the first three of these indicators are aggregated, it is important to avoid multiple counting 
of single service provision sites. This can be done by using a unique identifier code system common 
across multiple services (see section on unique identifier codes, page 46).
Part of the assessment of the quality of NSPs examines the processes of drug dependence treatment 
services for referral of clients to other services providing essential interventions (for example, HIV 
testing and counselling). Referring a client or patient to another service is only the first step in the 
referral process. Follow-up by the service from which the client is referred and support of the client by 
both services to facilitate a successful referral may also be required.
An established referral pathway may involve the following:
•	 The referring service has a roster of services to which clients may be referred and has formalized 
arrangements with these services.
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•	 Services to which clients are referred are sensitive, supportive and responsive to the needs of 
PWID, are located close to the referring service or are easily accessible to the client.
•	 Follow-up and continuity of care are strengthened through case management instituted by the 
referring service.
LOCATION	OF	SITES	WHERE	INTERVENTION	IS	AVAILABLE
Because NSP and OST typically require daily access, indicators are proposed that seek to map the 
availability of the intervention in areas where people who inject drugs are located. 
In an assessment of availability at the national level, it is recommended that the presence or absence 
of the intervention in different sub-national areas be examined. For the purpose of this assessment, 
various levels of sub-national division may be used. 
For the simplest application of this assessment, a country’s administrative divisions could be used: for 
example, in the Russian Federation it may be useful to look at availability in oblasts and in China, in 
provinces; while in India or Pakistan states might be examined. 
The percentage of cities/states/provinces/oblasts where injecting occurs and where the intervention 
is present is calculated using the following:
 Numerator the number of cities/states/provinces/oblasts where the intervention in question is present.
Denominator the number of cities/states/provinces/oblasts where injecting drug use is known to occur.
Injecting drug use may not be present throughout a country; it may be absent in some states or provinces. 
For the purpose of this indicator, the intervention in question is counted as present only in those cities/
states/provinces/oblasts where injecting is known to occur.
Because different countries will have different types and sizes of sub-national areas defined, it may 
not be possible to compare findings from different countries for this indicator.
It is also possible to use other geographic units with this indicator. For example, it might be useful to 
look just at urban centres and to measure the percentage of cites where an intervention is present. 
Programme planners may even wish to look at the availability of an intervention within a city and so 
may look at the percentage of city districts or suburbs where an intervention is present. 
This indicator offers a crude means to identify areas where people who inject drugs are located but 
services are lacking. Access to services is not determined by location alone, however, but also by 
factors such as hours of operation, acceptability of services to the intended clients, police activity and 
many other factors. These other factors are examined in more detail as part of indicators assessing 
service quality.
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3.4 MEASURING INTERVENTION COVERAGE 
The term “coverage” in the context of preventing HIV among people who inject drugs has been used 
to describe various aspects of reach and intervention effectiveness (118). 
In this guide “coverage” describes the extent to which an intervention is delivered to the target 
population. Various indicators are defined to estimate the scale of services delivered relative to the 
estimated size of the target population. 
The majority of the coverage indicators included in this Technical Guide involve the use of programme 
data and population size estimates to estimate percentage levels of coverage. For example, a generic 
coverage indicator to determine the percentage of the target population who have received an 
intervention can be defined as: 
  Number of people who received intervention 
x 100
Total number of people in the target population 
If a suitable population size estimate is not available to be used as a denominator, collecting 
and reporting the numerator data is still recommended. Even by themselves these data are 
valuable for assessing the scale of service delivery and progress over time. As noted above, it is 
important that countries still make efforts to estimate population size even where reliable and recent 
estimates are unavailable. It is important, also, that the population size estimate used as the denominator 
in these coverage indicators is appropriate for the intervention and numerator being measured. The 
reliability of coverage estimates derived by these methods depends upon the completeness and quality 
of both the programme data and the population size estimate. 
Different coverage measures are defined for the different interventions in the Comprehensive Package. 
These different indicators reflect the varied nature of these interventions, the manner in which they are 
provided and the type of exposure that is required for them to have the desired impact. For example, 
in order to be effective, some interventions such as OST require ongoing or daily exposure, while for 
others, such as HIV testing and counselling, contact needs to occur only periodically.
Coverage may also be assessed using surveys of samples from the target population. Many of the 
injecting drug use-related indicators in the Global AIDS Response progress report (previously referred 
to as UNGASS core indicators) involve this survey methodology. The reliability of the findings from 
such surveys depends on how representative the sample is of the broader population of people who 
inject drugs. Bias may be introduced, particularly when measuring intervention exposure, if a sample 
is recruited at a point of service delivery.
It is important to recognize the limitations of these different methods of estimating coverage. 
Triangulation may be possible if coverage estimates derived by several of these methodologies are 
available. 
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REPORTING PERIOD
The majority of the recommended coverage indicators described in this document measure the 
delivery of interventions over a defined reporting period. For the proposed indicators the duration of the 
recommended reporting period is typically 12 months, this being a natural reporting period for many 
registry and programmatic data collection systems. It may be useful and appropriate in some contexts, 
however, to define different reporting periods. In particular, donors such as the Global Fund or PEPFAR 
may require reporting at 3- or 6-month intervals.
UNIQUE IDENTIFIER CODE
For some of the recommended indicators, it is important to distinguish between the number of clients 
accessing a service and the number of client contacts for that service. A common problem in data 
collection is that programmes record the number of contacts with clients and then confuse this with the 
number of clients reached. To avoid such double-counting, a strictly anonymous system of identifying 
clients and recording their return visits may be necessary. A common method is to provide each client 
with a unique identifier code (UIC). This code enables a service to record individual clients’ patterns 
of attendance. In particular, it can reveal whether a client is reached regularly by a service such as a 
NSP (27,119), without the need to collect identifying information such as names or government-issued 
ID numbers. Coverage can be even more accurately measured if the same UIC is used across different 
services. Services in different countries have developed various but similar UIC systems. 
The coding system should be easy for a client to recall and must protect clients’ confidentiality by 
ensuring that the UIC cannot be decoded to reveal the identity of the client. 
Below is an example of the unique identifier code developed by Population Services International 
(PSI). Other organizations, including the WHO Western Pacific Regional Office, have developed similar 
approaches.
Below	is	an	example	of	the	unique	identifier	code	developed	by	Population	Services	International	(PSI).	
Other	organizations,	including	the	WHO	Western	Pacific	Regional	Office,	have	developed	similar	approaches.
Each individual is given a simple 7-character code composed of the following
•	 the	first	two	letters	of	the	client’s	mother’s	first	name
•	 the	first	two	letters	of	the	father’s	first	name	
•	 gender	(single	letter	M/F	or	number)
•	 year	of	birth	(last	two	digits).
For	example,	 for	a	male	client	 in	Ukraine,	born	 in	1972,	whose	mother’s	name	 is	Anastasiya	and	whose	
father’s	name	is	Grigor,	the	unique	identifier	code	would	be:	AN	GR	M	72.
These coding systems can be adapted to local contexts as needed. For example, in Viet Nam many 
names have the same first letters. Therefore, an additional 3-letter code for the client’s province of 
birth was inserted to ensure that codes are unique.
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It is important that services targeting PWID are easily accessible. To avoid creating any barriers to 
access, any identification coding system should not be compulsory or otherwise deter people from 
accessing a service. Maintaining privacy and confidentiality should be paramount, and clients should 
feel safe using these services. 
Sources of guidance on unique identifier code systems
•	 Unique	identifier	code.	USAID-funded	drug	demand	reduction	program	in	Uzbekistan,	Tajikistan	and	
the	Ferghana	Valley	region	of	Kyrgyzstan.	DDRP	Best	Practice	Collection.	Almaty,	Alliance	for	Open	
Society	International,	2007	(119).	 
http://www.aidsprojects.com/wp-content/themes/apmg-1.0.1/documents/UIC_Eng.pdf
•	 Guide to starting and managing needle and syringe programmes.	Geneva,	World	Health	Organization,	
2007	(27).	 
http://www.who.int/hiv/pub/idu/needleprogram/en/index.html
•	 Nga	NT	et	al.	Innovative data tools: a suite for managing peer outreach to key affected populations in 
Viet Nam.	Western	Pacific	Surveillance	and	Response	Journal,	2012	(136).	 
http://www2.wpro.who.int/NR/rdonlyres/42837210-F3DB-4FCC-9C26-220202E9CD55/0/201232003_LFF_
HIV_VNM_Nga.pdf
COLLECTING AND AGGREGATING DATA FROM PROGRAMMES
Most of the coverage indicators described in this document require collecting data from services 
either on the number of people who use that service or receive an intervention or else on the total 
quantity of condoms or injecting equipment distributed. These data must be gathered from multiple 
sources. To allow for aggregation of these data from multiple sources, the methods used need to be 
consistent across all sites. In most countries, however, these data are not collected by a single agency 
and not centrally organized or collated. Having a single, national-level agency responsible for regularly 
collating and reporting national data is highly advantageous. Web-based databases can facilitate data 
aggregation from different services. If the Internet is not available, offline computers or paper-based 
recording systems can be used. Use of UICs across different services avoids double counting when 
collating data from multiple services.
It is important that data remain confidential and that data and medical records identifying 
people as users of drugs are not shared with law enforcement agencies, particularly in countries 
where drug use is criminalized.
An example of a system collating data from different services is described in the following 
report:
•	 HIV/AIDS	Asia	Regional	Program	Technical	Support	Unit,	Yunnan	Provincial	HIV/AIDS	Prevention	
and	Control	Bureau,	Yunnan	Public	Health	Bureau.	Making it count: using online data for effective 
monitoring and evaluation of harm reduction activities in Yunnan Province, China.	Bangkok,	
Commonwealth	of	Australia,	AusAID,	2011	(120).	 
http://www.haarp-online.org/LinkClick.aspx?fileticket=Hbx6twF4x_E%3d&tabid=2348&mid=4554
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3.5 MEASURING INTERVENTION QUALITY 
Quality encompasses the scope, completeness, effectiveness, efficiency and safety of interventions 
and, importantly, acceptability to the target group. The quality of an intervention makes a vital difference 
to its impact on the epidemic (121). For example, the efficacy of OST in reducing drug use and HIV 
incidence is well established, but how OST is delivered influences the effectiveness of the programme: 
OST programmes delivering low-dose methadone have less impact than those delivering higher doses; 
OST provided in combination with psychosocial support is more effective and will have a greater impact; 
programmes that allow for take-home doses and referral for transfer to other OST programmes facilitate 
better coverage and better adherence to treatment (32,122).
Defined quality standards for the implementation of an intervention can be understood as either 
enhancing the effectiveness of the intervention or improving access to and, hence, the coverage of 
the intervention. 
The first version of the Technical Guide recommended that countries report whether or not interventions 
from the Comprehensive Package were implemented adhering to relevant national or international 
guidelines. In this revision a similar but expanded method of assessing quality is proposed for the two 
drug-user-specific interventions of the Comprehensive Package (NSP and OST) and for ART for PWID. 
Policy and service delivery checklists have been developed of “quality factors” that are important for 
these interventions to be most effective. These checklists are based on endorsed guidelines developed 
by WHO and other organizations.  
The policy checklists assess the presence of policy or legislation that facilitate or enhance the delivery 
and effectiveness of these interventions.
The service delivery checklists assess how these interventions are implemented at the programme 
or site level. These can be used individually (i.e. for a single site or programme), or the results can be 
aggregated at the national level to determine what proportion of sites adhere to a particular quality 
standard. For example, if 30 of the 40 NSP sites in a country report adhering to the quality standard 
“Systems are in place to ensure that stock-outs do not occur”, then 75% of the sites in the country 
adhere to this standard.
Not all the items in these checklists will be relevant in every context; these lists should be adapted to 
local settings. Adaptation should take into account evidence concerning which factors are important 
to the effectiveness of interventions.  
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In addition to these checklists, several recommended indicators measure the percentage of clients 
receiving an intervention that meets specific quality criteria. These include:
OST.Q.3: •	 Individuals	receiving	OST	continuously	for	at	least	six	months
OST.Q.4: •	 Patients	receiving	maintenance	OST	dose	greater	than	or	equal	to	the	recommended	minimum	dose
OST.Q.5: •	 Patients	on	maintenance	OST	receiving	psychological	support
ART.Q.3: •	 PWID	on	ART	receiving	adherence	support	
ART.Q.4: •	 PWID	on	ART	receiving	case	management
Several of the coverage and access indicators may also be considered to measure quality. These include:
HTC.A.1: •	 Number	of	PWID-targeted	services	where	HTC	is	provided
IEC.C.1: •	 Frequency	of	NSP	occasions	of	service	where	IEC	is	provided
3.6 MEASURING THE OUTCOME AND IMPACT OF INTERVENTIONS 
These guidelines are not primarily concerned with directly measuring the impact of interventions. 
However, a number of indicators measuring various outcomes are briefly described. 
HIV INCIDENCE
Changes in HIV incidence give the best indication of the impact of HIV prevention interventions, but 
they may be difficult to measure among populations of people who inject drugs. Various methods may 
be used to estimate incidence indirectly, but limitations of each method must be considered when 
interpreting results. 
HIV prevalence among new initiates to injecting drug use or among young people who inject drugs can 
be used as a proxy measure of incidence. Measurement of prevalence among new injectors requires 
integrated behavioural and sero-surveillance—the latter to measure prevalence and the former to allow 
for disaggregation on the basis of duration of injecting history. Measurement of prevalence among 
young people also requires surveillance data to be disaggregated by age.
Inferring incidence from case reporting systems for newly noted infections is problematic. An individual’s 
injecting drug use status or history may not be identified in these systems, and other transmission 
categories may be recorded even if an individual has a history of injecting drug use. In addition, 
presenting late, a considerable time after the initial infection, is not uncommon among people who 
inject drugs.
Using a serological recent infection testing algorithm (RITA) to identify new infections can offer some 
precision in estimating incidence (123). Its routine use in HIV surveillance systems may be beyond the 
resources and technical capacity available in many settings, however.
In addition, mathematical modelling may be used to estimate HIV incidence at the population level (124).
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HIV PREVALENCE
HIV prevalence can be measured more easily than incidence, but it must be interpreted carefully when 
attempting to discern changes in rates of new infection. Increases in observed HIV prevalence could 
be the result of improved surveillance and testing techniques; apparent decreases could be the result 
of increased stigmatization and, thus, greater reluctance of people who inject drugs to be tested, while 
real decreases could be the result of mortality or out-migration of PWID living with HIV. In addition, when 
access for PWID to effective HIV treatment and care is improved, HIV prevalence is likely to increase 
as the life expectancy of HIV-positive people who inject drugs increases, even if the incidence of HIV 
infection remains stable or decreases.
HIV RISK BEHAVIOURS
Model projections suggest that interventions that reduce injecting frequency and the sharing of used 
injecting equipment can reduce HIV transmission. Case studies suggest that high coverage of HIV 
prevention interventions for people who inject drugs may avert or delay a potential HIV epidemic in this 
group and its further spread to the general population (125,126).
Therefore, outcome indicators that examine changes in HIV risk behaviour, such as the use of injecting 
equipment used previously by someone else, frequency of injecting and condom use, can be useful in 
assessing the impact of the Comprehensive Package. Of course, observed changes in these behaviours 
will always be due to multiple factors and a combination of interventions. In most cases, changes cannot 
be attributable to a single, isolated intervention or to a single project or programme.
Of the nine outcome and impact indicators described in this document, five rely on data from behaviour 
surveillance surveys. Many countries already undertake such surveys as part of the ongoing monitoring 
of the HIV epidemic and may periodically survey injecting drug users as a specific population. The Family 
Health International Behaviour Surveillance Survey (BSS) (127) is commonly used; it assesses HIV risk-
related behaviours such as condom use and safe injecting practices as well as access to HIV testing. 
When undertaking behavioural or sero-surveillance studies of people who inject drugs, and when 
interpreting results from them, it is important to consider the representativeness of the samples recruited 
and the extent of potential bias associated with how and where participants are recruited. It may be 
difficult to recruit samples of people who inject drugs that are representative of the broader PWID 
population. Significant bias may result if samples are drawn from a limited number and range of locations 
or if recruitment occurs primarily through services such as treatment centres or NSPs. Methods such 
as respondent-driven sampling may reduce such bias, but they require specific technical capacity and 
resources and take time to complete (128). 
Collection of demographic and other data in surveillance studies makes possible useful disaggregation 
and analysis. For example, differences can be discerned between younger and older individuals and 
between men and women.  
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Sources of guidance on HIV surveillance
•	 UNAIDS/WHO	Working	Group	on	Global	HIV/AIDS	and	STI	Surveillance.	Guidelines on surveillance 
among populations most at risk for HIV.	Geneva,	Joint	United	Nations	Programme	on	HIV/AIDS,	2011	
(129).	 
http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2011/20110518_
Surveillance_among_most_at_risk.pdf
•	 Surveillance surveys: guidelines for repeated behavioural surveys in populations at risk of HIV.	
Raleigh,	Family	Health	International,	2000	(127).	 
http://www.fhi360.org/en/HIVAIDS/pub/guide/bssguidelines.htm
•	 Salganik	M,	Heckathorn	D.	Sampling	and	estimation	in	hidden	populations	using	respondent-driven	
sampling.	Sociological Methodology,	2004,	34(1):193−240	(128).
3.7 DISAGGREGATION 
Injecting drug user populations are diverse. Within these populations various characteristics may be 
associated with differing HIV risk, rates of service utilization and health outcomes. In the monitoring of 
the coverage and impact of the Comprehensive Package, it is valuable to disaggregate data in order 
to identify disparities that may exist and that should be addressed.
 
DISAGGREGATION BY GENDER
Compared with their male peers, women and girls who inject drugs often face additional barriers to 
accessing HIV prevention and care services (130). Furthermore, PWID who identify as transgender 
typically face significant levels of discrimination and marginalization. Therefore, it can be useful to 
collect gender-disaggregated data and to use these along with gender-specific denominator estimates 
to assess and monitor this disparity.
DISAGGREGATION BY AGE
In many settings young people may have poorer rates of access to HIV prevention and care services. This 
may be due to a variety of reasons, including age discrimination by programmes, laws or policies that deny 
services to people under a certain age, and young people’s feeling that services do not meet their needs. 
Therefore, we propose to disaggregate indicator data into three age groups1:
•	 18 years of age or younger (≤ 18 years)
•	 older than 18 years of age and younger than 25 years of age (>18 years and <25 years)
•	 25 years of age and over (≥25 years).
DISAGGREGATION BY TYPE OF DRUG INJECTED
The type of drug that a person injects can have some impact on HIV risk. For example, use of 
amphetamine-type stimulants is associated with elevated sexual risk and, in some instances, with 
increased frequency of injection. Also, the type of drug on which a person is dependent has important 
1 These age disaggregations were decided following consultation with partners.
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implications for treatment options. Disaggregating by drug type injected is recommended as follows: 
•	 opioids (including pharmaceutical opioids, heroin, other opium derivatives)
•	 stimulants (including cocaine and amphetamine-type stimulants)
•	 other (might include benzodiazepines, barbiturates and other depressants or psychotropic 
substances).
It is important to note that poly-drug use is common in many settings, with people using more than one 
type of drug, including some via injecting and others via other routes of administration.
3.8 SETTING TARGETS
It is important to set targets for each of the indicators described in the preceding sections in order 
to strategically plan and build an effective response to the epidemic among people who inject drugs. 
Targets should be set with the aim of achieving reductions in HIV risk sufficient to control the epidemic. 
Targets for outcome measures—in particular, the prevalence and incidence of HIV—also are important. 
In the 2011 Political Declaration on HIV/AIDS, Member States committed to reducing transmission of 
HIV among people who inject drugs by 50% by 2015 (8).
Targets will differ in different countries and should reflect local factors, including the nature of the HIV 
epidemic and of injecting drug use, the current stage of the response, the available resources and 
capacity, and structural factors that shape risk and influence the impact of interventions. It is therefore 
necessary for countries to undertake a process for setting targets relevant to their own epidemic and 
context. Targets should be aspirational but also achievable; a pragmatic approach is necessary. 
It is useful to measure first the scale of the current response and then to consider how much scale-up 
is possible within a set time period, given available resources and technical capacity and how much 
additional capacity and resources can be mobilized. 
Because the interaction of the numerous factors determining HIV risk and intervention impact in a 
particular setting is complex, there is no universal formula for target setting. It is possible, however, to 
draw on the various types of evidence available, gathered from a range of different settings, to propose 
evidence-based targets relevant to the local setting.
Multiple factors may affect the impact of an intervention in preventing HIV and should be considered 
when setting targets. In the case of preventing injecting-related HIV transmission, such factors include:
•	 availability and coverage of other interventions from the Comprehensive Package (interventions 
delivered in combination have the greatest impact)
•	 existing prevalence of HIV among people who inject drugs
•	 HIV prevalence among the general population
•	 the prevalence and frequency of using injecting equipment previously used by another person
•	 the length of time used syringes remain in circulation, during which time they may be reused 
multiple times
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•	 methods of disposal of used syringes, including the coverage and utilization of safe disposal 
systems for used equipment
•	 size and connectedness of injecting drug user networks and the mobility of people who inject drugs 
•	 on average, the number of other people whose used injecting equipment a PWID re-uses 
•	 frequency of injecting
•	 types of drugs injected
•	 types of syringes used (those with larger dead-space volume may pose greater risk of 
transmission) (28,29).
This	Technical	Guide	presents	indicative target levels	for	selected	indicators,	defined	broadly	as	low,	mid	
or	high. For	example:
•	 Percentage of PWID who were regularly reached by NSPs over the last 12 months	(NSP.C.2)
	 Low	<20%;	Mid	20%	–	60%;	High	>60%
•	 Percentage of opioid dependent people on OST	(OST.C.1)
	 Low	<20%;	Mid	20%	–	40%;	High	>40%
•	 Percentage of PWID living with HIV on ART	(ART.C.1)
	 Low	<25%;	Mid	25%	–	75%;	High	>75%
These targets are intended to be broadly indicative only, and countries will need to consider the local 
context to assess what levels they should aim to achieve. The targets selected should enable those 
implementing programmes to know whether they are making a difference to the epidemic and to what 
level services should be maintained or expanded to effectively control the epidemic. In the future, as 
new and more robust evidence emerges, these indicative target levels may be revised.
It important to note that when setting targets for indicators that require a reliable population 
size estimate, but where no such estimates are available it is still important to set targets for 
the numerator of these indicators. For example, if there is no population size estimate for PWID 
when setting targets for the distribution of clean injecting equipment it would be useful to set 
targets for the total dispense number of needles-syringes.
General principals to consider when setting target levels
•	 Intervention impact is greatest when multiple interventions are available—most significantly, when 
NSP, OST and ART are all available.
•	 Higher	quality	interventions	deliver	greater	impact	than	those	that	are	implemented	at	lower	quality.
•	 Greater	levels	of	coverage	are	superior	to	lower	levels,	usually	until	a	maximum	optimal	level	is	reached.
•	 While	greater	intervention	coverage	brings	about	greater	reductions	in	HIV	risk	and,	hence,	incidence,	
this	relationship	is	not	necessarily	linear.
•	 The	higher	the	level	of	HIV	prevalence	(both	in	the	general	population	and	among	people	who	inject	
drugs),	the	greater	the	level	of	prevention	coverage	that	will	be	required	(131).
•	 The	earlier	in	an	epidemic	that	an	intervention	is	introduced,	the	more	effective	it	can	be	in	controlling	
the	spread	of	HIV.
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How should countries go about setting targets?
•	 The	target	setting	process	should	be	collaborative	and	should	involve	input	from	a	range	of	stakeholders,	
including	representatives	from	government	and	civil	society,	PWID	representatives,	service	providers	
and	clinicians.
•	 A	useful	starting	point	is	for	countries	to	map	available	services	countrywide,	disaggregated	by	types	of	
services.
•	 Following	the	mapping	of	services,	the	next	step	would	be	to	measure	current	levels	of	coverage,	to	
serve	as	a	baseline	for	gauging	future	progress.
•	 Population	size	estimates	also	should	be	undertaken,	in	order	to	understand	the	scale	of	the	response	
required;	these	population	size	estimates	are	used	to	calculate	estimates	of	coverage	indicators.
•	 Countries	are	encouraged	to	determine	realistic	and	achievable	target	levels	that	they	wish	to	achieve	
and	the	time	period	in	which	to	achieve	them.
•	 It	is	also	recommended	to	establish	or	refine	existing	service	monitoring	practices	to	improve	the	tracking	
of	progress	toward	these	targets.	
•	 Countries	should	consider	what	resources	are	available	and	what	additional	resources	are	required	to	
reach	targets	and	have	an	impact	on	the	HIV	epidemic.
3.9 NEXT STEPS AFTER SETTING TARGETS
Once targets have been set, they need to be operationalized and monitored. This requires an operational 
plan and a monitoring and evaluation framework based on these targets. Guidance on this process is 
beyond the scope of this document but is provided in the documents listed below.
Sources of guidance on operationalization and on monitoring and evaluation of interventions
•	 Guide to starting and managing needle and syringe programmes.	Geneva,	World	Health	Organization,	
Department	of	HIV/AIDS,	2007	(27).	 
http://www.who.int/hiv/pub/idu/needleprogram/en/index.html
•	 Guidelines for psychosocially assisted pharmacotherapy for the management of opioid dependence.	
Geneva,	World	Health	Organization,	2009	(39).	 
http://www.who.int/hiv/pub/idu/opioid/en/index.html
•	 Drug abuse treatment and rehabilitation: a practical planning and implementation guide.	Vienna,	
United	Nations	Office	on	Drugs	and	Crime,	2003	(132).	 
http://www.unodc.org/pdf/report_2003-07-17_1.pdf
•	 A framework for monitoring and evaluating HIV prevention programmes for most-at-risk populations.	
Geneva,	Joint	United	Nations	Programme	on	HIV/AIDS,	2008	(133).	 
http://www.unaids.org/en/media/unaids/contentassets/documents/document/2010/17_Framework_
ME_Prevention_Prog_MARP_E.pdf
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4. INDICATORS
Each	indicator	has	a	reference	number	relating	to	the	type	of	indicator	and	the	intervention	it	examines;	
the	following	convention	is	used:
Abbreviations used to denote indicator type:
Pop	 Population	size	estimate
A	 Availability
C	 Coverage
Q	 Quality
OI	 Outcome/impact
Abbreviations used to denote intervention:
NSP	 Needle	and	syringe	programmes
OST	 Opioid	substitution	therapy
ODT	 Other	drug	dependence	treatment
HTC	 HIV	testing	and	counselling
ART	 Antiretroviral	therapy
STI	 Sexually	transmitted	infection	prevention,	diagnosis	and	treatment
Cdm	 Condom	distribution	programmes	for	PWID	and	their	sexual	partners
IEC	 Targeted	information,	education	and	communication	for	PWID	and	their	sexual	partners
Hep	 Prevention,	vaccination,	diagnosis	and	treatment	for	viral	hepatitis
TB	 Prevention,	diagnosis	and	treatment	of	tuberculosis
NSP A 1aIntervention r R Indicator number
Indicator type
q
4.1 SUMMARY OF INDICATORS
Listed below are indicators proposed for estimating population size and examining availability, 
coverage, quality and outcome/impact of the Comprehensive Package.
In the sections that follow each indicator is explained in greater detail. 
Indicators in bold and noted with an asterisk (✱) can be considered key indicators that countries should 
attempt to measure, as a minimum. Priority key indicators are noted with two asterisks (✱✱). Other 
indicators listed are useful to more fully monitor and evaluate the implementation of the Comprehensive 
Package, contributing to strategic programme development and improvement. 
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POPULATION SIZE ESTIMATES 
✱ Pop.1 Estimated number of people who inject drugs
Pop.2 Estimated	number	of	opioid-dependent	people
Pop.3 Estimated	number	of	opioid-dependent	people	who	inject	drugs
✱ Pop.4 Estimated number of people who inject drugs living with HIV
Pop.5 Estimated	number	of	people	living	with	HIV
Pop.6 Estimated	number	of	people	who	inject	drugs	living	with	HCV
NEEDLE AND SYRINGE PROGRAMMES
✱✱ NSP.A.1 Number and location of sites where needles and syringes are available
✱✱ NSP.C.1 Quantity of needles-syringes distributed
NSP.C.2 PWID	regularly	reached	by	NSPs
NSP.C.3 PWID	reached	by	NSPs
NSP.C.4 NSP	occasions	of	service	(total	contacts)
✱ NSP.Q.1 National policy and legislation—needle and syringe programmes
✱ NSP.Q.2 Quality of NSP service delivery
OPIOID SUBSTITUTION THERAPY AND OTHER DRUG DEPENDENCE TREATMENT 
OST.A.1 Presence	of	maintenance	OST
✱✱ OST.A.2 Number and location of maintenance OST sites
OST.A.3 OST	programme	capacity
ODT.A.1 Presence	of	drug	dependence	treatment,	other	than	maintenance	OST
ODT.A.2 Number	of	drug	dependence	treatment	sites,	other	than	maintenance	OST
✱✱ OST.C.1 Individuals receiving maintenance OST
ODT.C.1 Individuals	receiving	drug	dependence	treatment,	other	than	maintenance	OST
✱ OST.Q.1 National policy and legislation—opioid substitution therapy
✱ OST.Q.2 Quality of OST programme service delivery
✱ OST.Q.3 Individuals receiving maintenance OST continuously for at least 6 months
✱ OST.Q.4 Individuals receiving maintenance OST dose greater than or equal to the recommended minimum dose
OST.Q.5 Individuals	on	maintenance	OST	receiving	psychological	support
HIV TESTING AND COUNSELLING
✱ HTC.A.1 Number of PWID-targeted services where HTC is provided
✱✱ HTC.C.1 PWID tested for HIV in the last 12 months
ANTIRETROVIRAL THERAPY
✱ ART.A.1 Availability of antiretroviral therapy for PWID
ART.A.2 Number	of	PWID-targeted	services	where	ART	is	provided
✱✱ ART.C.1 PWID receiving ART
ART.C.2 Relative	access	to	ART
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✱ ART.Q.1 National policy and legislation—antiretroviral therapy for PWID 
✱ ART.Q.2 Quality of ART service delivery for PWID
ART.Q.3 PWID	on	ART	receiving	adherence	support
ART.Q.4 PWID	on	ART	receiving	case	management
SEXUALLY TRANSMITTED INFECTION PREVENTION, DIAGNOSIS AND TREATMENT
STI.C.1 PWID	screened	or	treated	for	STIs	at	services	targeting	PWID
CONDOM DISTRIBUTION PROGRAMMES FOR PWID AND THEIR SEXUAL PARTNERS
✱ Cdm.C.1 Quantity of condoms distributed by services targeting PWID
Cdm.C.2 PWID	receiving	condoms	in	a	12-month	period
TARGETED INFORMATION, EDUCATION AND COMMUNICATION FOR PWID AND THEIR SEXUAL PARTNERS
✱ IEC.C.1 Frequency of NSP occasions of service where IEC is provided
IEC.C.2 PWID	receiving	IEC
PREVENTION, VACCINATION, DIAGNOSIS AND TREATMENT FOR VIRAL HEPATITIS
Hep.A.1 Number	of	PWID-targeted	services	providing	HBV	vaccination	
Hep.A.2 Number	of	PWID-targeted	services	and	ART	provision	sites	providing	HBV	treatment	
✱ Hep.A.3 Availability of hepatitis C treatment for PWID
Hep.A.4 Number	of	PWID-targeted	services	and	ART	provision	sites	providing	HCV	management	and	treatment
✱ Hep.C.1 PWID receiving HBV vaccination from PWID-targeted services
Hep.C.2 PWID	receiving	HBV	treatment	from	PWID-targeted	services	and	ART	provision	sites	
✱ Hep.C.3 PWID receiving HCV treatment from PWID-targeted services and ART provision sites 
PREVENTION, DIAGNOSIS AND TREATMENT OF TUBERCULOSIS
TB.A.1 TB	infection	control	at	PWID-targeted	services
TB.A.2 Number	of	PWID-targeted	services	providing	TB	preventive	therapy
✱ TB.A.3 Number of PWID-targeted services providing TB diagnosis and treatment
TB.C.1 Assessment	of	PWID	TB	status	by	HIV	treatment	and	care	services
TB.C.2 PWID	living	with	HIV	starting	isoniazid	preventive	therapy	(IPT)
OUTCOME/IMPACT OF INDICATORS
✱ OI.1 Reduced HIV incidence among PWID
✱ OI.2 Reduced HIV prevalence among PWID
✱ OI.3 Increased use of sterile injecting equipment by PWID 
OI.4 Reduction	in	frequency	of	injection
OI.5 Increased	awareness	of	HIV	status	among	PWID
✱ OI.6 Decreased incidence of AIDS cases among PWID
OI.7 Decreased	AIDS-related	mortality	among	PWID
OI.8 Decreased	incidence	of	sexually	transmitted	infections	among	PWID
✱ OI.9 Increased use of condoms among PWID
✱	 Key indicator
✱✱	Priority key indicator
4.2 POPULATION SIZE ESTIMATES
Pop.1
ESTIMATED NUMBER OF PEOPLE WHO INJECT DRUGS (PWID)
Estimated number of active PWID, defined as the number of people who injected drugs 
at any time within the past 12 months
Suggested 
disaggregations
Gender:	Male,	female,	transgender
Age: ≤18	years;	>18	years	and	<25	years; ≥	25	years
Type of drug injected	(see	also	Pop.3,	below):	opioids,	stimulants	(including	
amphetamine-type	stimulants	and	cocaine	preparations),	other	(including	
benzodiazepines)
Indicators using 
estimate NSP.C.1			NSP.C.2			NSP.C.3			NSP.C.4			OST.C.1			ODT.C.1			HTC.C.1			STI.C.1			Cdm.C.1			IEC.C.2
Pop.2 ESTIMATED NUMBER OF OPIOID-DEPENDENT PEOPLE
Suggested 
disaggregations
Gender:	Male,	female,	transgender
Age: ≤18	years;	>18	years	and	<25	years; ≥	25	years
Indicators using 
estimate OST.C.1
Pop.3 ESTIMATED NUMBER OF OPIOID-DEPENDENT PEOPLE WHO INJECT DRUGS
Suggested 
disaggregations
Gender:	Male,	female,	transgender
Age: ≤18	years;	>18	years	and	<25	years; ≥	25	years
Indicators using 
estimate OST.C.1
Pop.4 ESTIMATED NUMBER OF PEOPLE WHO INJECT DRUGS LIVING WITH HIV
Recommended 
disaggregations
Gender:	Male,	female,	transgender
Age: ≤18	years;	>18	years	and	<25	years; ≥	25	years 
Type of drug injected	(see	also	Pop.3,	above):	opioids,	stimulants	(including	
amphetamine-type	stimulants	and	cocaine	preparations),	other	(including	
benzodiazepines)
Indicators using 
estimate ART.C.1					ART.C.2
Comments Derived	by	applying	estimated	HIV	prevalence	to	estimated	number	of	PWID.	
There	is	likely	to	be	significant	uncertainty	around	both	PWID	population	size	and	
HIV	prevalence	estimates;	consequently,	when	combined,	the	uncertainty	around	
estimates	of	the	number	of	PWID	living	with	HIV	may	be	substantial.	
HIV	register	data	may	be	used	also	but	are	likely	to	be	an	underestimate.
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✱
✱
Pop.5 ESTIMATED NUMBER OF PEOPLE LIVING WITH HIV
Recommended 
disaggregations
Gender:	Male,	female,	transgender
Age: ≤18	years;	>18	years	and	<25	years; ≥	25	years
Indicators using 
estimate ART.C.2
Pop.6
ESTIMATED NUMBER OF PEOPLE WHO INJECT DRUGS INFECTED WITH HEPATITIS C 
VIRUS
Recommended 
disaggregations
Gender:	Male,	female,	transgender
Age: ≤18	years;	>18	years	and	<25	years; ≥	25	years 
Type of drug injected:	opioids,	stimulants	(including	amphetamine-type	stimulants	and	
cocaine	preparations),	other	(including	benzodiazepines)
Indicators using 
estimate Hep.C.3
Comments Derived	by	applying	estimated	HCV	prevalence	to	estimated	number	of	PWID.	
There	will	likely	be	significant	uncertainty	around	both	PWID	population	size	and	
HCV	prevalence	estimates;	consequently,	when	combined,	the	uncertainty	around	
estimates	of	the	number	of	PWID	living	with	HCV	may	be	considerable.	
HCV	register	data	may	be	used	also	but	are	likely	to	be	an	underestimate.
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4.3 THE COMPREHENSIVE PACKAGE
1 NEEDLE AND SYRINGE PROGRAMMES
NSP.A.1
NUMBER AND LOCATION OF SITES WHERE NEEDLES AND SYRINGES ARE AVAILABLE
These indicators look at the number of sites where clean injecting equipment is available 
either free or for purchase, as well as the presence or absence of these outlets in locations 
where	people	who	inject	drugs	are	known	to	be	present.	
Recommended disaggregations: 
Community / Prisons and other closed settings
Indicator: Data sources: Comments:
NSP.A.1a Number	of	NSP	sites Programme	data NSPs	may	operate	in	a	variety	of	
locations	and	service	models,	including	
fixed	sites,	mobile	services	and	
outreach.	For	the	purpose	of	reporting	
this	indicator,	it	is	recommended	that,	
for	a	location	to	be	considered	a	“site”,	
the	following	conditions	must	be	met:
•	 It	is	the	location	of	a	fixed	site	or	
site	that	is	serviced	by	a	mobile	or	
outreach	service.
•	 If	a	fixed	site,	it	must	have	frequent	
and	regular	hours	of	operation.
•	 If	a	mobile	service,	the	service	must	
operate	at	the	site	on	a	frequent	and	
regular	basis.
•	 If	an	outreach	service,	the	specific	
site	or	defined	area	must	be	accessed	
on	a	frequent	and	regular	basis	by	
outreach	workers.
•	 This	count	includes	pharmacy	sites	
providing	needles	and	syringes	at	no	
cost	to	the	client	but	not	those	that	
only	sell	needles	and	syringes.
NSP.A.1b Number	of	pharmacies	
or	other	outlets	where	
needles	and	syringes	are	
available	for	purchase
Programme	data In	some	countries	injecting	equipment	
may	be	available	for	purchase	from	
any	pharmacy,	while	in	others	the	sale	
of	injecting	equipment	may	be	more	
restricted;	for	example,	only	certain	
outlets	provide	needles	and	syringes.
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Indicator: Data sources: Comments:
NSP.A.1c Number	of	cities/states/
provinces/ oblasts	where	
NSPs	are	present
Programme	data
See	section	3.4,	part	4,	for	more	
information	on	measuring	and	
interpreting	this	indicator.
Possible targets:
Low	 60% 	Mid	 80% 	High
NSP.A.1d Number	of	cities/states/
provinces/ oblasts	where	
pharmacies	or	other	
outlets	are	present	
that	offer	needles	and	
syringes	for	purchase	
Programme	data
NSP.A.1e Number	of	cities/states/
provinces/ oblasts	where	
PWID	are	known	to	be	
present
Situational	analysis,	
mapping	exercise
NSP.A.1f Percentage	of	cities/
states/ provinces/oblasts 
where	PWID	are	located	
and	NSPs	are	present
[NSP.A.1c]   
x	100
[NSP.A.1e]
NSP.A.1g Percentage	of	cities/
states/ provinces/oblasts 
where	PWID	are	located	
and	where	pharmacies	or	
other	outlets	are	present	
that	offer	needles	and	
syringes	for	purchase	
[NSP.A.1d]   
x	100
[NSP.A.1e]
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NSP.C.1
QUANTITY OF NEEDLES–SYRINGES DISTRIBUTED
This indicator looks at the total quantity of new/sterile needles–syringes that are distributed 
and, hence, estimates the total number of clean units of injecting equipment in circulation that 
might	be	used	by	the	population	of	injecting	drug	users.
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case	the	
PWID	population	estimate	used	as	the	denominator	should	be	relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
NSP.C.1a Total	number	of	needles–
syringes	distributed	
by	NSPs	in	the	last	
12 months
Programme	data NSPs	may	provide	various	types	
of	needles	and	syringes,	including	
separate	needles	and	syringe	or	
syringes	with	needles	attached.		
For	the	purpose	of	counting	the	number	
of	needles–syringes	for	this	indicator,	
it	is	recommended	to	count	the	total	
number	of	equivalent	single	sterile	
injecting	units	distributed.	For	example:	
if	10	separate	syringes	and	20	separate	
needles	are	dispensed,	a	total	of	10	
sterile	injecting	units	(each	comprising	
1	needle	and	1	syringe)	would	be	
counted;	similarly,	if	12	separate	
syringes	and	6	separate	needles	are	
dispensed,	a	total	of	6	sterile	injecting	
units	would	be	counted.	
To	allow	for	disaggregation	by	gender,	
age	or	drug	injected,	service-level	data	
collection	systems	must	record	these	
client	characteristics.
NSP.C.1b Total	number	of	needles–
syringes	sold	to	PWID	
by	pharmacies	or	other	
outlets	in	the	last	12	
months
Retail	data In	most	countries	it	is	unlikely	that	
these	data	will	be	available.	If	such	
data	are	collected	and	collated,	
however,	a	more	complete	picture	
of	the	total	number	of	needles	and	
syringes	in	circulation	and,	hence,	of	
coverage	can	be	seen.	
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Indicator: Data source: Comments:
NSP.C.1c Number	of	needles–
syringes	distributed	per	
PWID	per	year
[NSP.C.1a]+[NSP.C.1b]
[Pop.1]
Possible targets:
Low	 100 	Mid	 200 	High
These	target	levels	are	based	
upon	studies	in	developed-country	
settings	and	mathematical	modelling	
investigating	the	levels	of	syringe	
distribution	and	its	impact	on	HIV	
transmission	(124,134).
Note	that	the	levels	required	for	the	
prevention	of	HCV	are	likely	to	be	much	
higher	than	those	proposed	here.
This	indicator	should	still	be	calculated	
even	if	data	on	the	number	of	needles–
syringes	sold	by	pharmacies	is	not	
available.
This	indicator	is	included	in	the	Global	
AIDS	Response	progress	reporting	
2012	(12).
NSP.C.2
PWID REGULARLY REACHED BY NSPS
PWID who inject regularly require an ongoing supply of injecting equipment and, thus, 
continual	access	to	NSPs.	
For	the	purpose	of	these	indicators,	“regular reach” is	defined	as	once	per	month.	
If the quantity of injecting equipment that a client is able to obtain per visit is limited, it may be 
necessary for a PWID to access an NSP regularly more often than once per month to have a 
sufficient	supply	of	clean	injecting	equipment	and	avoid	used	needles	and	syringes.
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case	the	
PWID	population	estimate	used	as	the	denominator	should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other) 
Indicator: Data source: Comments:
NSP.C.2a Number	of	PWID	who	
accessed	an	NSP	once	
per	month	or	more	over	
the	specified	reporting	
period	(e.g.	last	12,	6	or	 
3	months)
Programme	data This	indicator	requires	that	service-
level	data	collection	systems	use	
unique	identifier	codes	(UIC;	see	
page	37	for	more	detail)	to	allow	the	
frequency	of	visits	by	each	NSP	client	
to	be	measured	over	a	period	of	time.	
NSP.C.2b Percentage	of	PWID	
who	were	regularly	
reached	by	NSPs	over	
the	specified	reporting	
period	(e.g.	last	12,	6	or	 
3	months)
[NSP.C.2a]   
x	100
   [Pop.1]
Possible targets:
Low	 20% 	Mid	 60% 	High
The	high	target	level	is	based	on	a	
retrospective	analysis	of	the	coverage	
required	to	reverse	the	HIV/AIDS	
epidemic	among	PWID	in	an	urban	
setting	in	a	high-income	country	(135).
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NSP.C.3
PWID REACHED BY NSPS
If	NSP	data	collection	systems	are	not	able	to	determine	clients’	frequency	of	contact	with	
NSPs but can record numbers of client contacts within reporting periods of different length, 
the following indicators investigating contacts within the last month and last 12 months can be 
used	to	give	an	indication	of	the	level	of	NSP	reach.	
These indicators may also be useful even when data on regular reach are available, as these 
more basic indicators may allow for comparison with other countries and with older data and 
thus	make	possible	tracking	of	progress.
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case	the	
PWID	population	estimate	used	as	the	denominator	should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
NSP.C.3a Number	of	PWID	who	
accessed	an	NSP	over	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)
Programme	data This	indicator	requires	services	to	have	
a	data	collection	system	using	unique 
identifier codes (UIC,	see	page	37	for	
more	detail)	to	allow	determination	of	
the	total	number	of	individual	clients	
accessing	the	service	within	the	
reporting	period	and	to	avoid	double-
counting	clients	who	access	the	
service	more	than	once.
NSP.C.3b Percentage	of	all	PWID	
who	were	reached	by	an	
NSP	over	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)
[NSP.C.3a]   
x	100
   [Pop.1]
A	1-month	reporting	period	can	be	used	
as	a	proxy	for	recent/current	coverage. 
Possible targets:
Low	 20% 	Mid	 60% 	High
NSP.C.3c Number	of	PWID	who	
accessed	an	NSP	in	the	
last	1	month
Programme	data These	indicators	requires	services	
to	have	a	data	collection	system	
using	unique identifier codes (UIC,	
see	page	37	for	more	detail)	to	allow	
determination	of	the	total	number	of	
individual	clients	accessing	the	service	
within	the	reporting	period	and	to	avoid	
double-counting	clients	who	access	
the	service	more	than	once.
NSP.C.3d Number	of	PWID	who	
accessed	an	NSP	in	the	
last	12	months
Programme	data
NSP.C.3e Percentage	of	all	PWID	
reached	by	an	NSP	in	the	
last	12	months	who	were	
also	reached	in	the	last	
1 month
[NSP.C.3c]   
x	100
[NSP.C.3d]
If	it	is	not	possible	to	measure	the	
frequency	of	access	by	PWID	within	
a	period	of	time,	this	indicator	can	be	
a	proxy	for	estimating	the	frequency	
of	contact,	by	comparing	the	number	
of	PWID	who	have	accessed	an	NSP	
recently,	in	the	last	1	month,	with	the	
total	number	who	have	accessed	an	
NSP	in	the	last	12	months.
Possible targets:
Low	 30% 	Mid	 70% 	High
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NSP.C.4
NSP OCCASIONS OF SERVICE (TOTAL CONTACTS)
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case	the	
PWID	population	estimate	used	as	the	denominator	should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
NSP.C.4a Number	of	NSP	
occasions	of	service	
(total	contacts)	in	
specified	reporting	
period
Programme	data Total	number	of	all	NSP	client	service	
events,	or	occasions	of	service;	this	
includes	every	visit	to	an	NSP	service	
in	which	needles	and	syringes	were	
dispensed.	Multiple	visits	by	the	same	
client	are	included	in	this	count.	
The	service	data	collection	system	
does	not	require	unique	identifier	
codes.
NSP.C.4b Ratio	of	the	number	of	
NSP	occasions	of	service	
in	specified	reporting	
period	per	100	PWID
[NSP.C.4a]   
x	100
   [Pop.1]
Possible targets:
Low	 30 	Mid	 70 	High
NSP.Q.1 
NATIONAL POLICY AND LEGISLATION RELATING TO NEEDLE AND SYRINGE PROGRAMMES
Are the following standards and programme features included in national legislation, policy 
and guidance?
NSP.Q.1a Legislation specifically supports the distribution of injecting equipment through NSPs
The	distribution	and	collection	of	injecting	equipment	and	the	operation	of	NSPs	are	
authorized	under	the	law.	Legislation	is	not	ambiguous	on	the	legal	status	of	NSPs	or	on	the	
distribution	and	collection	of	injecting	equipment.	
NSP.Q.1b National police guidelines and policy specifically support the operation of NSPs
Police	guidelines	stipulate	that	police	activities	do	not	deter	or	prevent	PWID	from	accessing	
NSPs	or	from	being	in	possession	of	new	or	used	injecting	equipment.	Police	routinely	receive	
training	and	education	relating	to	drug	use,	HIV	and	harm	reduction	principals	and	services.
NSP.Q.1c Legislation supports the provision of NSP services in closed settings
In	closed	settings	various	delivery	models	for	the	distribution	of	injecting	equipment	have	
been	implemented	in	different	countries.	These	include	distribution	by	prison	health	staff,	by	
peer-educators,	by	NGO	representatives	and	from	dispensing	machines. 
NSP.Q.1d National strategy includes steps to secure long-term and sufficient levels of funding to 
ensure sustainability of NSPs and the achievement of other quality standards described here
Long-term	government	funding	should	be	committed	to	the	ongoing	operation	of	NSPs;	if	
services	are	funded	by	external	sources,	sustainability	of	this	funding	should	be	assessed,	
and	contingencies	for	funding	gaps	should	be	determined.	Funding	levels	must	be	adequate	
to	ensure	high-quality	NSP	services,	with	high	levels	of	access	and	coverage,	including,	for	
example,	the	distribution	of	a	range	of	appropriate	injecting	equipment	(NSP.Q.1o)	and	no	
restrictions	on	the	quantity	of	equipment	that	can	be	distributed	(NSP.Q.1m).
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✱
NSP.Q.1e National policy stipulates PWID be actively involved in the planning of NSP services
This	involves	consultation	with	and	meaningful	involvement	of	PWID	in	the	development	of	
services	to	ensure	that	they	are	appropriate	and	acceptable	to	the	target	population.
NSP.Q.1f National guidelines recommend PWID be actively involved in the delivery of NSP services
PWID	may	be	involved	in	the	delivery	of	NSP	services.	This	commonly	entails	training	PWID	
to	serve	as	peer-educators	and	outreach	workers	and	involving	them	in	the	distribution	of	
injecting	equipment.
NSP.Q.1g National guidelines stipulate that NSP services regularly seek anonymous feedback from 
clients
Mechanisms	are	in	place	whereby	clients	can	confidentially/anonymously	provide	feedback	
on	the	service.	The	service	should	be	responsive	to	this	information.
NSP.Q.1h National guidelines outline training and supervision requirements for NSP workforce
Services	train	staff	in	line	with	national	training	standards	on	staff	knowledge	and	skills.	Staff	
receives	supervision	in	line	with	national	standards.	Funding	is	allocated	for	staff	training	
and	supervision.	Staff	members	are	respectful	towards	PWID,	have	credibility	with	the	target	
population	and	are	non-judgemental	in	their	attitude	towards	drug	users.
NSP.Q.1i National guidelines stipulate that NSPs be located in areas known to be accessible to PWID
Mapping	of	the	target	population	may	be	required	to	determine	the	accessibility	of	locations	
for	PWID.	For	example,	sites	should	be	easily	and	affordably	accessible	by	public	transport.
NSP.Q.1j National guidelines recommend that a range of NSP service delivery models be employed to 
maximize reach.
The	mix	of	service	delivery	models	should	maximize	the	accessibility	of	injecting	equipment,	
including	at	all	times	of	the	day	and	week;	and	may	include:	fixed-site	services,	mobile	
services,	vending	machines,	outreach,	home	delivery	and	secondary	distribution	through	
other	services	such	as	sexual	health	clinics,	drug	treatment	services	and	hospital	emergency	
services.	
NSP.Q.1k National policy stipulates that NSPs maintain client confidentiality
Services	have	systems	in	place	to	ensure	that	client	records	are	kept	securely	and	remain	
confidential.	Clients	are	not	required	to	show	identification	or	provide	personal	details	in	
order	to	utilize	services	or	obtain	injecting	equipment.	Client	information	is	not	shared	with	
other	services	or	law	enforcement	without	client	consent,	unless	required	by	law.	Programme	
data	collection	systems	do	not	contain	clients’	personal	or	identifiable	information.
NSP.Q.1l National policy stipulates that NSP services are “low-threshold” and do not require PWID to 
meet specific criteria in order to access services or receive injecting equipment
Services	do	not	restrict	access	on	the	basis	of	minimum	age,	proof	of	injecting	status,	proof	
of	residence,	gender	or	HIV	status,	citizenship	status,	residential	status,	incarceration	or	
criminal	history,	nor	should	drug	users	be	required	to	register	in	order	to	receive	services.
NSP.Q.1m National guidelines stipulate that there be no limit on the quantity of injecting equipment 
provided
This	distribution	policy	seeks	to	maximize	the	quantity	of	injecting	equipment	dispensed.
NSP.Q.1n National guidelines stipulate that the return of used injecting equipment is not a prerequisite 
for clients to receive new injecting equipment
While	returning	used	injecting	equipment	should	not	be	a	prerequisite	for	receiving	new	
injecting	equipment,	PWID	should	be	encouraged	and	helped	to	dispose	of	injecting	
equipment	safely.
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NSP.Q.1o National guidelines stipulates that NSPs provide a range of injecting equipment that is 
appropriate for local injecting practices and substances injected and that is acceptable to 
the target population
Needles	and	syringes	provided	should	be	suited	to	the	local	drug	market	and	context	and	
acceptable	to	clients.	PWID	should	be	consulted	to	determine	the	most	appropriate	and	
acceptable	equipment	for	distribution.	Ideally,	the	smallest	gauge	needles	should	be	provided	
in	order	to	cause	minimal	tissue	damage	at	the	site	of	injection.	Larger	gauge	needles	
may	be	required	for	the	injection	of	some	drugs,	including	those	that	are	more	viscous	in	
solution	and	in	some	instances	where	drugs	may	be	of	poorer	quality.	Syringes	should	be	of	
appropriate	volume	(larger	for	substances	that	are	injected	in	greater	volumes.	Needles	and	
syringes	should	have	minimal	dead-space,	as	larger	syringe	dead-space	may	retain	greater	
quantity	of	infective	particles,	thus	increasing	risk	of	infection	on	reuse	(28,29).	Other,	related	
materials	should	also	be	provided	where	appropriate,	including	sterile	water,	safe	sharps	
disposal	containers,	filters,	mixing	vessels	(e.g.	spoons),	disposable	tourniquets,	acidifiers	
(e.g.	ascorbic	or	citric	acid	powders)	and	materials	to	encourage	non-injecting	routes	of	
administration	as	a	safer	alternative	to	injecting,	such	as	sterile	pipes,	papers	or	foil. 
NSP.Q.1p National guidelines stipulate that NSPs provide targeted information, education and 
communication (IEC), including overdose prevention, for PWID
IEC	material	and	messages,	developed	to	suit	the	local	context,	should	address	the	following:	
safe	injecting	technique;	condom	use	and	safer	sex;	drug	effects	and	harms;	blood-borne	
viruses	risks,	prevention,	health	impact	and	treatment;	overdose	risk,	prevention	and	
responses,	which	may	including	the	provision	of	naloxone	and	training	in	its	use	for	opioid	
users;	drug	treatment	options;	legal	rights	and	responsibilities;	safe	disposal	of	injecting	
equipment;	and	access	to	medical,	welfare	and	other	services.	PWID	should	be	involved	in	
the	development	and	testing	of	these	materials.
NSP.Q.1q National guidelines stipulate that formalized referral pathways between NSPs and other 
relevant service providers are established, and NSP clients referred to these services as 
appropriate
Relevant	services	include:	drug	dependence	treatment;	HIV,	viral	hepatitis,	and	TB	testing,	
management,	treatment	and	care;	viral	hepatitis	vaccination;	sexual	health	services	
(including	STI	testing	and	treatment);	reproductive	health	services;	mental	health	services;	
general	medical	services;	welfare;	accommodation	services;	legal	services;	education	
services;	and	primary	health	care.	These	services	may	be	external	to	the	NSP	or	may	be	
within	the	same	facility,	if	services	are	integrated.	Established	referral	pathways	should	meet	
the	following	criteria:
•	 The	referring	service	has	a	roster	of	nominated	services	to	which	clients	may	be	referred	and	
has	links	with	these	services.
•	 Services	to	which	clients	are	referred	are	sensitive,	supportive	and	responsive	to	the	needs	of	
PWID	and	are	located	close	to	the	referring	service	or	are	easily	accessible	to	the	client.
•	 Follow-up	and	continuity	of	care	are	strengthened	through	case	management	instituted	by	the	
referring	service.
NSP.Q.1r National guidance outlines systems to prevent NSP stock-outs
NSPs	need	to	store	sufficient	amounts	of	injecting	equipment	and	to	have	reliable	supply	
chains	and	robust	procurement	processes	to	ensure	there	is	no	interruption	in	the	provision	
of	injecting	equipment.
2012 Revision
57
NSP.Q.2 
QUALITY OF NSP SERVICE DELIVERY
These	indicators	examine	the	adherence	to	quality	standards	at	the	service	level.
These	indicators	can	be	used	to	assess	service	delivery	of	an	individual	service	or	NSP	site.	
Results from multiple services may be aggregated to determine the proportion of all services 
adhering	to	each	quality	standard.	
NSP.Q.2a Long-term	funding	has	been	secured	to	ensure	the	sustainability	of	the	NSP	service (see 
NSP.Q.1d)
NSP.Q.2b The	programme	has	actively	involved	PWID	in	the	planning	of	NSP	services (see	NSP.Q.1e)
NSP.Q.2c PWID	are	actively	involved	in	the	delivery	of	NSP	services	(see	NSP.Q.1f)
NSP.Q.2d The	service	regularly	seeks	anonymous	feedback	from	clients	(see	NSP.Q.1g)
NSP.Q.2e The	NSP	workforce	has	received	training	and	is	supervised (see	NSP.Q.1h)
NSP.Q.2f The	NSP	is	situated	in	a	location	known	to	be	accessible	to	PWID	(see	NSP.Q.1i)
NSP.Q.2g The	programme	employs	a	range	of	NSP	service	delivery	models	to	maximize	reach (see 
NSP.Q.1j)
NSP.Q.2h The	NSP	service	maintains	client	confidentiality	(see	NSP.Q.1k)
NSP.Q.2i The	NSP	service	is	“low-threshold”	and	does	not	require	PWID	to	meet	specific	criteria	in	
order	to	access	services	or	receive	injecting	equipment	(see	NSP.Q.1l)
NSP.Q.2j There	are	no	limits	on	the	quantity	of	injecting	equipment	provided	(see	NSP.Q.1m)
NSP.Q.2k The	return	of	used	injecting	equipment	is	not	a	prerequisite	for	clients	to	receive	new	
injecting	equipment	(see	NSP.Q.1n)
NSP.Q.2l The	service	provides	a	range	of	injecting	equipment	that	is	appropriate	for	local	injecting	
practices	and	substances	injected	and	that	is	acceptable	to	the	target	population (see 
NSP.Q.1o)
NSP.Q.2m The	NSP	service	provides	targeted	information,	education	and	communication	(IEC),	including	
overdose	prevention,	for	PWID	(see	NSP.Q.1p)
NSP.Q.2n Formalized	referral	pathways	between	the	NSP	service	and	other	relevant	service	providers	
have	been	established,	and	NSP	clients	are	referred	to	these	services	as	appropriate (see 
NSP.Q.1q)
NSP.Q.2o A	system	to	prevent	stock-outs	has	been	implemented	(see	NSP.Q.1r)
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✱
2 OPIOID SUBSTITUTION THERAPY AND OTHER DRUG DEPENDENCE 
TREATMENT
OST.A.1
PRESENCE OF OPIOID SUBSTITUTION THERAPY (OST)
Recommended disaggregations: 
Community / Prisons and other closed settings
Indicator: Responses: Comments:
OST.A.1a Availability	of	OST,	
involving	the	use	of	
opioid	agonists	for	
maintenance	treatment	
of	opioid	dependence
Present	/	Absent Includes	the	use	of	opioid	agonists	
for	the	purpose	of	maintenance	
substitution	therapy;	does not	include	
short-term	substitution	therapy	for	
detoxification.	
OST.A.1b Availability	of	methadone	
for	maintenance	
treatment	for	opioid	
dependence
Present	/	Absent Includes	the	use	of	methadone	for	the	
purpose	of	maintenance	substitution	
therapy;	does not	include	short-term	
substitution	therapy	for	detoxification.	
OST.A.1c Availability	of	
buprenorphine	for	
maintenance	treatment	
for	opioid	dependence
Present	/	Absent Includes	the	use	of	buprenorphine	
for	the	purpose	of	maintenance	
substitution	therapy;	does not	include	
short-term	substitution	therapy	for	
detoxification.	
OST.A.1d Availability	of	other	
opioid	agonists	for	
maintenance	treatment	
for	opioid	dependence
Present	/	Absent Other	opioid	agonists	that	may	be	used	
in	maintenance	treatment	include:
•	 diamorphine	(pharmaceutical	heroin)
•	 slow-release	morphine	preparations
•	 tincture	of	opium
•	 other;	these	should	be	specified	when	
reported.
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OST.A.2
NUMBER AND LOCATION OF MAINTENANCE OST SITES
These indicators look at the number of sites where OST is provided; because prescription and 
dispensing	may	take	place	at	different	locations,	these	are	examined	separately.
Recommended disaggregations: 
Private / Public service providers
Community / Prisons and other closed settings
Indicator: Data sources: Comments:
OST.A.2a Number	of	sites	where	
OST	is	prescribed
Programme	data Sites	where	OST	is	prescribed	may	
include:	specialist	services,	general	
practitioner	prescribers/office-based,	
and	other	primary	care	settings.
OST.A.2b Number	of	sites	where	
OST	is	dispensed
Programme	data Sites	where	OST	is	dispensed	may	
include:	pharmacies,	specialist	
services,	mobile	dispensing	services.
OST.A.2c Number	of	cities/states/
provinces/	oblasts	where	
OST	is	available
Programme	data See	section	3.4,	part	4,	for	more	
information	on	measuring	and	
interpreting	this	indicator.
Possible targets:
Low	 60% 	Mid	 80% 	High
OST.A.2d Number	of	cities/states/	
provinces/oblasts	where	
injecting	drug	users	are	
known	to	be	present
Situational	analysis,	
mapping	exercise
OST.A.2e Percentage	of	cities/
states/	provinces/oblasts	
where	injecting	drug	
users	are	located	and	
where	OST	is	available
[OST.A.2c]   
x	100
[OST.A.2d]
OST.A.3
OST PROGRAMME CAPACITY 
This indicator can provide a measure of the extent to which demand for OST is matched by the 
capacity	of	the	programme.
Recommended disaggregations: 
Private / Public service providers 
Community / Prisons and other closed settings
Indicator: Data source: Comments:
OST.A.3a Number	of	people	on	
waiting	list	for	OST	on	
specified	date
Programme	data
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ODT.A.1
PRESENCE OF DRUG DEPENDENCE TREATMENT, OTHER THAN MAINTENANCE OST
Recommended disaggregations: 
Private / Public service providers
Community / Prisons and other closed settings
Indicator: Responses: Comments:
ODT.A.1a Availability	of	inpatient 
detoxification
Present	/	Absent Supported	drug	withdrawal	in	an	
inpatient	setting,	typically	for	a	period	
lasting	less	than	10 days.
ODT.A.1b Availability	of	outpatient 
drug	dependence	
treatment
Present	/	Absent Provision	of	drug	dependence	
treatment	services	(other	than	OST)	
in	an	outpatient	setting.	May	include	
such	treatment	modalities	as	group	or	
individual	counselling.
ODT.A.1c Availability	of	inpatient	
short-term	treatment	for	
drug	dependence
Present	/	Absent Short-term	inpatient	treatment	for	drug	
dependence	is	defined	as	treatment	
lasting	up	to	4	months.
ODT.A.1d Availability	of	inpatient	
long-term	care	or	
residential	treatment
Present	/	Absent Long-term	inpatient	or	residential	
treatment	for	drug	dependence	is	
defined	as	treatment	lasting	4	months	
or	longer.
ODT.A.1e Availability	of	peer-based	
support	groups
Present	/	Absent Also	known	as	self-help	groups.	
Describes	groups	in	which	participants	
support	each	other	in	recovering	
or	maintaining	recovery	from	drug	
dependence	and	related	problems	
without	professional	therapy	or	
guidance.	Examples	include	Narcotics	
Anonymous	(NA).
ODT.A.1f Availability	of	NSPs,	or	
other	services	targeting	
PWID,	providing	brief	
intervention	for	drug-
dependent	clients
Present	/	Absent Brief	interventions,	based	on	
motivational	principles,	may	be	offered	
for	the	treatment	of	substance	use	
disorders	in	non-specialist	settings	
(i.e.	non-drug-dependence	treatment	
settings)	such	as	NSPs.	Brief	
interventions	are	offered	with	a	view	
to	referral	at	later	stages	to	specialized	
treatment	services.
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ODT.A.2
NUMBER OF DRUG DEPENDENCE TREATMENT SITES, OTHER THAN MAINTENANCE OST
Recommended disaggregations: 
Private / Public service providers
Community / Prisons and other closed settings
Indicator: Data source: Comments:
ODT.A.2a Number	of	sites	where	
inpatient	detoxification	is	
provided
Programme	data
ODT.A.2b Number	of	sites	
where	outpatient	drug	
dependence	treatment	is	
provided
Programme	data
ODT.A.2c Number	of	sites	where	
inpatient	short-term 
treatment	for	drug	
dependence	is	provided
Programme	data
ODT.A.2d Number	of	sites	where	
inpatient	long-term 
residential	treatment	is	
provided
Programme	data
ODT.A.2e Number	of	sites	where	
peer-based	support	
groups	are	available
Programme	data
ODT.A.2f Number	of	NSP	sites	that	
provide	brief	intervention	
for	drug-dependent	
clients
Programme	data
ODT.A.2g Percentage	of	NSP	
sites	that	provide	brief	
intervention	for	drug-
dependent	clients
[ODT.A.2f]   
x	100
[NSP.A.1a]
WHO, UNODC, UNAIDS Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users
62
OST.C.1
INDIVIDUALS RECEIVING MAINTENANCE OST 
Because the availability of data will likely vary in different settings, a variety of indicators to 
examine	the	scale	of	OST	provision	relative	to	the	size	of	the	target	population	are	described.	
Where possible, however, efforts should be made to collect the data that most closely measure 
treatment	delivery	against	need—ideally,	using	indicators	OST.C.1c	and	OST.1C.d.
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage, the population size estimate used as the denominator should be 
relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Community / Prisons and other closed settings
Indicator: Data source: Comments:
OST.C.1a Number	of	all individuals 
on	OST	at	a	specified	
date	or	over	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)
Programme	data This	number	includes	all	patients,	
regardless	of	injecting	drug	use	history	
or	status.
If	the	number	of	patients	in	treatment	
at	a	specified	date	is	not	available,	the	
number	of	patients	who	received	OST	
at	any	time	over	a	specified	reporting	
period	can	be	examined.
It	is	important	to	ensure	that	there	
is	no	double-counting	of	individuals	
who	may	have	dropped	out	of	OST	and	
then	resumed	treatment	at	a	later	date	
within	the	specified	reporting	period.
OST.C.1b Number	of	PWID	on	
OST	at	a	specified	date	
or	over	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)
Programme	data This	number	includes	patients	who	
have	a	history	of	ever	having	injected	
drugs.
If	the	number	of	patients	in	treatment	
at	a	specified	date	is	not	available,	the	
number	of	patients	who	received	OST	
at	any	time	over	a	specified	reporting	
period	can	be	examined.
It	is	important	to	ensure	that	there	
is	no	double-counting	of	individuals	
who	may	have	dropped	out	of	OST	and	
then	resumed	treatment	at	a	later	date	
within	the	specified	reporting	period.
OST.C.1c Percentage	of	opioid-
dependent	people	on	OST
[OST.C.1a]   
x	100
   [Pop.2]
Denominator	is	the	estimated	number	
of	all opioid-dependent	people	[Pop.2].
Possible targets:
Low	 20% 	Mid	 40% 	High
The	high	target	level	is	based	on	levels	
of	coverage	achieved	in	countries	with	
well-established	OST	programmes.
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Indicator: Data source: Comments:
OST.C.1d Percentage	of	opioid-
dependent	PWID	on	OST
[OST.C.1b]   
x	100
   [Pop.3]
Denominator	is	the	estimated	number	
of	opioid-dependent	PWID	[Pop.3].
Possible targets:
Low	 20% 	Mid	 40% 	High
The	high	target	level	is	based	on	levels	
of	coverage	achieved	in	countries	with	
well-established	OST	programmes.
OST.C.1e Ratio	of	the	number	
of	PWID	on	OST	per	
100 PWID
[OST.C.1b]   
x	100
   [Pop.1]
Denominator	is	the	estimated	number	
of	all	PWID	[Pop.1].
Lacking	OST	programme	data	on	
clients’	injecting	drug	use	history	or	
status	and	without	estimates	of	the	
size	of	the	opioid-dependent	PWID	
population,	this	indicator	may	be	the	
only	measure	of	OST	provision	relative	
to	PWID	population	size	that	can	be	
reported.	
The	very	significant	limitations	of	
this	indicator	must	be	appreciated,	
however,	it	does	not	directly	measure	
treatment	need	(demand).
This	indicator	is	most	appropriate	
in	settings	where	most	PWID	are	
opioid-dependent	and	where	most	OST	
recipients	are	PWID.
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ODT.C.1
INDIVIDUALS RECEIVING DRUG DEPENDENCE TREATMENT, OTHER THAN MAINTENANCE OST
Drug dependence treatment providers may offer services for a wide range of patients in 
addition to those who may inject drugs, including, for example, those dependent on alcohol or 
cannabis.
It is desirable, for the purpose of assessing drug dependence treatment as part of the 
response to HIV among PWID, to assess the coverage of drug dependence treatment for PWID 
specifically.	To	do	this,	however,	requires	data	collection	at	the	service	level	that	identifies	
patients’	injecting	drug	use	status	and	allows	for	disaggregation	accordingly.	Many	data	
collection systems may not allow this type of disaggregation; the indicators described here are 
for	application	where	data	collection	systems	do	allow	for	reporting	such	disaggregated	data.
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Community / Prisons and other closed settings
Indicator: Data source: Comments:
ODT.C.1a Number	of	all individuals 
receiving	inpatient	drug	
detoxification	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)
Programme	data This	number	includes	all	patients,	
regardless	of	injecting	drug	use	history	
or	status.
ODT.C.1b Number	of	PWID 
receiving	inpatient	drug	
detoxification	during	
the	specified	reporting	
period
Programme	data
These	indicators	can	be	reported	only	
if	patients’	injecting	drug	use	status	is	
recorded	in	the	data	collection	system.ODT.C.1c Percentage	of	PWID	
receiving	inpatient	drug	
detoxification	during	
the	specified	reporting	
period
[ODT.C.1b]   
x	100
   [Pop.1]
ODT.C.1d Number	of	individuals	
receiving	outpatient	drug	
dependence	treatment	
during	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3 months)
Programme	data This	number	includes	all	patients,	
regardless	of	injecting	drug	use	history	
or	status.
ODT.C.1e Number	of	PWID	
receiving	outpatient	drug	
dependence	treatment	
during	the	specified	
reporting	period
Programme	data
These	indicators	can	be	reported	only	
if	patients’	injecting	drug	use	status	is	
recorded	in	the	data	collection	system.ODT.C.1f Percentage	of	PWID	
receiving	outpatient	drug	
dependence	treatment	
during	the	specified	
reporting	period
[ODT.C.1e]   
x	100
   [Pop.1]
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Indicator: Data source: Comments:
ODT.C.1g Number	of	individuals	
receiving	inpatient	
short-term	treatment	for	
drug	dependence	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)
Programme	data This	number	includes	all	individuals,	
regardless	of	injecting	drug	use	history	
or	status.
ODT.C.1h Number	of	PWID	
receiving	inpatient	
short-term	treatment	for	
drug	dependence	during	
the	specified	reporting	
period
Programme	data
These	indicators	can	be	reported	only	if	
individuals’	injecting	drug	use	status	is	
recorded	in	the	data	collection	system.ODT.C.1i Percentage	of	PWID	
receiving	inpatient	
short-term	treatment	for	
drug	dependence	during	
the	specified	reporting	
period
[ODT.C.1h]   
x	100
   [Pop.1]
ODT.C.1j Number	of	individuals	
receiving	inpatient	
long-term	treatment	for	
drug	dependence	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)
Programme	data This	number	includes	all	patients,	
regardless	of	injecting	drug	use	history	
or	status.
ODT.C.1k Number	of	PWID	
receiving	inpatient	
long-term	treatment	for	
drug	dependence	during	
the	specified	reporting	
period
Programme	data
These	indicators	can	be	reported	only	
if	patients’	injecting	drug	use	status	is	
recorded	in	the	data	collection	system.ODT.C.1l Percentage	of	PWID	
receiving	inpatient	
long-term	treatment	for	
drug	dependence	during	
the	specified	reporting	
period
[ODT.C.1k]   
x	100
   [Pop.1]
ODT.C.1m Number	of	individuals	
participating	in	peer-
based	support	groups	
during	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)
Programme	data This	number	includes	all	patients,	
regardless	of	injecting	drug	use	history	
or	status.
ODT.C.1n Number	of	PWID	
participating	in	peer-
based	support	groups	
during	the	specified	
reporting	period
Programme	data
These	indicators	can	be	reported	only	
if	patients’	injecting	drug	use	status	is	
recorded	in	the	data	collection	system.ODT.C.1o Percentage	of	PWID	
participating	in	peer-
based	support	groups	
during	the	specified	
reporting	period
[ODT.C.1n]   
x	100
   [Pop.1]
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OST.Q.1 
NATIONAL POLICY AND LEGISLATION – OPIOID SUBSTITUTION PROGRAMMES
Are the following standards and programme features included in national legislation, policy 
and guidance?
OST.Q.1a Legislation explicitly supports the provision of OST
The	provision	of	opioid	substitution	therapy	is	authorized	under	the	law,	and	legislation	is	not	
ambiguous	on	the	legal	status	of	OST	programs.
OST.Q.1b National police guidelines and policy specifically support the operation of OST programmes
Police	guidelines	stipulate	that	police	activities	do	not	deter	or	prevent	PWID	from	accessing	
OST	programmes.	Police	routinely	receive	training	and	education	relating	to	drug	use,	HIV	
and	harm	reduction	principals	and	services.
OST.Q.1c National OST guidelines are developed at the country level or lower
These	guidelines	are	detailed,	comprehensive	and	evidence-based	and	reflect	local	laws,	
policies	and	conditions	and	are	consistent	with	international	guidance	(e.g.	relevant	WHO	
guidelines).
OST.Q.1d National strategy includes steps to secure long-term and sufficient levels of funding to 
ensure sustainability of OST programmes and the achievement of other quality standards 
described here
Long-term	government	funding	should	be	committed	to	the	ongoing	operation	of	OST	
programmes.	If	services	are	funded	by	external	sources,	sustainability	of	this	funding	should	
be	assessed,	and	contingencies	for	funding	gaps	should	be	determined.	Funding	levels	must	
be	adequate	to	ensure	high-quality	NSP	services,	with	high	levels	of	access	and	coverage.
OST.Q.1e National policy stipulates that PWID be actively involved in the planning of OST services
This	involves	consultation	with	and	meaningful	involvement	of	PWID	in	the	development	of	
services	to	ensure	that	they	are	appropriate	and	acceptable	to	the	target	population.
OST.Q.1f National guidelines stipulate that OST services regularly seek anonymous feedback from 
clients
Mechanisms	are	in	place	whereby	clients	can	confidentially/anonymously	provide	feedback	
on	the	service.	The	service	should	be	responsive	to	this	information.
OST.Q.1g National policy stipulates a clear chain of accountability within OST services, and within 
the health system more broadly, to ensure that minimum standards for the provision of OST 
are met
OST.Q.1h National policy requires OST prescribers to receive accredited training and to be registered
OST	prescribers	are	required	to	take	accredited	post-graduate	training	in	OST,	participate	
in	continuing	education,	monitoring	and	evaluation,	and	be	registered	to	prescribe	OST.	
Prescribers	are	respectful	towards	PWID,	have	credibility	with	the	target	population	and	be	
non-judgemental	in	their	attitude	towards	drug	users.
OST.Q.1i National policy requires that OST dispensing staff receive training in line with national 
guidelines
Funding	is	allocated	for	staff	training	and	supervision.	Training	includes	responding	to	
adverse	events	and	assessment	of	patient	pre-dosing.	
OST.Q.1j National policy stipulates that OST services be “low-threshold”, and access unrestricted
Criteria	for	OST	should	be	based	on	clinical	indications	for	treatment.	Access	should	not	be	
restricted	on	the	basis	of	non-clinical	criteria	such	as	minimum	age,	injecting	status	(both	
PWID	and	non-PWID	who	are	opioid-dependent	should	be	able	to	access	treatment),	gender,	
HIV	status	(either	HIV-positive	or	negative),	citizenship	status,	having	a	permanent	address,	
incarceration	or	criminal	history.
OST.Q.1k National guidelines recommend that OST programmes operate through a range of service 
delivery models that allow for access to OST by all opioid-dependent people
May	include:	general	practitioner	prescribers/office-based	and	prescription	by	specialist/
from	specialist	services;	provision	for	“take	home”	medication;	outreach	or	mobile	services.
OST.Q.1l National guidelines require OST prescribers and dispensing services to be located in areas 
known to be accessible to PWID
Mapping	of	the	target	population	may	be	required	to	determine	the	accessibility	of	locations	
for	PWID.	For	example,	sites	should	be	easily	and	affordably	accessible	by	public	transport.
✱
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OST.Q.1m National guidelines stipulate that dispensing of OST is available at various times of the day 
and beyond standard office hours if required
Accessibility	of	OST	is	enhanced	by	the	availability	of	dispensing	at	various	times	of	the	
day,	including	outside	regular	business	hours	and	on	weekends	to	allow	patients	who	are	
employed	to	access	the	service.	Patients	who	work	at	night	(e.g.	sex	workers)	may	require	
access	outside	of	regular	business	hours.
OST.Q.1n National policy includes provision to ensure that OST is affordable, so as to maximize 
access
The	cost	of	OST	can	be	a	significant	barrier	to	treatment	access	for	many	opioid-dependent	
people.	To	increase	accessibility,	OST	may	be	offered	free	of	charge	(this	would	be	the	best	
practice	but	likely	not	possible	in	the	majority	of	resource-limited	settings),	the	costs	covered	
by	health	insurance	provisions,	the	costs	to	patients	partly	subsidized,	or	provided	free	or	at	
reduced	cost	especially	for	financially	disadvantaged	patients.
OST.Q.1o National guidelines stipulate that patient identity must be confirmed and history of recent 
opioid use established for a patient to be eligible for OST
OST.Q.1p National guidelines specify that comprehensive patient assessment protocols are 
consistently applied
Patient	assessment	for	OST	includes	the	following:
•	 drug	use	history	
•	mental	health	history	and	current	state
•	 comorbid	medical	conditions
•	 psychosocial	assessment	(including	assessment	of	accommodation,	employment,	family,	
cultural	issues,	education	status	and	legal	issues	including	past	incarceration)
•	 clinical	examination,	including	for	physical	signs	of	injecting-related	complications
•	 investigations:	STI	screen;	HIV	treatment	and	care;	hepatitis	screen;	pregnancy	test;	and	
possibly	a	drug	urine	screen.
OST.Q.1q National policy requires all patients to provide informed consent for OST
OST.Q.1r National guidelines require all OST recipients to be registered on a national registration 
system
This	national	registration	system	is	secure	and	maintains	client	confidentiality.	Client	
information	is	not	shared	with	other	services	or	law	enforcement	without	client	consent,	
unless	required	by	law.
OST.Q.1s National guidelines require complete medical records to be kept for all patients
OST.Q.1t National policy stipulates that OST programmes maintain client confidentiality
Services	have	systems	in	place	to	ensure	that	client	records	are	kept	securely	and	remain	
confidential.	Client	information	is	not	shared	with	other	services	or	law	enforcement	without	
client	consent,	unless	required	by	law.	Programme	data	collection	systems	do	not	contain	
clients’	personal	or	identifiable	information.
OST.Q.1u National guidelines require patients to be provided information on potential risks and 
adverse events associated with OST
OST	patients	receive	information	on	adverse	events,	such	as	overdose,	interactions	with	
drugs	and	other	medications	and	information	on	how	to	avoid	these	adverse	events	and	how	
to	respond	should	they	occur.
OST.Q.1v National guidelines stipulate that during OST induction patients are regularly reviewed by a 
clinician in accordance with protocol
The	following	schedule	is	an	example:	
•	 day	1
•	 day	3	or	4
•	 end	of	week	1
•	weekly	for	month	1	or	until	stable	dose	achieved
•	 every	2	weeks	for	first	3	months
•	monthly	thereafter
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OST.Q.1w National guidelines stipulate the maximum initial dose for methadone maintenance 
treatment (MMT) and buprenorphine maintenance treatment (BMT) in line with international 
recommendations
Initial	dose:		<30	mg	for	MMT;	<8	mg	for	BMT.
OST.Q.1x National guidelines stipulate the minimum maintenance does for MMT and BMT
Maintenance	dose:	>60	mg	for	MMT;	>8	mg	for	BMT.
OST.Q.1y National guidelines recommend duration of OST to be 6 months or longer, and no maximum 
duration of treatment is set
OST.Q.1z National guidelines recommend that psychosocial assessment and support are offered to all 
patients
Psychosocial	support	may	include,	as	a	minimum:
•	 assessment	of	psychosocial	needs
•	 supportive	counselling
•	 links	to	existing	family	and	community	services.
Where	resources	and	capacity	permit,	a	variety	of	structured	psychosocial	interventions	are	
offered,	according	to	the	needs	of	the	patient.	These	may	include:
•	 counselling	and	psychotherapy
•	 assistance	with	social	needs	including	accommodation,	employment,	education,	welfare	and	
legal	issues
•	 onsite	psychosocial	support	and	psychiatric	treatment.
OST.Q.1aa National guidelines outline circumstances necessitating involuntary discharge from OST 
Involuntary	discharge	occurs	only	when	it	is	necessary	for	the	safety	of	staff	or	other	clients;	
drug	use	is	not	a	reason	for	discharge	from	OST.	
OST.Q.1ab National guidelines require OST dispensing protocol to be followed
The	process	for	dispensing	OST	is	clear	and	well-described	in	national	guidelines	and	
includes:
•	 patient	identification	must	be	established
•	 dose	is	checked
•	 patient	is	assessed	to	ensure	that	it	is	safe	to	administer	dose
•	 dosing	is	supervised
•	 records	of	dosing	are	kept
•	medication	is	stored	safely.
OST.Q.1ac National guidelines outline systems to prevent OST stock-outs
OST	dispensing	services	must	store	sufficient	quantities	of	opioid	substitution	medication	to	
avoid	stock-outs	and	must	have	reliable	supply	chains	and	robust	procurement	processes.
OST.Q.1ad National guidelines require formalized referral pathways to be established between OST 
programmes and other relevant service providers, and OST clients are referred to these 
services as appropriate
Relevant	services	include:	needle	and	syringe	programmes;	other	drug	dependence	
treatment;	HIV,	viral	hepatitis,	and	TB	testing,	management,	treatment	and	care;	viral	
hepatitis	vaccination;	sexual	health	services	(including	STI	testing	and	treatment);	
reproductive	health	services;	mental	health	services;	general	medical	services;	welfare;	
accommodation	services;	legal	services;	education	services;	and	primary	health	care.	
These	services	may	be	external	to	the	NSP	or	may	be	within	the	same	facility,	if	services	are	
integrated.	Established	referral	pathways	should	meet	the	following	criteria:
•	 The	referring	service	has	a	roster	of	nominated	services	to	which	clients	may	be	referred	and	
has	links	with	these	services.
•	 Services	to	which	clients	are	referred	are	sensitive,	supportive	and	responsive	to	the	needs	of	
PWID	and	are	located	close	to	the	referring	service	or	are	easily	accessible	to	the	client.
•	 Follow-up	and	continuity	of	care	are	strengthened	through	case	management	instituted	by	the	
referring	service.
OST.Q.1ae National guidelines require that OST patients who are detained in closed settings continue 
to receive OST while detained
OST.Q.1af National guidelines require OST recipients in closed settings to be transferred to 
community-based programmes on release
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OST.Q.2 
QUALITY OF OST PROGRAMME SERVICE DELIVERY
These	indicators	examine	the	adherence	to	quality	standards	at	the	service	level.
These	indicators	can	be	used	to	assess	service	delivery	of	an	individual	OST	programme.	
Results from multiple services may be aggregated to determine the proportion of all services 
adhering	to	each	quality	standard.	
OST.Q.2a Long-term	funding	has	been	secured	to	ensure	the	sustainability	of	the	OST	programme (see 
OST.Q.1d)
OST.Q.2b The	programme	has	actively	involved	PWID	in	the	planning	of	OST	services	(see	OST.Q.1e)
OST.Q.2c The	programme	regularly	seeks	anonymous	feedback	from	clients	(see	OST.Q.1f)
OST.Q.2d The	programme	has	a	clear	chain	of	accountability	to	ensure	that	minimum	standards	for	OST	
provision	are	met (see	OST.Q.1g)
OST.Q.2e All	OST	prescribers	have	received	accredited	training	and	are	registered	(see	OST.Q.1h)
OST.Q.2f All	OST	dispensing	staff	has	received	training	in	line	with	national	guidelines	(see	OST.Q.1i)
OST.Q.2g The	OST	programme	is	“low-threshold”,	and	access	is	unrestricted	(see	OST.Q.1j)
OST.Q.2h The	OST	programme	employs	a	range	of	OST	service	delivery	models	to	maximize	reach (see 
OST.Q.1k)
OST.Q.2i The	service	is	situated	in	locations	known	to	be	accessible	to	PWID	(see	OST.Q.1l)
OST.Q.2j The	OST	programme	offers	dispensing	of	OST	at	various	times	of	the	day	(see	OST.Q.1m)
OST.Q.2k The	programme	provides	OST	at	a	cost	that	is	affordable	(see	OST.Q.1n)
OST.Q.2l The	identity	and	history	of	recent	opioid	use	of	all	patients	is	confirmed	prior	to	initiation	of	
OST	(see	OST.Q.1o)
OST.Q.2m Comprehensive	patient	assessment	protocols	are	consistently	applied	(see	OST.Q.1p)
OST.Q.2n All	patients	provide	informed	consent	for	OST	(see	OST.Q.1q)
OST.Q.2o All	OST	recipients	are	registered	on	the	national	registration	system	(see	OST.Q.1r)
OST.Q.2p Complete	medical	records	are	kept	for	all	patients	(see	OST.Q.1s)
OST.Q.2q The	programme	maintains	client	confidentiality	(see	OST.Q.1t)
OST.Q.2r All	patients	receive	information	on	potential	risks	and	adverse	events	associated	with	OST 
(see	OST.Q.1u)
OST.Q.2s During	OST	induction	all	patients	are	regularly	reviewed	by	a	clinician	in	accordance	with	
protocol (see	OST.Q.1v)
OST.Q.2t Initial	dose	for	all	OST	patients	is	less	than	the	maximum	recommended	dose	(see	OST.Q.1w)
OST.Q.2u No	maximum	duration	of	treatment	is	set	(see	OST.Q.1y)
OST.Q.2v Psychosocial	assessment	and	support	are	offered	to	all	patients	(see	OST.Q.1z)
OST.Q.2w Involuntary	discharge	from	OST	occurs	only	when	conditions	outlined	in	national	guidelines	
are	breached	(see	OST.Q.1aa)
OST.Q.2x OST	dispensing	protocol	is	followed	(see	OST.Q.1ab)
OST.Q.2y A	system	to	prevent	OST	stock-outs	has	been	implemented	(see	OST.Q.1ac)
OST.Q.2z Formalized	referral	pathways	between	OST	programmes	and	other	relevant	service	providers	
have	been	established,	and	OST	clients	are	referred	to	these	services	as	appropriate (see 
OST.Q.1ad)
✱
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OST.Q.3
INDIVIDUALS RECEIVING MAINTENANCE OST CONTINUOUSLY FOR AT LEAST 6 MONTHS 
This indicator examines the retention of patients in OST for a minimum period of 6 months; 
evidence demonstrates that maximum benefit from OST is gained when treatment lasts at 
least 6 months (39).	Hence,	this	indicator	can	be	understood	as	a	measure	both	of	how	OST	is	
prescribed	and	of	patient	retention.	
This	indicator	makes	use	of	OST	register	data,	using	a	cohort	study-type	approach.	This	
approach is similar to that used to monitor ART retention and survival and has been piloted in 
the	monitoring	of	programmes	funded	by	the	Global	Fund.			
Indicator: Data source: Comments:
OST.Q.3a Number	of	people	
starting	OST	during	time	
period	defined	as	the	
cohort	recruitment	period
Programme	data OST	register	data	can	be	used	to	
determine	the	number	of	people	
starting	OST	in	the	defined	period,	as	a	
cohort.
OST.Q.3b Number	of	people	
from	the	cohort	still	in	
treatment	6	months	after	
starting	OST
Programme	data OST	register	data	can	be	used	to	
determine	the	number	of	people	from	
the	defined	cohort	(see	above)	who	
are	still	in	treatment	at	6	months	after	
starting	OST.
OST.Q.3c Percentage	of	individuals	
receiving	OST	who	
received	treatment	for	at	
least	6	months
[OST.Q.3a]   
x	100
[OST.Q.3b]
Possible targets:
Low	 60% 	Mid	 80% 	High
OST.Q.4
PATIENTS RECEIVING MAINTENANCE DOSE OF OST GREATER THAN OR EQUAL TO THE 
RECOMMENDED MINIMUM DOSE
Indicator: Data source: Comments:
OST.Q.4a Number	of	people,	
at	a	specified	date,	
maintained	on	MMT	
receiving	a	dose	≥60	mg	
or	currently	maintained	
on	BMT	receiving	a	dose	
of	≥12	mg	
Programme	data OST	register	data	can	be	used	if	these	
registers	record	patients’	OST	dose	
received.
Alternatively,	service-level	data	can	be	
used.	If	service-level	data	collection	
systems	do	not	include	patient	dose,	
then	audit	of	patient	charts	(medical	
records)	can	be	undertaken;	this	
could	be	limited	to	a	random	sample	of	
patient	records	or	could	be	a	review	of	
all	patients,	if	resources	allow.
OST.Q.4b Number	of	people	
receiving	maintenance	
dose	of	OST	at	a	
specified	date	
Programme	data This	number	does	not	include	patients	
currently	being	inducted	into	OST	and	
who	are	yet	to	reach	the	maintenance	
dose;	also	does	not	include	patients	on	
reducing	doses	of	OST.
OST.Q.4c Percentage	of	patients	
receiving	maintenance	
dose	of	OST	greater	
than	or	equal	to	the	
recommended	minimum	
dose
[OST.Q.4a]   
x	100
[OST.Q.4b]
Possible targets:
Low	 60% 	Mid	 90% 	High
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OST.Q.5 INDIVIDUALS ON MAINTENANCE OST RECEIVING PSYCHOSOCIAL SUPPORT 
Indicator: Data source: Comments:
OST.Q.5a Number	of	individuals	on	
OST	who	have	received	
psychosocial	support	in	
the	last	12	months
Programme	data Psychosocial	support	may	include,	as	a	
minimum:
•	assessment of psychosocial needs
•	 supportive counselling
•	 links to existing family and community 
services.
OST.Q.5b Number	of	individuals	
receiving	OST	in	the	last	
12	months	
Programme	data
OST.Q.5c Percentage	of	individuals	
on	OST	receiving	
psychosocial	support	
[OST.Q.5a]   
x	100
[OST.Q.5b]
Possible targets:
Low	 50% 	Mid	 80% 	High
3 HIV TESTING AND COUNSELLING
HTC.A.1
NUMBER OF PWID-TARGETED SITES WHERE HTC IS PROVIDED
For	non-PWID-specific	interventions,	such	as	HTC,	recommended	indicators	focus	on	the	
provision of HTC by PWID-targeted services such as NSPs and drug dependence treatment 
services,	as	well	as	integrated	service	provision	and	referral	to	other	services.	
Indicator: Data source / response: Comments:
HTC.A.1a Number	of	NSP	sites	that	
provide	HIV	testing	and	
counselling	
Programme	data Should	include	only	sites	where	HIV	
testing	is	undertaken	with	informed	
consent,	is	confidential,	and	is	
accompanied	by	counselling.
HTC.A.1b Percentage	of	NSP	sites	
that	provide	HIV	testing	
and	counselling
[HTC.A.1a]   
x	100
[NSP.A.1a]
HTC.A.1c Number	of	drug	
dependence	treatment	
services	that	provide	HIV	
testing	and	counselling
Programme	data Includes	OST	sites	as	well	as	other	drug	
dependence	treatment	service	providers.
Should	include	only	sites	where	HIV	
testing	is	undertaken	with	informed	
consent,	is	confidential,	and	is	
accompanied	by	counselling.
HTC.A.1d Total	number	of	drug	
dependence	treatment	
sites
[OST.A.2a]+[OST.A.2b]+ 
[ODT.A.2a]+[ODT.A.2b]+ 
[ODT.A.2c]+[ODT.A.2d] 
Some	drug	dependence	treatment	sites	
may	offer	more	than	one	type	of	drug-
treatment	intervention.	Each	of	these	
sites	should	be	counted	only	once	in	
the	total	for	this	indicator.
HTC.A.1e Percentage	of	drug	
dependence	treatment	
services	that	provide	HIV	
testing	and	counselling
[HTC.A.1c]   
x	100
[NSP.A.1d]
HTC.A.1f Are	there	mobile	or	
outreach	services	targeting	
PWID	that	provide	HIV	
testing	and	counselling	in	
community	settings?
Yes	/	No
If	yes,	describe	service.
Community-based	testing	can	increase	
the	reach	of	HTC.	Rapid	testing	
techniques	are	particularly	useful	in	
this	context	to	make	testing	and	results	
available	during	the	same	contact.
✱
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HTC.C.1
PWID TESTED FOR HIV IN THE LAST 12 MONTHS
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
HTC.C.1a Number	of	PWID	
tested	for	HIV	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	
3	months)	by	NSPs,	drug	
treatment	services,	or	
other	services	targeting	
PWID	(including	mobile	
or	outreach	services)
Programme	data To	avoid	double-counting,	services	
contributing	data	to	this	indicator	must	
share	a	common	unique	identifier	code	
system.
Clients	tested	on	multiple	occasions	during	
the	12-month	reporting	period	should	be	
counted	only	once	for	this	indicator.
To	be	eligible	to	be	counted	in	this	
indicator,	clients	tested	should	have	
received	their	results.	
HTC.C.1b Percentage	of	all	PWID	
tested	for	HIV	during	
the	specified	reporting	
period	by	NSPs,	drug	
treatment	services,	or	
other	services	targeting	
PWID	(including	mobile	
or	outreach	services)
[HTC.C.1a]   
x	100
   [Pop.1]
Possible targets:
Low	 40% 	Mid	 75% 	High
HTC.C.1c Percentage	of	PWID	who	
were	tested	for	HIV	in	the	
last	12	months	and	who	
know	the	results.	
Behavioural	surveys This	indicator	is	included	in	the	Global	
AIDS	Response	progress	reporting	2012	
(12)	and	in	the	FHI-BSS	(127)	as	follows:
•	 Q1114:	“I	don’t	want	to	know	the	result,	
but	have	you	ever	had	an	HIV	test?”
•	 Q1116:	“Please	do	not	tell	me	the	
result,	but	did	you	find	out	the	result	of	
your	test?”
•	 Q1117:	“When	did	you	have	your	most	
recent	test?”
Note	that	PWID	living	with	HIV	who	
became	aware	of	their	HIV	status	prior	
to	the	last	12 months	will	not	have	been	
tested	in	the	last	12	months	but	would	
answer	yes	to	question	Q1114.
If	linked	to	HIV	sero-surveillance	
(including	anonymous	surveillance),	
the	percentage	of	those	who	are	HIV-
positive	but	unaware	of	their	status	can	
be	determined.
Potential	sampling	bias	should	be	
considered	when	interpreting	results	of	
this	indicator.		
Possible targets:
Low	 40% 	Mid	 75% 	High
✱✱
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4 ANTIRETROVIRAL THERAPY
ART.A.1 AVAILABILITY OF ANTIRETROVIRAL THERAPY FOR PWID
Indicator: Responses: Comments:
ART.A.1a Presence	of	restrictions	
that	limit	access	to	ART	
based	on	a	history	of	
injecting	drug	use	or	
current	injecting	drug	use	
status
Present	/	Absent Restrictions	limiting	access	may	occur	
at	various	levels:	
•	 restrictions	set	out	in	national	policy	
and	guidelines
•	 service-level	restrictions	on	access
•	 restrictions	relating	to	prescriber	
practice/reluctance	to	provide	
treatment	to	PWID.	
If	restrictions	are	present,	their	nature	
and	extent	should	be	described	when	
reported.
ART.A.2
NUMBER OF PWID-TARGETED SITES WHERE ART IS PROVIDED
For	non-PWID-specific	interventions,	such	as	ART,	recommended	indicators	focus	on	the	
provision of ART by PWID-targeted services, such as NSPs and drug treatment services, as 
well	as	integrated	service	provision	and	referral	to	other	services.
Indicator: Data source / responses: Comments:
ART.A.2a Number	of	drug	
treatment	services	that	
provide	ART
Programme	data Sites	provide	assessment,	monitoring,	
prescription	and	dispensing	of	ART.
ART.A.2b Total	number	of	drug	
dependence	treatment	
sites
[OST. A. 2a]+[OST.A.2b]+ 
[ODT. A. 2b]+[ODT.A.2e]+ 
[ODT. A. 2h]+[ODT.A.2k] 
Some	drug	treatment	sites	may	offer	
more	than	one	type	of	drug	treatment	
intervention.	These	sites	should	be	
counted	only	once	in	the	total	for	this	
indicator.	Sites	offering	only	peer-
based	support	groups	are	not	included	
in	this	total.
ART.A.2c Percentage	of	drug	
treatment	services	that	
provide	ART
[ART.A.2a]   
x	100
[ART.A.2b]
ART.A.2d Availability	of	mobile	
or	outreach	services	
targeting	PWID	that	
provide	ART
Present	/	Absent
ART.A.2e Number	of	other	services	
targeting	PWID	that	
provide	ART
Programme	data Other	services	that	target	PWID	might	
include	NSPs,	other	harm	reduction	
services	and	drop-in	centres	targeting	
drug	users.
Sites	provide	assessment,	monitoring,	
prescription	and	dispensing	of	ART.
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✱
ART.C.1
PWID RECEIVING ART
These indicators may be difficult to report on due to the difficulties of identifying ART recipients 
who	have	a	history	of	injecting	drug	use.
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug type injected (opioids/stimulants/other)
Indictor: Data source: Comments:
ART.C.1a Number	of	PWID	
receiving	ART	at a 
specified date
Programme	data This	number	counts	all	ART	recipients	
with	a	history	of	ever	having	engaged	
in	injecting	drug	use,	including	those	
who	are	currently	active	PWID.
It	may	be	difficult	to	determine	which	
ART	recipients	have	a	history	of	
injecting	drug	use.	Typically,	ART	
and	pre-ART	registers	do	not	record	
injecting	drug	use	status	or	history.	
If	these	registers	do	include	this	
information,	it	is	critical	that	client	
confidentiality	is	maintained,	that	
injecting	drug	use	history	or	status	
is	not	shared	with	law	enforcement	
agencies,	and	that	drug	use	history	or	
status	does	not	prejudice	access	to	
treatment.
ART	registration	systems	may	record	
only	the	probable	transmission	
category.	Some	PWID	may	have	
a	different	transmission	category	
recorded	(other	than	injecting),	hence	
underestimating	the	number	of	PWID	
receiving	ART.
ART.C.1b Percentage	of	all	HIV-
positive	PWID	receiving	
ART at a specified date
[ART.C.1a]   
x	100
   [Pop.4]
ART	coverage	of	100%	of	all	HIV-
positive	PWID	is	generally	not	feasible	
or	necessary;	ART	will	not	be	indicated	
for	all	those	living	with	HIV.	Hence,	since	
the	denominator	does	is	not	an	estimate	
of	the	number	of	PWID	in	need	of	ART,	
this	indicator	does	not	directly	measure	
unmet	need.
Possible targets:
Low	 25% 	Mid	 75% 	High
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ART.C.2
RELATIVE PWID ACCESS TO ART
This indicator is a measure of the equity of access to ART for PWID who are HIV-positive 
compared	with	that	for	all	HIV-positive	people.	Commonly,	PWID	have	poorer	access	to	ART	
than non-PWID, despite evidence that provision of ART to PWID has population-wide health 
benefits and that PWID can successfully undergo treatment and benefit from ART (55–57).	
Indicator: Data source: Comments:
ART.C.2a Number	of	all ART 
recipients	at a specified 
date
Programme	data This	number	includes	all	recipients	(i.e.	
PWID	and	non-PWID).	
ART.C.2b Ratio	of	PWID	
receiving	ART	to	
general	population	ART	
coverage
[ART.C.1a]	/	[ART.C.2a]
[Pop.4]	/	[Pop.5]
Target: >1	is	desirable
ART.Q.1 
NATIONAL POLICY AND LEGISLATION – ART FOR PWID
Are the following standards and programme features included in national legislation, policy 
and guidance?
ART.Q.1a National policy supports the provision of ART to PWID living with HIV
ART.Q.1b National ART guidelines are developed at the country level or lower and include the provision 
of ART to PWID
These	guidelines	are	detailed,	comprehensive	and	evidence-based	and	reflect	local	laws,	
policies	and	conditions;	they	are	consistent	with	international	guidance	(e.g.	relevant	WHO	
guidelines)	and	include	the	provision	of	ART	to	current	and	former	PWID.
ART.Q.1c National strategy includes steps to secure long-term funding to ensure sustainability of 
providing ART for PWID 
Long-term	government	funding	should	be	committed	to	the	ongoing	operation	of	programmes	
providing	ART	for	PWID;	if	services	are	funded	by	external	sources,	the	sustainability	of	this	
funding	should	be	assessed,	and	contingencies	for	funding	gaps	should	be	determined.	
ART.Q.1d National policy stipulates that PWID be actively involved in the planning of ART provision for 
PWID
This	involves	consultation	with	and	meaningful	involvement	of	PWID	in	the	development	of	
services	to	ensure	that	they	are	appropriate	and	acceptable	to	the	target	population. 
ART.Q.1e National guidelines stipulate that ART services regularly seek anonymous feedback from 
clients 
Mechanisms	are	in	place	whereby	clients	can	confidentially/anonymously	provide	feedback	
on	the	service.	The	service	should	be	responsive	to	this	information. 
ART.Q.1f National policy stipulates a clear chain of accountability within ART services, and within 
the health system more broadly, to ensure that minimum standards for the provision of ART 
are met.
ART.Q.1g National policy requires that ART prescribers receive accredited training
All	ART	prescribers	are	required	to	take	accredited	post-graduate	training	and	encouraged/
required	to	participate	in	continuing	education,	monitoring	and	evaluation.	Prescribers	
are	respectful	towards	PWID,	have	credibility	with	the	target	population	and	are	non-
judgemental	in	their	attitude	towards	drug	users.
✱
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ART.Q.1h National policy stipulates that ART services are “low-threshold” and do not require PWID to 
meet specific criteria in order to access ART
Only	clinical	criteria	determine	access	to	ART;	access	is	not	restricted	on	the	basis	of	
minimum	age,	injecting	history	or	current	status,	gender,	or	citizenship	or	residency	status,	
incarceration	or	criminal	history.
ART.Q.1i National guidelines require ART prescription to be provided via a range of service delivery 
models 
Includes:	general	practitioner	prescribers/office-based	and	prescription	by	specialist/from	
specialist	services.
ART.Q.1j National guidelines require that ART prescribers and dispensing services are located in 
areas accessible to PWID
Mapping	of	the	target	population	may	be	required	to	determine	accessibility	of	a	location	for	
PWID.
ART.Q.1k National policy includes provision to ensure that ART is affordable 
The	cost	of	ART	can	be	a	significant	barrier	to	treatment	access	if	patients	are	required	to	
cover	these	costs	themselves,	particularly	for	PWID.	To	increase	accessibility,	ART	may	
be	offered	free	of	charge	(this	would	be	the	best	practice	but	may	not	be	possible	in	many	
resource-limited	settings),	the	costs	covered	by	health	insurance	provisions,	the	costs	to	
patients	partly	subsidized,	or	provided	free	or	at	reduced	costs	especially	for	financially	
disadvantaged	patients.
ART.Q.1l National guidelines stipulate that ART service providers involve multidisciplinary teams in 
the provision of HIV treatment and care
Multidisciplinary	teams	for	the	provision	of	HIV	treatment	and	care	may	include	physicians,	
nurses,	counsellors/psychologists,	social	workers,	peer	educators/supporters.
ART.Q.1m National guidelines specify comprehensive patient assessment protocols that include PWID-
specific issues 
Issues	particularly	relating	to	PWID	that	should	be	addressed	during	assessment	include:	
•	 drug	use	history—particularly	current	use;	signs	of	drug	use	and	related	conditions	and	
complications	on	examination	(unless	suspected	drug	use	is	denied	by	the	client,	drug	urine	
testing	is	not	necessarily	indicated,	as	it	is	unlikely	to	change	management);
•	 experience	with	drug	dependence	treatment—past	and	present;
•	 history	of	mental	illness;	current	state	assessed	using	standardized	screening	instruments,	in	
particular	depression	and	psychotic	symptom	scales;
•	 signs	and	symptoms	of	opportunistic	infections	(bearing	in	mind	that	PWID	may	often	present	
late,	with	advanced-stage	disease);
•	 detailed	social	assessment,	including	social	stability	and	support	(family,	community);	
accommodation	stability	(homelessness);	major	life	events/crises;	employment	status	and	
financial	security;	legal	issues,	prior	incarceration,	pending	criminal	charges;	and	education	
status;
•	 assessment	of	preparedness	for	treatment;
•	 HBV,	HCV	exposure,	infection,	immunization	(HBV),	plus	investigations—serology,	liver	
function	tests;
•	 TB:	exposure,	infection,	prevention,	symptoms	and	signs.
ART.Q.1n National guidelines recommend that ART be initiated for all people living with HIV, including 
PWID, when WHO-defined criteria are met
Current	WHO	criteria	(2010)	recommend	that	ART	be	initiation	in	any	of	the	following	
circumstances:
•	 CD4	count	≤350	cells/mm3
•	 symptomatic	and	WHO	clinical	stage	3	or	4
•	 pregnant	and	WHO	clinical	stage	3	or	4
•	 Active	TB
•	 treatment	for	HBV	required.
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ART.Q.1o National policy requires that all patients provide informed consent for ART
ART.Q.1p National guidelines require complete medical records to be kept for all patients
ART.Q.1q Nation policy stipulates that ART programmes maintain client confidentiality 
Services	have	systems	in	place	to	ensure	that	client	records	are	kept	securely	and	remain	
confidential.	Client	information	is	not	shared	with	other	services	or	law	enforcement	without	
client	consent,	unless	required	by	law.	Programme	data	collection	systems	do	not	contain	
clients’	personal,	or	identifiable,	information.	
ART.Q.1r National guidelines stipulate pre-treatment counselling be provided to all patients including 
PWID
Issues	that	should	be	addressed	when	providing	pre-treatment	counselling	for	PWID	living	
with	HIV	include:
•	 implications	of	infection	status
•	 implications	of	disclosure
•	 partners	and	other	contacts
•	 risk	of	super-infection
•	 HIV	risk	reduction	strategies
•	 implications	of	drug	use	for	ART	treatment,	including	interactions
•	 drug	dependence	treatment	options,	including	interactions
•	 need	for	ongoing	monitoring
•	 opportunistic	infections
•	 HCV,	HBV	and	TB	prevention,	infection	and	implications
•	 social	supports:	family,	social/community	contacts	and	intimate	partnerships
•	 preparedness	for	treatment.
ART.Q.1s National guidelines require that ART recipients receive information on potential risks, side-
effects and drug interactions associated with ART
ART	clients	should	receive	information	on	adverse	events	and	interactions	with	drugs	and	
other	medications.	Clients	should	receive	information	on	how	to	avoid	these	adverse	events,	
what	the	warning	signs	are,	how	to	respond	should	they	occur,	and	when	to	seek	medical	
assistance.
ART.Q.1t National guidelines stipulate that all people living with HIV, including PWID, who do not 
meet criteria for ART receive regular monitoring of viral load and CD4 count per WHO 
guidelines
WHO	guidelines	recommend	measuring	viral	load	and	CD4	count	every	6	months	in	persons	
living	with	HIV	pre-ART.
ART.Q.1u National guidelines stipulate that all ART recipients, including PWID, are reviewed regularly 
per WHO guidelines
•	 The	frequency	and	intervals	for	monitoring	ART	recipients	differ	among	ART	regimens.
•	 Viral	load	and	CD4	count	help	to	gauge	the	success	of	treatment.
•	 Additional	tests	include	liver	function	tests,	lipids	and	renal	function.
Patients	should	be	assessed	for	toxicity	and	side-effects	and	these	responded	to,	if	detected.
ART.Q.1v National guidelines recommend that all ART recipients, including PWID, are offered case 
management.
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ART.Q.1w National guidelines recommend protocols for adherence strategies and offering adherence 
support to all patients, including appropriate strategies for PWID
Adherence	support	strategies	for	PWID	include:
•	management	of	drug	dependence
•	 education	and	information	on	the	need	for	ART
•	 clear	and	accurate	information	addressing	concerns	and	misconceptions
•	 regular	patient	evaluation
•	 peer	support
•	 strengthening/facilitating	social	and	family	support
•	 addressing	social	issues	such	as	accommodation,	financial	insecurity	(provide	social	
protection),	legal	and	other	issues
•	 provide	accurate	and	clear	information	on	side-effects,	alarm	signals	and	when	to	see	a	
doctor
•	 information	on	interactions	with	other	drugs,	both	prescribed	and	extra-medical
•	 treating	comorbid	mental	health	conditions
•	 directly	observed	ARV	treatment,	particularly	when	linked	to	drug	dependence	(e.g.	OST)	or	
other	infectious	disease	(e.g.	TB)	treatment	for	which	supervised	treatment	may	already	take	
place	
•	 dispensing	medication	in	small	amounts	at	frequent	intervals	to	detect	non-adherence.
ART.Q.1x National guidelines recommend providing access to drug dependence treatment services for 
drug dependent ART recipients
Adherence	to	drug	dependence	treatment	is	NOT	a	pre-requisite	for	access	to	ART.	OST	
should	be	considered	a	first-line	treatment	for	opioid	dependence	among	persons	living	
with	HIV.	Drug-dependent	people	on	ART	should	have	drug	dependence	addressed	by	their	
management	plan.
ART.Q.1y National guidelines recommend providing psychosocial support to all ART patients, 
including approaches appropriate for PWID
Psychosocial	support	may	include,	as	a	minimum:
•	 assessment	of	psychosocial	needs
•	 supportive	counselling
•	 links	to	existing	family	and	community	services.
Best	practice:	Where	resources	and	capacity	permit,	a	variety	of	structured	psychosocial	
interventions	should	be	offered,	according	to	the	needs	of	the	patient.	These	may	include:
•	 different	forms	of	counselling	and	psychotherapy
•	 assistance	with	social	needs	including	finances,	accommodation,	employment,	education,	
welfare	and	legal	issues
•	 onsite	psychosocial	support	and	psychiatric	treatment.
ART.Q.1z National guidelines recommend that ART recipients, including PWID, undergo a mental 
health assessment and receive counselling, treatment and support when indicated
ART.Q.1aa National guidelines include protocols for providing prophylaxis for opportunistic infections 
in people living with HIV, including PWID, pre-ART and with ART, if indicated
ART.Q.1ab National guidelines require ART programmes to ensure that patients who are co-infected 
with TB, HCV or HBV receive appropriate treatment for these infections
See	also	indicators	related	to	services	for	the	prevention,	diagnosis	and	treatment	of	viral	
hepatitis	(Hep.A.1–Hep.A.4;	Hep.C.1–Hep.C.3)	and	TB	(TB.A.1–TB.A.3;	TB.C.1,	TB.C.2)
ART.Q.1ac ART patients who are detained in closed settings continue to receive ART while detained, 
and treatment interruptions are prevented
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ART.Q.2
QUALITY OF ART SERVICE DELIVERY FOR PWID
These	indicators	examine	the	adherence	to	quality	standards	at	the	service	level.
These	indicators	can	be	used	to	assess	service	delivery	of	an	individual	ART	programme.	
Results from multiple services may be aggregated to determine the proportion of all services 
adhering	to	each	quality	standard.	
ART.Q.2a Long-term	funding	has	been	secured	to	ensure	the	sustainability	of	providing	ART	for	PWID 
(see	ART.Q.1c)
ART.Q.2b The	programme	has	actively	involved	PWID	in	planning	ART	provision	for	PWID (see	ART.Q.1d)
ART.Q.2c The	programme	seeks	regular	anonymous	feedback	from	clients (see	ART.Q.1e)
ART.Q.2d The	programme	has	a	clear	chain	of	accountability	to	ensure	that	minimum	standards	for	the	
provision	of	ART	are	met.	(see	ART.Q.1f)
ART.Q.2e All	ART	prescribers	receive	accredited	training (see	ART.Q.1g)
ART.Q.2f The	ART	provision	is	“low-threshold”	and	does	not	require	PWID	to	meet	specific	criteria	in	
order	to	access	ART	(see	ART.Q.1h)
ART.Q.2g The	service	is	situated	in	a	location	known	to	be	accessible	to	PWID (see	ART.Q.1j)
ART.Q.2h The	programme	provides	ART	at	a	cost	that	is	affordable (see	ART.Q.1k)
ART.Q.2i A	multidisciplinary	team	provides	HIV	treatment	and	care (see	ART.Q.1l)
ART.Q.2j Comprehensive	patient	assessment	protocols	that	include	PWID-specific	issues	are	
consistently	applied (see	ART.Q.1m)
ART.Q.2k ART	is	initiated	for	all	people	living	with	HIV,	including	PWID,	when	WHO-defined	criteria	are	
met (see	ART.Q.1n)
ART.Q.2l All	patients	provide	informed	consent	for	ART (see	ART.Q.1o)
ART.Q.2m Complete	medical	records	are	kept	for	all	patients (see	ART.Q.1p)
ART.Q.2n The	programme	maintains	client	confidentiality (see	ART.Q.1q) 
ART.Q.2o Pre-treatment	counselling	is	provided	to	all	patients,	including	PWID (see	ART.Q.1r)
ART.Q.2p ART	recipients	receive	information	on	potential	risks,	side-effects	and	drug	interactions	
associated	with	ART (see	ART.Q.1s)
ART.Q.2q All	patients	living	with	HIV,	including	PWID,	who	do	not	meet	criteria	for	ART	receive	regular	
monitoring	of	viral	load	and	CD4	count,	per	WHO	guidelines (see	ART.Q.1t)
ART.Q.2r All	ART	recipients,	including	PWID,	are	reviewed	regularly,	per	WHO	guidelines (see 
ART.Q.1u)
ART.Q.2s All	ART	recipients,	including	PWID,	are	offered	case	management (see	ART.Q.1v)
ART.Q.2t Adherence	support	is	offered	to	all	patients,	including	appropriate	strategies	for	PWID (see 
ART.Q.1w)
ART.Q.2u Access	to	drug	dependence	treatment	services	is	provided	for	drug	dependent	ART	recipients 
(see	ART.Q.1x)
ART.Q.2v Psychosocial	support	is	provided	to	all	ART	patients,	including	approaches	appropriate	for	
PWID (see	ART.Q.1y)
ART.Q.2w ART	recipients,	including	PWID,	undergo	a	mental	health	assessment	and	receive	
counselling,	treatment	and	support	when	indicated (see	ART.Q.1z)
ART.Q.2x Protocols	are	followed	for	providing	prophylaxis	for	opportunistic	infections	in	people	living	
with	HIV,	including	PWID,	pre-ART	and	with	ART	if	indicated (see	ART.Q.1aa)
ART.Q.2y Patients	who	are	co-infected	with	TB,	HCV	or	HBV	receive	appropriate	treatment	for	these	
infections (see	ART.Q.1ab)
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ART.Q.3 PWID ON ART RECEIVING ADHERENCE SUPPORT
Indicator: Data source: Comments:
ART.Q.3a Number	of	PWID	on	
ART	who	have	received	
adherence	support
Programme	data See	ART.Q.1w	for	examples	of	
adherence	support.
ART.Q.3b Number	of	PWID	on	ART Programme	data
ART.Q.3c Percentage	of	PWID	on	
ART	who	also	receive	
adherence	support
[ART.Q.3a]   
x	100
[ART.Q.3b]
Possible targets:
Low	 60% 	Mid	 80% 	High
ART.Q.4 PWID ON ART RECEIVING CASE MANAGEMENT
Indicator: Data source: Comments:
ART.Q.4a Number	of	PWID	on	ART	
who	have	received	case	
management
Programme	data Requires	ART	registers	to	record	
injecting	drug	use	status	and	whether	
or	not	patient	has	received	case	
management.ART.Q.4b Number	of	PWID	on	ART Programme	data
ART.Q.4c Percentage	of	PWID	on	
ART	who	have	received	
case	management
[ART.Q.4a]   
x	100
[ART.Q.4b]
Possible targets:
Low	 60% 	Mid	 80% 	High
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5 SEXUALLY TRANSMITTED INFECTION PREVENTION, DIAGNOSIS AND 
TREATMENT
STI.C.1
PWID SCREENED OR TREATED FOR STIS AT SERVICES TARGETING PWID
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
STI.C.1a Total	number	of	PWID	
screened	or	treated	for	
STIs	at	NSP	sites,	drug	
treatment	service	sites	
(including	OST)	and	other	
service	targeting	PWID	
during	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)
Programme	data
STI.C.1b Percentage	of	PWID	
screened	or	treated	
for	STIs	at	NSP	sites,	
drug	treatment	service	
sites,	and	other	services	
targeting	PWID	during	
the	specified	reporting	
period
[STI.C.1a]   
x	100
   [Pop.1]
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6 CONDOM	DISTRIBUTION	PROGRAMMES	FOR	PWID	AND	THEIR	SEXUAL	
PARTNERS
Cdm.C.1
QUANTITY OF CONDOMS DISTRIBUTED BY SERVICES TARGETING PWID
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
Cdm.C.1a Total	number	of	condoms	
distributed	by	NSPs,	drug	
treatment	service	sites	
(including	OST)	and	other	
services	targeting	PWID	
during	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3 months)
Programme	data This	count	includes	both	male	and	
female	condoms.	Disaggregation	by	
condom	type	(male/female)	may	be	
undertaken	if	desired.
Cdm.C.1b Number	of	condoms	
distributed	by	PWID-
targeted	services	
per	PWID	during	the	
specified	reporting	
period	
[Cdm.C.1a]
[Pop.1]
Possible targets:
Low	 50 	Mid	 100 	High
Cdm.C.2
PWID RECEIVING CONDOMS IN THE LAST 12 MONTHS
Recommended disaggregations: 
Gender (male/female/transgender)
Age (<25 years of age/≥25 years of age)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
Cdm.C.2a Percentage	of	PWID	who	
report	having	been	given	
condoms	through	an	
outreach	service,	drop-in	
centre	or	sexual	health	
clinic	during	the	last	12	
months
Behavioural	surveys This	indicator	is	included	in	the	Global	
AIDS	Response	progress	reporting	
2012	(12).	It	can	be	collected	in	a	
behavioural	surveillance	survey.	It	is	
important	to	consider	issue	of	sample	
representativeness	and	bias.
Possible targets:
Low	 40% 	Mid	 75% 	High
✱
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7 TARGETED	INFORMATION,	EDUCATION	AND	COMMUNICATION	FOR	PWID	
AND THEIR SEXUAL PARTNERS
IEC.C.1
FREQUENCY OF NSP OCCASIONS OF SERVICE WHERE IEC IS PROVIDED
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
IEC.C.1a Number	of	NSP	
occasions	of	service	
in	which	PWID	were	
provided	with	targeted	
IEC	during	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)
Programme	data Data	collection	for	this	indicator	
requires	services	to	record	instances	
when	a	client	receives	IEC.
IEC.C.1b Percentage	of	NSP	
occasions	of	service	
in	which	PWID	were	
provided	with	targeted	
IEC	during	the	specified	
reporting	period
 [IEC.C.1a]     
x	100
[NSP.C.4a]
Possible targets:
Low	 25% 	Mid	 50% 	High
✱
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IEC.C.2
PWID RECEIVING IEC
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
IEC.C.2a Number	of	PWID	
receiving	targeted	IEC	
provided	by	NSPs,	drug	
treatment	service	sites	
(including	OST)	and	other	
services	targeting	PWID	
during	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)
Programme	data This	indicator	requires	services	to	have	
a	data	collection	system	using	unique 
identifier codes (UIC,	see	page	37	for	
more	detail)	to	allow	determination	of	
the	total	number	of	individual	clients	
accessing	the	service	during	the	
reporting	period	and	avoid	double-
counting	clients	who	access	the	
service	more	than	once.	It	also	requires	
services	to	record	instances	when	a	
client	receives	IEC.
IEC	and,	hence,	related	data	may	come	
from	multiple	types	of	services;	use	
of	the	same	UIC	system	and	linkage	of	
data	collection	systems	is	required	for	
this	indicator.
IEC.C.2b Percentage	of	PWID	
receiving	targeted	IEC	
provided	by	NSPs,	drug	
treatment	service	sites	
(including	OST)	and	other	
services	targeting	PWID	
during	the	reporting	
period
[IEC.C.2a]   
x	100
   [Pop.1]
Possible targets:
Low	 50% 	Mid	 90% 	High
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8 PREVENTION, VACCINATION, DIAGNOSIS AND TREATMENT FOR VIRAL 
HEPATITIS 
Hep.A.1
NUMBER OF PWID TARGETED SERVICES PROVIDING HEPATITIS B VACCINATION 
For	non-PWID-specific	interventions,	such	as	HBV	vaccination,	recommended	indicators	
focus on the provision of HBV vaccination by PWID-targeted services, such as NSPs and drug 
treatment	services,	as	well	as	integrated	service	provision	and	referral	to	other	services.
The provision of HBV vaccination is of relevance in settings where childhood vaccination 
programmes are either absent or where these programmes are yet to result in coverage of the 
adult	population.	
Indicator: Data source: Comments:
Hep.A.1a Number	of	NSP	sites	that	
provide	HBV	vaccination
Programme	data
Hep.A.1b Percentage	of	NSP	
sites	that	provide	HBV	
vaccination
[Hep.A.1a]   
x	100
[NSP.A.1a]
Hep.A.1c Number	of	drug	
treatment	sites	(including	
OST)	that	provide	HBV	
vaccination
Programme	data
Hep.A.1d Total	number	of	drug	
treatment	sites
[OST.A.2a]+[OST.A.2b]+ 
[ODT.A.2a]+[ODT.A.2b]+ 
[ODT.A.2c]+[ODT.A.2d]
Some	drug	treatment	sites	may	offer	
more	than	one	type	of	drug	treatment	
intervention.	These	sites	should	be	
counted	only	once	in	the	total	for	this	
indicator.	Sites	offering	only	peer-
based	support	groups	are	not	included	
in	this	total.
Hep.A.1e Percentage	of	drug	
treatment	sites	(including	
OST	sites)	that	provide	
HBV	vaccination
[Hep.A.1c]   
x	100
[Hep.A.1d]
Hep.A.2
NUMBER OF PWID-TARGETED SERVICES AND ART PROVISION SITES PROVIDING HBV 
TREATMENT 
The presence of chronic active hepatitis B infection requiring treatment among those infected 
with	HIV	is	an	indication	for	the	initiation	of	ART.	ART	services,	therefore,	have	cause	to	
manage	hepatitis	treatment	among	co-infected	individuals.
Indicator: Data source: Comments:
Hep.A.2a Number	of	ART	provision	
sites	that	provide	HBV	
treatment
Programme	data
Hep.A.2b Number	of	ART	provision	
sites
Programme	data
Hep.A.2c Percentage	of	ART	
provision	sites	that	
provide	HBV	treatment
[Hep.A.2a]   
x	100
[Hep.A.2b]
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Indicator: Data source: Comments:
Hep.A.2d Number	of	drug	
treatment	sites	(including	
OST)	that	provide	HBV	
treatment
Programme	data
Hep.A.2e Total	number	of	drug	
treatment	sites
[OST.A.2a]+[OST.A.2b]+ 
[ODT.A.2a]+[ODT.A.2b]+ 
[ODT.A.2c]+[ODT.A.2d] 
Some	drug	treatment	sites	may	offer	
more	than	one	type	of	drug	treatment	
intervention.	These	sites	should	be	
counted	only	once	in	the	total	for	this	
indicator.	Sites	offering	only	peer-
based	support	groups	are	not	included	
in	this	total.
Hep.A.2f Percentage	of	drug	
treatment	sites	(including	
OST	sites)	that	provide	
HBV	treatment
[Hep.A.2d]   
x	100
[Hep.A.2e]
Hep.A.2g Number	of	other	services	
targeting	PWID	that	
provide	HBV	treatment
Programme	data This	number	might	include	primary	
health	care	settings	targeting	PWID	
specifically.
Hep.A.3 AVAILABILITY OF HEPATITIS C TREATMENT FOR PWID
Indicator: Responses: Comments:
Hep.A.3a Presence	of	restrictions	
that	limit	access	to	HCV	
treatment	based	on	a	
history	of	injecting	drug	
use	or	current	injecting	
drug	use	status
Present	/	Absent Restrictions	limiting	access	may	occur	
at	various	levels	including:	restrictions	
set	out	in	national	policy	and	
guidelines;	service-level	restrictions	
on	access;	and	restrictions	relating	to	
prescriber	practice.	
If	restrictions	are	present,	their	nature	
and	extent	should	be	described	when	
reported.
✱
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Hep.A.4
NUMBER OF PWID-TARGETED SERVICES AND ART PROVISION SITES PROVIDING HEP C 
MANAGEMENT AND TREATMENT 
Indicator: Data source: Comments:
Hep.A.4a Number	of	ART	provision	
sites	that	provide	
HCV	management	and	
treatment
Programme	data
Hep.A.4b Number	of	ART	provision	
sites
Programme	data
Hep.A.4c Percentage	of	ART	
provision	sites	that	
provide	HCV	management	
and	treatment
[Hep.A.4a]   
x	100
[Hep.A.4b]
Hep.A.4d Number	of	drug	
treatment	sites	(including	
OST)	that	provide	HCV	
treatment
Programme	data
Hep.A.4e Total	number	of	drug	
treatment	sites
[OST.A.2a]+[OST.A.2b]+ 
[ODT.A.2b]+[ODT.A.2e]+ 
[ODT.A.2h]+[ODT.A.2k]  
Some	drug	treatment	sites	may	offer	
more	than	one	type	of	drug	treatment	
intervention.	These	sites	should	be	
counted	only	once	in	the	total	for	this	
indicator.
Hep.A.4f Percentage	of	drug	
treatment	sites	(including	
OST	sites)	that	provide	
HCV	treatment
[Hep.A.4d]   
x	100
[Hep.A.4e]
Hep.A.4g Number	of	other	services	
targeting	PWID	that	
provide	HCV	treatment
Programme	data This	might	include	primary	health	care	
settings	that	specifically	target	PWID.
Hep.C.1
PWID RECEIVING HBV VACCINATION FROM PWID-TARGETED SERVICES
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
Hep.C.1a Total	number	of	PWID	
receiving	HBV	vaccination	
provided	by	NSPs,	drug	
treatment	services	and	
other	services	targeting	
PWID,	including	mobile	or	
outreach	services,	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)
Programme	data Reporting	these	data	requires	the	
data	collection	systems	of	all	PWID-
targeted	services	providing	HBV	
vaccination	to	record	the	number	of	
PWID	receiving	HBV	vaccination.
✱
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Hep.C.2
PWID RECEIVING HBV TREATMENT FROM PWID-TARGETED SERVICES AND ART 
PROVISION SITES
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
Hep.C.2a Total	number	of	PWID	
receiving	treatment	for	
HBV	provided	by	drug	
treatment	services	and	
other	services	targeting	
PWID,	including	mobile	or	
outreach	services,	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)	or	at	a	specified	
date
Programme	data Reporting	these	data	requires	the	
data	collection	systems	of	all	PWID-
targeted	services	providing	HBV	
treatment	to	record	the	number	of	
PWID	receiving	HBV	treatment.	
If	12-month	data	are	reported,	the	
count	includes	the	number	of	PWID	
receiving	treatment	at	the	start	of	the	
12-month	period	and	the	total	number	
of	PWID	started	on	HBV	treatment	
during	the	12-month	period.
Hep.C.2b Total	number	of	PWID	
receiving	treatment	for	
HBV	provided	by	ART	
service	sites	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)	or	at	a	specified	
date
Programme	data Reporting	these	data	requires	ART	
service-level	data	collection	systems	
to	record	the	number	of	patients	
receiving	HBV	treatment.	If	these	data	
collection	systems	also	record	patient	
history	of	injecting	drug	use,	then	the	
number	of	PWID	receiving	treatment	
from	these	sites	can	be	reported.	If	this	
information	is	not	available,	the	number	
of	all	patients	receiving	HBV	treatment	
provided	by	ART	services	can	be	
reported.
If	12-month	data	are	reported,	the	
count	includes	the	number	of	patients	
receiving	treatment	at	the	start	of	the	
12-month	period	and	the	total	number	
of	patients	started	on	HBV	treatment	
during	the	12-month	period.
It	is	critical	that	client	confidentiality	
is	maintained,	that	injecting	drug	use	
history	or	status	is	not	shared	with	law	
enforcement	agencies,	and	that	drug	
use	history	or	status	does	not	prejudice	
access	to	treatment.
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Hep.C.3
PWID RECEIVING HCV TREATMENT FROM PWID-TARGETED SERVICES AND ART 
PROVISION SITES
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID, the population size estimate used as the denominator 
should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Drug injected (opioids/stimulants/other)
Indicator: Data source: Comments:
Hep.C.3a Total	number	of	PWID	
receiving	HCV	treatment	
provided	by	NSPs,	drug	
treatment	services	and	
other	services	targeting	
PWID,	including	mobile	or	
outreach	services,	during	
the	specified	reporting	
period	(e.g.	last	12,	6	or	3	
months)	or	at	a	specified	
date
Programme	data Reporting	these	data	requires	the	
data	collection	systems	of	all	PWID-
targeted	services	providing	HCV	
treatment	to	record	the	number	of	
PWID	receiving	HCV	treatment.	
If	12-month	data	are	reported,	the	
count	includes	the	number	of	PWID	
receiving	treatment	at	the	start	of	the	
12-month	period	and	the	total	number	
of	PWID	started	on	HCV	treatment	
during	the	12-month	period.
Hep.C.3b Total	number	of	PWID	
receiving	HCV	treatment	
provided	by	ART	services	
during	the	specified	
reporting	period	(e.g.	last	
12,	6	or	3	months)	or	at	a	
specified	date
Programme	data Reporting	these	data	requires	ART	
service-level	data	collection	systems	
to	record	the	number	of	patients	
receiving	HCV	treatment.	If	these	data	
collection	systems	also	record	patient	
history	of	injecting	drug	use,	then	the	
number	of	PWID	receiving	treatment	
from	these	sites	can	be	reported.	If	this	
information	is	not	available,	the	number	
of	all	patients	receiving	HCV	treatment	
provided	by	ART	services	can	be	
reported.
If	12-month	data	are	reported,	the	
count	includes	the	number	of	patients	
receiving	treatment	at	the	start	of	the	
12-month	period	and	the	total	number	
of	patients	started	on	HCV	treatment	
during	the	12-month	period.
It	is	critical	that	client	confidentiality	
is	maintained,	that	injecting	drug	use	
history	or	status	is	not	shared	with	law	
enforcement	agencies,	and	that	drug	
use	history	or	status	does	not	prejudice	
access	to	treatment.
✱
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Indicator: Data source: Comments:
Hep.C.3c Total	number	of	PWID	
receiving	HCV	treatment	
as	recorded	on	HCV	
treatment	registries
Programme	data As	with	ART	and	pre-ART	registries,	
some	countries	may	have	developed	
HCV	treatment	registries.	If	this	is	the	
case,	and	if	patients’	injecting	drug	use	
history	is	recorded,	the	total	number	of	
PWID	receiving	HCV	treatment	can	be	
reported.
If	these	registers	do	include	injecting	
drug	use	history,	it	is	critical	that	client	
confidentiality	is	maintained,	that	
injecting	drug	use	history	or	status	
is	not	shared	with	law	enforcement	
agencies,	and	that	drug	use	history	or	
status	does	not	prejudice	access	to	
treatment.
Hep.C.3d Percentage	of	HCV-
infected	PWID	receiving	
HCV	treatment	during	
the	specified	reporting	
period	or	at	a	specified	
date
[Hep.C.3a]+[Hep.C.3b]
	x	100
            [Pop.6]
OR:
[Hep.C.3c]   
x	100
   [Pop.6]
If	a	complete	HCV	treatment	register	
exists	and	injecting	drug	use	history	
is	recorded,	it	may	be	possible	to	
estimate	coverage	of	treatment	
relative	to	the	current	PWID	population	
infected	with	HCV.
If	registration	data	are	not	available,	
it	may	be	possible	to	aggregate	
HCV	treatment	data	across	service	
providers	if	PWID	on	treatment	can	
be	counted	in	these	systems.	This	
aggregation	may	not,	however,	include	
all	PWID	currently	receiving	HCV	
treatment	if	treatment	is	also	provided	
at	other	services.
It	is	important	to	note	that	in	either	
case	this	indicator	measures	the	
number	of	those	in	treatment	with	a	
history	of	injecting	drug	use	against	the	
number	of	current	PWID	who	are	HCV-
infected.	Those	infected	with	HCV	who	
have	a	history	of	injecting	drug	use	
but	who	have	not	injected	in	the	last	
12 months	(as	per	the	definition	used	
in	this	guide	and	elsewhere)	will	not	
be	included	in	the	estimated	number	of	
past-year	injectors	with	HCV,	used	as	
the	denominator	for	this	indicator.
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9 PREVENTION, DIAGNOSIS AND TREATMENT OF TUBERCULOSIS 
TB.A.1
TB INFECTION CONTROL AT PWID-TARGETED SERVICES
It is recommended that simple TB infection control measures be implemented by all health 
care	settings	where	patients	congregate,	including	drug	services.	TB	infection	control	should	
include environmental and personal protection measures to reduce the risk of TB transmission, 
including the protection of personnel and any potential contacts of people with possible or 
confirmed	TB.	Environmental	control	measures	include	ventilation,	air	cleaners	and	ultraviolet	
germicidal irradiation (96,97).	
Indicator: Data source: Comments:
TB.A.1a Number	of	drug	
treatment	sites	where	
demonstrable	infection	
control	practices	include	
TB	infection	control
Programme	data For	a	service	to	be	identified	as	having	
a	TB	infection	control	policy	consistent	
with	international	guidelines,	the	
following	criteria	must	be	met,	and	
relevant	documentation	should	be	
available:
•	 The	service	has	a	written	infection	
control	plan,	and	a	hard	copy	of	this	
plan	is	available.
•	 The	service	has	a	person	responsible	
for	implementing	the	TB	infection	
control	plan.
•	 All	areas	where	clients	congregate—
for	example,	waiting	areas—are	well-
ventilated	(e.g.	windows	and	doors	
open).
•	 Clients	suspected	of	having	TB	are	
identified	on	arrival	at	the	facility	and	
separated	from	other	clients.
•	 TB	cases	reported	among	health	care	
workers	are	routinely	monitored	and	
reported.
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TB.A.2
NUMBER OF PWID-TARGETED SERVICES PROVIDING TB PREVENTIVE THERAPY
Isoniazid preventive therapy is recommended for injecting drug users living with HIV once 
active TB has been reasonable excluded (96,97).
Indicator: Data source: Comments:
TB.A.2a Number	of	NSP	sites	that	
provide	TB	preventive	
therapy
Programme	data
TB.A.2b Percentage	of	NSP	
sites	that	provide	TB	
preventive	therapy
 [TB.A.2a]    
x	100
[NSP.A.1a]
TB.A.2c Number	of	drug	
treatment	sites	(including	
OST)	that	provide	TB	
preventive	therapy
Programme	data
TB.A.2d Total	number	of	drug	
treatment	sites
[OST.A.2a]+[OST.A.2b]+ 
[ODT.A.2b]+[ODT.A.2e]+ 
[ODT.A.2h]+[ODT.A.2k]  
Some	drug	treatment	sites	may	offer	
more	than	one	type	of	drug	treatment	
intervention.	These	sites	should	be	
counted	only	once	in	the	total	for	this	
indicator.
TB.A.2e Percentage	of	drug	
treatment	sites	(including	
OST	sites)	that	provide	
TB	preventive	therapy
[TB.A.2a]   
x	100
[TB.A.2d]
TB.A.2f Number	of	other	services	
targeting	PWID	that	
provide	TB	preventive	
therapy
Programme	data
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TB.A.3 NUMBER OF PWID-TARGETED SERVICES PROVIDING TB DIAGNOSIS AND TREATMENT
Indicator: Data source: Comments:
TB.A.3a Number	of	NSP	sites	that	
provide	TB	diagnosis	and	
treatment
Programme	data
TB.A.3b Percentage	of	NSP	sites	
that	provide	TB	diagnosis	
and	treatment
 [TB.A.3a]    
x	100
[NSP.A.1a]
TB.A.3c Number	of	drug	
treatment	sites	(including	
OST)	that	provide	TB	
diagnosis	and	treatment
Programme	data
TB.A.3d Total	number	of	drug	
treatment	sites
[OST.A.2a]+[OST.A.2b]+ 
[ODT.A.2a]+[ODT.A.2b]+ 
[ODT.A.2c]+[ODT.A.2d] 
Some	drug	treatment	sites	may	offer	
more	than	one	type	of	drug	treatment	
intervention.	These	sites	should	be	
counted	only	once	in	the	total	for	this	
indicator.	Sites	offering	only	peer-
based	support	groups	are	not	included	
in	this	total.
TB.A.3e Percentage	of	drug	
treatment	sites	(including	
OST	sites)	that	provide	
TB	diagnosis	and	
treatment
[TB.A.3c]   
x	100
[TB.A.3d]
TB.C.1
ASSESSMENT OF PWID TB STATUS BY HIV TREATMENT AND CARE SERVICES
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID living with HIV, the population size estimate used as 
the	denominator	should	be	relevant	to	the	area	examined.
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Indicator: Data source: Comments:
TB.C.1a Number	of	PWID	with	
HIV	whose	TB	status	
was	assessed	and	
recorded	at	the	last	visit	
to	an	HIV	treatment	and	
care	service	during	the	
reporting	period
Programme	data It	is	recommended	that	HIV	treatment	
and	care	services	record	the	results	of	
TB	status	assessments	of	HIV	patients	
in	ART	and	pre-ART	registers.	If	these	
registers	also	record	patients’	injecting	
drug	use	status	or	history,	it	may	be	
possible	to	report	on	this	indicator.
If	these	registers	do	record	patients’	
injecting	drug	use	history	or	status,	
it	is	critical	that	client	confidentiality	
is	maintained,	that	injecting	drug	use	
history	or	status	is	not	shared	with	
law	enforcement	agencies,	and	that	
injecting	drug	use	history	or	status	
does	not	prejudice	access	to	treatment.
✱
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TB.C.2
PWID LIVING WITH HIV STARTING ISONIAZID PREVENTIVE THERAPY (IPT)
Isoniazid preventive therapy is recommended for drug users living with HIV, once active TB has 
been	excluded.	
Level of application:
These	indicators	can	be	applied	at	the	national,	regional,	city	or	service	level.	In	each	case,	
when measuring coverage among PWID living with HIV, the population size estimate used as 
the	denominator	should	be	relevant	to	the	area	examined.	
Recommended disaggregations: 
Gender (male/female/transgender)
Age (≤18 years; >18 years and <25 years; ≥25 years)
Indicator: Data sources: Comments:
TB.C.2a Number	of	PWID,	
diagnosed	as	HIV-
positive,	who	were	
started	on	TB	preventive	
therapy	during	the	
defined	reporting	period
Programme	data
ART	and	pre-ART	
registers
Provision	of	IPT	to	PLWHIV	may	be	
recorded	in	ART	and	pre-ART	registers.	
If	these	registers	also	record	patients’	
injecting	drug	use	status	or	history,	
it	may	be	possible	to	report	on	these	
indicators.
If	these	registers	do	record	patients’	
injecting	drug	use	history	or	status,	
it	is	critical	that	client	confidentiality	
is	maintained,	that	injecting	drug	use	
history	or	status	is	not	shared	with	
law	enforcement	agencies,	and	that	
injecting	drug	use	history	or	status	
does	not	prejudice	access	to	treatment.
TB.C.2b Number	of	PWID	
diagnosed	as	HIV-
positive	during	the	
defined	reporting	period
ART	and	pre-ART	
registers	
TB.C.2b Percentage	of	PWID,	
diagnosed	as	HIV-
positive,	who	were	
started	on	TB	preventive	
therapy	during	the	defined	
reporting	period
[TB.C.2a]   
x	100
[TB.C.2b]
Possible targets:
Low	 30% 	Mid	 60% 	High
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4.4 OUTCOME/IMPACT INDICATORS
OI.1
REDUCED HIV INCIDENCE AMONG PWID
Relevant to the following interventions: 
Needle and syringe programmes
Opioid substitution therapy
Other drug dependence treatment
Antiretroviral therapy for HIV
Prevention and treatment of sexually transmitted infections
Condom distribution programmes
Targeted information, education and communication
Indicator: Data sources: Comments:
OI.1.a Incidence	of	HIV	among	
PWID
•	 HIV	surveillance
•	 case	reporting	
systems
•	mathematical	
modelling	exercises.
Limitations	of	various	estimation	
techniques	must	be	considered	
when	interpreting	results	from	these	
techniques;	see	section	3.6	(page	40)	
for	more	information.	
OI.2
REDUCED HIV PREVALENCE AMONG PWID
Relevant to the following interventions: 
Needle and syringe programmes
Opioid substitution therapy
Other drug dependence treatment
Antiretroviral therapy for HIV
Prevention and treatment of sexually transmitted infections
Condom distribution programmes
Targeted information, education and communication
Indicator: Data source: Comments:
OI.2.a Prevalence	of	HIV	among	
PWID
HIV	sentinel	
surveillance	
Sero-prevalence	studies	should	be	
used,	rather	than	self-reported	HIV	
status.	
As	noted	in	section	3.4,	limitations	
of	sampling	strategies,	bias	and	
likely	representativeness	should	be	
considered.
Observed	increases	in	prevalence	
may	be	due	to	improved	surveillance	
or	testing	techniques	or	increased	
uptake	of	testing,	rather	than	to	actual	
increases	in	the	number	of	infections.
Apparent	decreases	in	prevalence	
may	result	from	reduced	testing;	
actual	decreases	in	infections	may	
be	the	result	of	out-migration	or	
mortality	rather	than	prevention	of	new	
infections.
Increased	HIV	treatment	coverage	can	
reduce	mortality	among	persons	living	
with	HIV	and	thus	increase	prevalence	
even	if	incidence	remains	stable	or	
decreases.	
✱
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OI.3
INCREASED USE OF STERILE INJECTING EQUIPMENT BY PWID
Relevant to the following interventions: 
Needle and syringe programmes
Opioid substitution therapy
Other drug dependence treatment
Targeted information, education and communication
Indicator: Data source: Comments:
OI.3a Percentage	of	PWID	
reporting	the	use	
of	sterile	injecting	
equipment	the	last	time	
they	injected	drugs
Repeated	behavioural	
surveys
This	indicator	is	included	in	the	Global	
AIDS	Response	progress	reporting	
2012	(12)	as	well	as	in	the	FHI-BSS	(127) 
as	follows:
Q301:	“Think	about	the	last	time	you	
injected	drugs.	Did	you	use	a	needle	or	
syringe	that	had	previously	been	used	
by	someone	else?”
OI.3b Percentage	of	PWID	
who	report	always	
using	sterile	injecting	
equipment	during	the	last	
one	month
Repeated	behavioural	
surveys
This	indicator	is	included	in	the	FHI-
BSS (127)	as	follows:
Q302:	“Think	about	all	the	times	you	
injected	during	the	past	one month.	
How	often	was	it	with	a	needle	or	
syringe	that	had	previously	been	
used	by	someone	else?”	Responses:	
“Always;	Most	times;	About	half	the	
time;	Occasionally;	Never.”
OI.4
REDUCTION IN FREQUENCY OF INJECTING
Relevant to the following interventions: 
Opioid substitution therapy
Other drug dependence treatment
Indicator: Data source: Comments:
OI.4a Percentage	of	PWID	
injecting	once	per	day	or	
more
Behavioural	surveillance	
survey
This	indicator	is	included	in	the	
FHI-BSS	(127)	as	follows:
Q205:	“During	the	past	one	month,	
how	often	would	you	say	you	
injected	drugs?”	Responses: “Only	
once;	2–3	times;	about	once	a	
week;	2–3	times	a	week;	4–6	times	
a	week;	about	once	a	day;	2–3	
times	a	day;	4 or	more	times	a	day”.
✱
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OI.5
INCREASED AWARENESS OF HIV STATUS AMONG PWID
Relevant to the following interventions: 
HIV testing and counselling
Indicator: Data source: Comments:
OI.5a Percentage	of	PWID	who	
were	tested	for	HIV	in	
the	last	12 months	and	
who	know	the	results
Repeated	behavioural	
surveys
This	indicator	is	included	in	the	FHI-
BSS (127)	as	follows:
•	 Q1114:	“I	don’t	want	to	know	the	
result,	but	have	you	ever	had	an	HIV	
test?”
•	 Q1116:	“Please	do	not	tell	me	the	
result,	but	did	you	find	out	the	result	of	
your	test?”
•	 Q1117:	“When	did	you	have	your	most	
recent	test?”
Note	that	PWID	living	with	HIV	who	
became	aware	of	their	HIV	status	prior	
to	the	last	12 months	will	not	have	been	
tested	in	the	last	12	months	but	would	
answer	yes	to	questions	Q114.	
OI.6
DECREASED INCIDENCE OF AIDS CASES AMONG PWID
Relevant to the following interventions: 
Antiretroviral therapy
HIV testing and counselling
Indicator: Data source: Comments:
OI.6a Number	of	AIDS	incident	
cases	among	PWID	in	the	
past	12 months
HIV/AIDS	registration	
data
Available	data	may	have	significant	
limitations.	AIDS	registration	data	may	
not	include	details	of	injecting	drug	
use	history	or	status;	in	some	cases	
injecting	drug	use	may	be	included	only	
when	recorded	as	the	likely	exposure	
category.	
If	these	registers	do	include	this	
information,	it	is	critical	that	
confidentiality	is	maintained,	that	
injecting	drug	use	history	or	status	
is	not	shared	with	law	enforcement	
agencies,	and	that	drug	use	history	or	
status	does	not	prejudice	access	to	
treatment.
✱
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OI.7
DECREASED AIDS-RELATED MORTALITY AMONG PWID
Relevant to the following interventions: 
Antiretroviral therapy
HIV testing and counselling
Indicator: Data sources: Comments:
OI.7a Number	of	AIDS-related	
deaths	among	PWID	in	
the	past	12 months
•	 HIV/AIDS	registration	
data
•	 national	mortality	data
•	 data	from	longitudinal	
PWID	cohort	studies
Available	data	may	have	significant	
limitations.
National	mortality	data	are	unlikely	to	
include	information	on	injecting	drug	
use	history	or	status	unless	drug	use	
was	noted	as	associated	with	cause	of	
death.	
This	indicator	is	more	easily	reported	if	
there	is	data	linkage	between	HIV/AIDS	
registration	and	mortality	records.
If	cohorts	of	PWID	are	followed,	data	
from	these	studies	may	also	be	useful;	
representativeness	and	potential	bias	
need	to	be	considered.
OI.8
DECREASED INCIDENCE OF SEXUALLY TRANSMITTED INFECTIONS AMONG PWID
Relevant to the following interventions: 
Sexually transmitted infection prevention, detection and treatment
Condom distribution programmes
Targeted information, education and communication
Indicator: Data source: Comments:
OI.8a Percentage	of	PWID	
who	report	having	had	
symptoms	of	an	STI	
during	the	last	12	months
Repeated	behavioural	
surveys
This	indicator	is	included	in	the	FHI-
BSS (127)	as	follows:
•	 Q1004:	“Have	you	had	a	genital	
discharge	during	the	past	12	months?”
•	 Q1005:	“Have	you	had	a	genital	ulcer/
sore	during	the	past	12	months?”
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OI.9
INCREASED USE OF CONDOMS AMONG PWID
Relevant to the following interventions: 
Condom distribution programmes
Targeted information, education and communication
Indicator: Data source: Comments:
OI.9a Percentage	of	PWID	
who	had	sex	in	the	last	
month	who	report	using	a	
condom	the	last	time	they	
had	sexual	intercourse
Repeated	behavioural	
surveys	
This	indicator	is	included	in	the	Global	
AIDS	Response	progress	reporting	
2012	(12).
The	FHI-BSS	(127)	includes	questions	
regarding	the	use	of	condoms	the	last	
time	a	participant	had	sex	but	does	so	
separately	for	each	type	of	partner,	as	
follows:
•	 Q603:	“The	last	time	you	had	sex	with	
your	regular	partner,	did	you	and	your	
partner	use	a	condom?”
•	 Q704:	“The	last	time	you	had	sex	with	
a	commercial	partner,	did	you	and	
your	partner	use	a	condom?”
•	 Q804:	“The	last	time	you	had	sex	with	
a	non-regular	partner,	did	you	and	
your	partner	use	a	condom?”
✱
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